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ABSTRACT 
 
Inositol dehydrogenase (IDH, EC 1.1.1.18) from Bacillus subtilis catalyzes the 
reversible NAD+-dependent oxidation of the axial hydroxyl group of myo-inositol to 
form 2-keto-myo-inositol, NADH and H+. IDH is the first enzyme in catabolism of 
myo-inositol, and Bacillus subtilis is able to grow on myo-inositol as the sole carbon 
source. Our laboratory has previously shown that this enzyme has an unusual active 
site that can accommodate large hydrophobic substituents at 1L-4-position of 
myo-inositol.  
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In this dissertation, the further characterization of this IDH is described, with focus on 
the mechanism, inhibition, kinetics, substrate binding, and alteration of substrate 
specificity. A kinetic isotope effect study revealed that the chemical step of the 
reaction was not rate-limiting. In order to probe the inositol-binding site, five inositol 
analogues were synthesized and evaluated as competitive inhibitors. Recently the 
crystal structures of the apo-IDH, holo-IDH and ternary complex have been solved. 
Using structural information, as well as modeling and sequence alignment approaches, 
we predicted the active site structure of the enzyme. On the basis of these predictions, 
coenzyme specificity was converted from entirely NAD+-dependent to 6-fold 
preference for NADP+ over NAD+ by site-directed mutagenesis. The critical residues 
for coenzyme recognition were therefore identified. Besides coenzyme specificity 
alteration, eleven amino acid residues in and around the proposed myo-inositol active 
site were also modified to test their roles in order to improve our understanding of 
substrate binding and activation.  
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1. INTRODUCTION 
 
1.1 Inositol 
 
A cyclohexanehexol was first isolated from muscle and named as “inosit” (from inos, 
the Greek root for muscle) by Scherer in 18501,2. Since then “inositol” became a term 
for 1,2,3,4,5,6-cyclohexanehexols in English, and it is also called “cyclitol” in some 
papers. There are nine possible stereoisomers of inositol: allo-inositol, D-chiro-inositol, 
L-chiro-inositol, cis-inositol, epi-inositol, muco-inositol, myo-inositol, neo-inositol, 
and scyllo-inositol (Figure 1.1). Of these nine stereoisomers, myo-, scyllo-, D-chiro-, 
L-chiro-, muco-, and neo-inositol are naturally occurring while allo-, epi-, and 
cis-inositol have not been found in nature, only known as chemically synthesized 
molecules3. D-chiro-inositol and L-chiro-inositol are an enantiomeric pair, and the 
remaining seven are optically inactive1. myo-Inositol is the most prevalent inositol in 
nature so far, which is rich in soil and also common in plants and animals. Some 
microorganisms, including Bacillus subtilis4, Cryptococcus melibiose5, Aerobacter 
aerogenes (now reclassified as Enterobacter aerogenes)6, Rhizobium leguminosarum 
bv. Viciae7, Sinorhizobium meliloti8, Sinorhizobium fredii9, Corynebacterium 
glutamicum10, and Lactobacillus casei11 are able to grow on myo-inositol by utilizing it 
as the sole carbon source.  
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Figure 1.1 Structures and nomenclature of the inositols. When the term “inositol” is used without a 
prefix, it generally refers to be the myo isomer, whereas the term ‘inositols’ refers to all nine inositols. 
The term “cyclitol” can also be used to refer to the nine inositols collectively. 
 
The numbering of the carbon chain of inositol is confusing since several different rules 
have been published. Of them, the D/L naming system according to the 
recommendations of the Nomenclature Committee of the International Union of 
Biochemistry (NC-IUB) is commonly used12,13. myo-Inositol can be named as 
1L-myo-inositol (clockwise) or 1D-myo-inositol (counterclockwise) depending on the 
substituent location as shown in Figure 1.2. To avoid confusion, the myo-inositol 
molecule can be visualized three dimensionally as a turtle, which is known as 
“Agranoff's turtle” 1,12. The head of this turtle always is positioned as number 2. 
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Looking down from above, the numbers are clockwise when the left front limb labels 
as number 1 (L system); the numbers are counterclockwise when the right front limb 
labels as number 1 (D system). 
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Figure 1.2 Examples of the D/L naming system of myo-inositol and myo-inositol derivatives. 
 
For convenience, in the rest of this dissertation, when the word inositol is used without 
a prefix, it refers to myo-inositol and all the myo-inositol derivatives are named based 
on the 1L-myo-inositol system no matter the location of the substituent(s). 
 
 
1.2 myo-Inositol catabolism  
 
myo-Inositol and its derivatives are widely distributed in nature14. They play important 
roles in a myriad of cellular events such as membrane formation, signal transmission, 
growth regulation, stress response, seed germination, membrane trafficking, hormone 
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transport, protein anchoring, health maintenance, RNA export, and so on1, 15-25. Two 
catabolic pathways have been discovered for the degradation of myo-inositol. It was 
found that the pathway in higher eukaryotes is completely different from the bacterial 
pathway26.  
 
 
1.2.1 myo-Inositol catabolism in eukaryotes 
 
The catabolism pathway of myo-inositol in eukaryotes has been well studied, in which, 
myo-inositol is converted to D-glucuronate by the enzyme myo-inositol oxygenase 
(MIOX, EC 1.13.99.1). MIOX was first found in rat kidney in 195727, which catalyzes 
the cleavage of C1 and C6 of myo-inositol ring28 (Figure 1.3). This oxidation reaction 
is the first step in the only known inositol catabolism pathway in mammals which is 
associated with diabetes. It has been suggested that inhibition of MIOX activity may 
be a future cure for diabetic complications29.  
 
In the following steps of myo-inositol catabolism pathway, two branches have been 
discovered. In animals and yeast, the subsequent steps of this inositol oxidation 
reaction are shown in Figure 1.3. The D-glucuronate is converted into L-gulonate, and 
then 3-keto-L-gulonate, L-xylulose, xylitol, D-xylulose, and D-xylulose 5-phosphate 
which enters the pentose phosphate cycle30,31. In plants all oxygenase-generated 
glucuronate is transformed into D-glucuronate 1-phosphate and then into 
UDP-glucuronate which is a major precursor for nucleotide sugars such as 
UDP-galacturonate, UDP-D-apiose, UDP-xylose, UDP-L-arabinose15,32. 
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Figure 1.3 The oxidation pathway of myo-inositol catabolism in eukaryotes. a: myo-inositol 
oxygenase (MIOX); b: NADPH-dependent D-glucuronate reductase; c: L-gulonate-3-oxidoreductase; d: 
3-keto-L-gulonate carboxylase; e: L-xylulose reductase; f: xylitol dehydrogenase; g: D-xylulokinase; h: 
glucuronokinase; i: glucuronate-1-phosphate uridylyltransferase. 
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1.2.2 myo-Inositol catabolism in bacteria 
 
The breakdown of myo-inositol in bacteria follows a completely different pathway 
from eukaryotes. Relatively fewer studies have been done to demonstrate the 
myo-inositol catabolism pathway in bacteria. In 1971, Anderson et al reported the first 
proposed pathway in Aerobacter aerogenes (now reclassified as Enterobacter 
aerogenes) in which decomposition of myo-inositol yielded acetyl-CoA, 
dihydroxyacetone phosphate, and CO2 33. Later, myo-inositol catabolism in Bacillus 
subtilis was explored, in which operon iolABCDEFGHIJ was assigned for the function 
of inositol catabolism4. Experimental characterizations demonstrated A. aerogenes and 
B. subtilis shared a similiar myo-inositol catabolism pathway which is shown in Figure 
1.434. The only difference is the intermediate between 
D-2,3-diketo-4-deoxy-epi-inositol and 2-deoxy-5-keto-glucuronic acid. Anderson et al 
thought D-2,3-diketo-4-deoxy-epi-inositol was isomerized by keto-enol 
tautomerization and then the ring scission took place between C2 and C3 to form 
2-deoxy-5-keto-glucuronic acid in A. aerogenes33; whereas, 5-deoxy-glucuronic acid 
was reported as the intermediate in B. subtilis34. 
 
In B. subtilis, myo-inositol is first converted to 2-keto-myo-inositol by 
myo-inositol-2-dehydrogenase (IDH, encoded by gene iolG) instead of forming 
D-glucuronate35 as mentioned in 1.2.1. The second step is a dehydration of previous 
product 2-keto-myo-inositol to D-2,3-diketo-4-deoxy-epi-inositol [also called 
3D-(3,5/4)-trihydroxycyclohexane-1,2-dione], which is catalyzed by 
2-keto-myo-inositol dehydratase (encoded by gene iolE)36. Next, a hydrolase (encoded 
by gene iolD) cleaves the C2-C3 bond of the dehydration product to form 
5-deoxy-D-glucuronic acid. The fourth step is catalyzed by an isomerase (encoded by 
gene iolB) to give 2-deoxy-5-keto-glucuronic acid which is phosphorylated in the fifth 
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step by a kinase (encoded by gene iolC)34. The resulting 2-deoxy-5-keto-glucuronic 
acid 6-phosphate is cleaved into dihydroxyacetone phosphate and malonic 
semialdehyde by an aldolase (encoded by gene iolJ) in the sixth step. The last step is 
catalyzed by a malonic semialdehyde dehydrogenase (encoded by gene iolA), acting on 
malonic semialdehyde to produce acetyl-CoA and CO237. Since the functions of 
enzymes involved inositol decomposition in B. subtilis have been identified, recently, 
many bacteria have been claimed to contain myo-inositol catabolism genes based on 
the sequence similarity to B. subtilis iol genes.  
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Figure 1.4 The proposed myo-inositol catabolic pathway in B. subtilis. a: 
myo-inositol-2-dehydrogenase (IDH, IolG); b: 2-keto-myo-inositol dehydratase (IolE); c: hydrolase 
(IolD); d: isomerase (IolB); e: kinase (IolC); f: aldolase (IolJ); g: malonic semialdehyde dehydrogenase 
(IolA). The molecule in blue is a proposed intermediate in myo-inositol catabolic pathway in A. 
aerogenes. 
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1.3 Dehydrogenases 
 
Dehydrogenase, also called oxidoreductase, is an enzyme that catalyzes 
oxidation-reduction reaction by transferring a hydride between the substrate and 
coenzyme, and usually uses -nicotinamide adenine dinucleotide (NAD), 
-nicotinamide adenine dinucleotide phosphate (NADP), or flavin adenine 
dinucleotide (FAD) as a coenzyme. It is known that dehydrogenases comprise a large 
group of gene products within nearly every genome. It was reported that NAD is the 
most common coenzyme (41–49%), followed by NADP (30–38%), and FAD is the 
least common coenzyme (21%) in all organisms38. Although NAD and NADP are 
structurally similar, their biochemistry is substantially different. NAD is used almost 
exclusively in the oxidative degradations and acts as an oxidant; however, NADP is, 
with a few exceptions, involved in the reactions of reductive biosynthesis and acts as a 
reductant39. In this dissertation, NAD or NADP as a coenzyme will be discussed. 
 
Based on distinct sequence motifs, protein chain length, mechanistic features and 
structural comparisons of dehydrogenases, superfamilies of short-, medium-, and 
long-chain dehydrogenases/reductases has been classified40-42. This concept was first 
established in 198143. Of these three superfamilies, the long-chain 
dehydrogenases/reductases superfamily is the least defined one. In contrast, 
short-chain dehydrogenases/reductases superfamily and medium-chain 
dehydrogenases/reductases superfamily have been characterized in great detail 
including their structure-function relationships. 
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1.3.1 NAD/NADP and the Rossmann fold  
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Figure 1.5 Transformation between oxidized dinucleotide (NAD+/NADP+) and reduced 
dinucleotide (NADH/NADPH).  
 
-Nicotinamide adenine dinucleotide (NAD) is a coenzyme that serves as a hydride 
carrier for the enzymatic oxidation-reduction reaction. There are two forms of NAD 
(Figure 1.5). NAD+ is the oxidized form, and it accepts hydride from the substrate 
and becomes NADH which is the reduced form. Vice versa, NADH can donate a 
hydride to form NAD+. The reduced form NADH absorbs light at 340 nm, whereas 
the oxidized form NAD+ does not. The nicotinamide ring of NAD+ is the redox active 
moiety and the C4 position can reversibly accept hydrides, and thereby converts to the 
1,4-dihydropyridine form of NADH. The C4 of nicotinamide ring is prochiral, and the 
enzymatic hydride transfer is stereospecific (attack from re- face or si- face of 
nicotinamide). Thus, the hydrogens on C4 of 1,4-dihydropyridine can be labelled as 
pro-R or pro-S. NADP is the phosphorylated NAD, as shown in Figure 1.5. NADP 
acts the same way as NAD chemically. Some enzymes are exclusive to NAD or 
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NADP, and a few enzymes can accommodate both NAD and NADP as coenzymes.  
 
Most of the NAD/NADP-dependent dehydrogenases bind the coenzyme in a 
structurally conserved domain named the Rossman fold. This Rossman fold consists of 
a six-stranded parallel -sheet and four associated-helices with the topological order 
in which  helix pairs are on both sides of the plane formed by 
strands44. A classical Rossmann fold is shown in Figure 1.6 using dogfish M4 
lactate dehydrogenase as an example. Almost all of the characterized Rossmann fold 
show glycine rich motif in a GX1-2GX1-2G(A) pattern after , where ‘X’ denotes any 
amino acid residue. 
 
Figure 1.6 The model of Rossmann fold of dogfish M4 lactate dehydrogenase structure (PDB code: 
3LDH) with NAD+ binding inside. NAD+ molecule is indicated in sticks (carbon in green, oxygen in 
red, phosphorus in orange, nitrogen in blue); -helix is indicated in cyans; -sheet is indicated in 
magenta; loop is indicated in salmon pink. Image was generated using PyMOL68. 
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1.3.2 General mechanism of NAD/NADP-dependent dehydrogenases 
 
The general reaction for NAD/NADP-dependent dehydrogenases can be represented 
by Equation 1.1, in which, AH2 is a reduced form of substrate; A is an oxidized form; 
E is a dehydrogenase. 
 
AH2 + NAD(P)+ A + NAD(P)H + H+
E
       Equation 1.1 
 
The general chemical mechanism of an alcohol dehydrogenase can be summarized as 
Figure 1.7. In the oxidization reaction, while a general base deprotonates a hydroxyl, 
the displaced hydride attacks C4 of the nicotinamide ring of NAD+ to form the 
oxidized product and NADH. In the reverse direction, the hydride transfers from 
NADH to C of oxidized product and the carbonyl group is reprotonated, thus, alcohol 
and NAD+ are produced. 
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Figure 1.7 General chemical mechanism of an oxidation-reduction reaction catalyzed by an 
alcohol dehydrogenase. B is a general base, usually is Tyr, His, or Lys; R1 and R2 can be any 
substituent; R' = H, PO32-.  
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1.3.3 Short-chain dehydrogenases/reductases 
 
Short-chain dehydrogenases/reductases (SDRs, with subunits typically of ~ 250  
residues) is one of the largest enzyme superfamilies with 46,000 members and over 
300 crystal structures deposited in protein data bank (PDB). About 25% of all 
dehydrogenases belong to the SDR superfamily and about 75% of all known SDR 
enzymes are from bacteria45. SDR enzymes play critical roles in lipid, amino acid, 
carbohydrate, cofactor, hormone, retinoid, and xenobiotic metabolism as well as in 
redox sensor mechanisms. In humans over 70 SDR genes have been identified and a 
variety of inherited metabolic diseases have been identified as their underlying cause 
genetic defects in SDR genes46, 47.  
 
Table 1.1 Coenzyme and active site conserved sequence motifs for five SDR families. 
Family Coenzyme binding motif Active site 
Classical family TGXXX[AG]XG YXXXK 
Extended family [ST]GXXGXXG YXXXK 
Intermediate family [GA]XXGXX[GA] YXXXK 
Divergent family GXXXXXSXA YXXMXXXK 
Complex family GGXGXXG YXXXN 
 
According to the conserved sequence motifs and subunit size, the SDR superfamily is 
classified as classical family, extended family, divergent family, intermediate family, 
and complex family (Table 1.1)48. Sequence identities of SDR enzymes are typically 
15-30%, and the most conserved feature is the N-terminal Rossmann-fold where the 
coenzyme binds. Typically, the dinucleotide coenzyme binds in a conformation that 
allows transfer of the 4-pro-S hydride of nicotinamide to the substrate45. Substrate 
specificity is determined by the variable C-terminal segment and the active site 
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contains a conserved Tyr as the genral base/acid41,49. SDR enzymes not only catalyze 
the interconversion of hydroxyl/carbonyl groups, but also catalyze reduction of C=C 
and C=N double bonds, dehydration, dehalogenation, isomerization, and 
decarboxylation reactions (Figure 1.8)50. A database of SDR families is available on 
the website www.sdr-enzymes.org. 
 
 
 
Figure 1.8 Examples of the SDR catalyzed reactions50.  
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1.3.4 Medium-chain dehydrogenases/reductases 
 
Medium-chain dehydrogenases/reductases (MDRs, with subunits typically of ~ 350 
residues) comprise a superfamily that contains 2684 enzymes, and the structures of 43 
enzymes have been solved as of 200951,149. MDRs are wildly occurred and are 
involved in metabolism, regulatory processes, and protection against cell damage42,52.  
 
On the basis of sequence similarities analyzed, MDRs are classified into 29 families 
named from mdr1 to mdr29 and the sequence identity of each family varies from 30% 
to 70%. The Medium-Chain Dehydrogenase/Reductase Engineering Database 
(MDRED) has been created and is available on the website 
www.mdred.uni-stuttgart.de51. All identified MDRs use NAD or NADP as their 
coenzyme and the dinucleotide binds in a conformation that allows transfer of the 
4-pro-R hydride of nicotinamide to the substrate50. Some MDR members have one 
zinc ion with catalytic function binding at the active site. Therefore, MDRs are also 
divided into zinc-containing and non-zinc-containing MDRs42,53. 
 
 
1.3.5 Long-chain dehydrogenases/reductases 
 
Long-chain dehydrogenases/reductases (LDRs, with subunits typically of ~ 360-550 
residues) have not been well defined in terms of structural relationships among protein 
modules and functional properties. LDRs display similarities in some segments of the 
amino acid sequence but do not have entire chain homology. Unlike SDRs and MDRs, 
the number of strictly conserved residues in LDRs is extremely low40. To my 
knowledge, only one family, polyol-specific long-chain dehydrogenases/reductases 
(PSLDRs), has been reported on the basis of sequence similarity, which consists of 66 
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NAD/NADP-dependent oxidoreductases54,55. Besides PSLDRs, other 
NAD/NADP-dependent enzymes including D-glucose 6-phosphate 
dehydrogenases40,56, isocitrate dehydrogenases57, isopropylmalate dehydrogenases58, 
tartrate dehydrogenases59, malic enzyme60, metalin dependent 6-phosphogluconate 
dehydrogenases61, UDP-glucose dehydrogenase62, and iron-activated long-chain 
dehydrogenases63 also were reported as LDRs. In addition, some FAD-dependent 
enzymes such as fumarate reductase, succinate dehydrogenase, lipoamide 
dehydrogenase, methoxyneurosporene dehydrogenase, glycerol-3-phosphate 
dehydrogenase, glucose dehydrogenase, and flavine reductase40 were also assigned to 
the LDR superfamily.  
 
Although they have low amino acid sequence identity (for example, PSLDRs only 
have 3 residues strictly conserved), LDRs demonstrate similar domain architecture as 
MDRs and SDRs, which is constructed with the coenzyme-binding domain and the 
substrate-binding domain55,64. A common feature to all three superfamilies of 
dehydrogenases/reductases (SDR, MDR, and LDR) is the occurrence of a 
Rossmann-fold dinucleotide-binding domain.  
 
 
1.4 myo-Inositol-2-dehydrogenase from Bacillus subtilis 
 
Bacillus subtilis is a spore-forming bacterium commonly found in soil, which is able to 
form a tough, protective endospore, allowing the organism to tolerate extreme 
environment conditions. Like other soil bacteria, Bacillus subtilis can grow on 
myo-inositol as the sole carbon source65. After inositol is transported into the cell, 
myo-inositol is dehydrogenated to 2-keto-myo-inositol with the conversion of NAD+ to 
NADH by myo-inositol-2-dehydrogenase (IDH). This reaction is showed in Figure 1.9. 
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The whole inositol catabolism pathway in Bacillus subtilis has been described in 1.2.2. 
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Figure 1.9 Interconversion of myo-inositol and 2-keto-myo-inositol catalyzed 
by myo-inositol-2-dehydrogenase (IDH). 
 
 
1.4.1 Physical properties and catalytic properties of native B. subtilis IDH 
 
A myo-inositol dehydrogenase (IDH, EC 1.1.1.18) was first discovered in vegetative 
cells of B. subtilis in 197666. Three years later, the native B. subtilis IDH was isolated 
and characterized.  Ramaley et al reported that the active B. subtilis IDH is tetrameric, 
being composed of four identical subunits of 39,000 daltons, each with an independent 
active site65. This enzyme reacts preferentially with myo-inositol, and also can 
recognize some other compounds such as D-glucose and D-xylose as its substrates. In 
addition, trace activity was observed with D-ribose and D-fructose, and no activity was 
observed with scyllo-inositol, D-mannose, D-sorbitol, D-mannitol, GDP-D-mannose, 
ADP-D-glucose, D-mannose-6-phosphate, CDP-D-glucose, D-glucose-6-phophate, 
2-deoxy-D-glucose-6-phosphate, D-erythrose, D-glucosamine, D-sorbitol, 
N-acetyl-D-glucosamine, and D-erythritol. It is apparent that IDH reacts with 
myo-inositol-like compounds, with only one axial hydroxyl group at position 2 
(corresponding to position 1 of glucose). By measurement of transfer of tritium from 
2-3H-myo-inositol, it was concluded that myo-inositol is oxidized by IDH at the 
2-position to form 2-keto-myo-inositol (also called scyllo-inosose)65. IDH is an 
exclusive NAD-dependent enzyme and can not recognize NADP as the coenzyme. 
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Optimum activity for the oxidation reaction presents at pH 9.5 and for reduction 
reaction presents at pH 7.0. Although IDH can react with D-glucose, it is distinct from 
glucose dehydrogenase (EC 1.1.1.47), which reacts with -D-glucose or 
-2-deoxy-D-glucose, but does not react with myo-inositol, and is able to use either 
NAD or NADP as a coenzyme65,67.  
 
B. subtilis IDH has not been assigned to any superfamily of SDR, MDR, or LDR, but 
its homolog D-glucose 6-phosphate dehydrogenase was reported as a member of LDR 
superfamily40,56. The sequence of the gene iolG encoding the IDH enzyme and the 
regulation of this gene were reported in 1990s35. And then the gene iolG was 
successfully cloned into pET-28b and overexpressed in Escherichia coli in this 
laboratory69. 
 
1.4.2 Glucose-fructose oxidoreductase and IDH homology model 
 
B. subtilis IDH was assigned to the GFO/IDH/MOCA superfamily in Swiss-Prot. 
While some proteins identified by sequence alignment were named as inositol 
2-dehydrogenase, there was no structural or functional information available until 2008, 
when the crystal structures of IolG1 (claimed as myo-inositol 2-dehydrogenase) from 
Lactobacillus plantarum WCFS1 (PDB code: 3CEA) and myo-inositol dehydrogenase 
from Corynebacterium glutamicum (PDB code: 3EUW) were deposited in RSCB 
protein data bank (www.rcsb.org/pdb) without reporting further functional 
characterization. 
 
When we started the project, little was known about IDH and in particular no 
three-dimensional structure of IDH was solved. We knew, though, glucose-fructose 
oxidoreductase (GFOR, EC 1.1.99.28) from Zymomonas mobilis70,71, a 
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NADP-dependent enzyme that catalyzes the coupled intermolecular 
oxidation-reduction of D-glucose and D-fructose in the sorbitol-gluconate pathway72,73 
(Figure 1.10), was the best characterized member of the GFO/IDH/MOCA 
superfamily. In addition, the high-resolution crystal structures of the wild-type GFOR 
and several mutants have been determined by X-ray crystallography74. Z. mobilis 
GFOR demonstrated 18% sequence identity with B. subtilis IDH. According to the 
sequence alignment in Figure 1.11, primary structures in N-terminal parts of IDH and 
GFOR show significant similarities. The fingerprint motif of the  dinucleotide 
binding fold, GXGXXG, is conserved in IDH, suggesting that the dinucleotide-binding 
domain contains the Rossmann fold. Another highly conserved motif in IDH is CEKP, 
which is proposed as the fingerprint of dehydrogenases whose substrates are 
structurally similar to glucose75. In addition, the catalytic dyad in GFOR, Asp265 and 
Tyr269 (residue numbering taken from PDB file), aligns with Asp172 and His176 in 
IDH, which has a potential to act as a catalytic dyad. This sequence alignment allows 
us to predict the roles of corresponding residues in IDH. 
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Figure 1.10 The oxidation-reduction reaction GFOR catalyzed.  
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Figure 1.11 Sequence alignment of IDH from B. subtilis and GFOR from Z. mobilis. Amino acid 
sequences were aligned using CLUSTALW 1.8376 and generated using ESPript77, with the BLOSUM 62 
scoring matrix (gap penalty = 10, gap extension penalty = 0.5). Red highlighted residues are identical 
residues. Asp265 and Tyr269 of GFOR are indicated by blue arrows   . 
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Figure 1.12 Superpositioned models of the crystal structure of GFOR from Z. mobilis (blue) and 
the homology model of IDH (red). NADH and 1L-4-O-benzyl-2-keto-myo-inositol docked in IDH are 
shown in sticks (oxygen in red, nitrogen in blue, phosphorus in orange, carbon in grey). Image was 
generated using PyMOL68. 
 
 
Since no three-dimensional structure of IDH was available at that time, a homology 
model was needed to make further predictions and activity interpretation. In 2007, the 
first IDH homology model was built using GFOR as the template and the coenzyme 
NADH and substrate 1L-4-O-benzyl-2-keto-myo-inositol were docked manually78. 
The resulting model is shown in Figure 1.12. This homology model was used to 
predict active site residues and substrate/coenzyme binding properties before the IDH 
crystal structure was solved. 
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1.4.3 Substrate specificity 
 
 
Figure 1.13 The IDH homology model in which the proposed hydrophobic cavity formed by the 
motif YGY. The coenzyme NAD+ and substrate 1L-4-O-benzyl-myo-insitol are indicated in sticks 
(oxygen in red, nitrogen in blue, phosphorus in orange, carbon in grey). Image was generated using 
PyMOL68. 
 
 
As mentioned in 1.2.2, IDH, a strictly NAD-dependent enzyme, catalyzes the first 
reaction in the inositol catabolism pathway. myo-Inositol is the natural substrate of 
IDH, and it is regioselectively oxidized at the 2-position, and D-glucose and D-xylose 
can be recognized as substrates65. Previous results of this laboratory revealed that 
-D-glucose, -D-xylose, 1L-4-O-substituted myo-inositol, and 6-substituted 
-D-glucose (Figure 1.14) were also substrates of IDH69,78. Interestingly, derivatives 
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with charged substituents, myo-inositol-4-O-phosphate and glucose 6-phosphate, can 
not be oxidized as the substrates. It was thus proposed that there was a hydrophobic 
pocket formed by motif YGY near the inositol active site to accommodate those 
substituted groups69 (Figure 1.13).  
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Figure 1.14 Compounds that can be oxidized by IDH.  
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1.4.4 Inhibition 
 
Inhibitors are compounds that interfere with catalysis, slowing or halting enzymatic 
reactions. As blocking an enzymatic activity can kill a pathogen or correct a metabolic 
imbalance, many drugs are enzyme inhibitors79,80. The study of enzyme inhibitors also 
can provide valuable information about enzyme catalytic mechanisms and help define 
kinetic mechanisms in some cases (examples in 1.4.5). The binding mode of an 
inhibitor to an enzyme is either reversible or irreversible. Irreversible inhibitors usually 
react with the enzyme and modify key amino acid residues needed for enzymatic 
activity. On the other hand, reversible inhibitors bind to enzymes non-covalently. On 
the basis of inhibitor binding sites and binding sequence, reversible inhibitors are 
further classified as competitive, uncompetitive, and mixed inhibitors (when the 
binding affinity of an inhibitor to free enzyme and to the ES complex is the same, the 
mixed inhibitor is called a noncompetitive inhibitor)81, and the corresponding binding 
modes are shown in Figure 1.15. 
 
In order to diagnose the binding mode by which an inhibitor interacts with the enzyme, 
three sets of graphical methods could be utilized. They are the double reciprocal plot 
(or Lineweaver-Burk plot), Dixon plot, and Cornish-Bowden plot82,83. These plots are 
generated by measuring the initial velocities of the enzymatic reaction as a function of 
several substrate concentrations at several fixed inhibitor concentrations. With the 
pattern of the straight lines exibited in the corresponding plot, the inhibitor can be 
identified as a competitive, uncompetitive, or mixed inhibitor (Table 1.2). 
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a. Competitive inhibition 
E + S ES E + P
+
I
EI
Ki
 
 
b. Uncompetitive inhibition 
E + S ES E + P
+
I
ESI
Ki'
 
 
c. Mixed inhibition/noncompetitive inhibition 
E + S ES E + P
+
I
EI
Ki
+
I
ESI
Ki'
+ S  
 
Figure 1.15 Three types of reversible inhibition. E represents an enzyme; S represents a substrate; I 
represents an inhibitor. Ki is the equilibrium constant for inhibitor binding to E; Ki' is the equilibrium 
constant for inhibitor binding to ES. (a) Competitive inhibitor binds to the active site. (b) Uncompetitive 
inhibitor binds at a separate site and binds only to the ES complex. (c) Mixed inhibitor binds at a 
separate site and can bind to either E or ES (Ki = Ki', named as noncompetitive inhibitor). 
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Table 1.2 The characteristic patterns of competitive, uncompetitive, and mixed inhibitor 
presented in double reciprocal plot, Dixon plot, and Cornish-Bowden plot, respectively. a: 
competitive inhibitor; b: uncompetitive inhibitor; c: mixed inhibitor. 
  Double reciprocal plot Dixon plot Cornish-Burden plot 
 
 
a 
  
 
 
 
 
 
 
b 
 
 
 
 
 
 
 
 
 
 
 
c 
  
 
 
 
  
 
 
 
 
 
1/v 1/v 
[S]/v 1/v 1/v 
1/v [S]/v 1/v 
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 [I] 
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 [I] 
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1/[S] 
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 [I] 
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 [I] 
decreasing [S] 
decreasing [S] 
 [I] 
[S]/v 
 [I] 
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1/[S] 
decreasing [I] 
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1.4.5 Bi Bi mechanism  
 
IDH requires NAD+ and myo-inositol as its two substrates, and yields 
2-keto-myo-inositol (also called as scyllo-inosose or inosose) and NADH as the two 
products. This enzymatic reaction is named as a Bi Bi reaction82, as shown in 
Equation 1.2,  
A + BH + E AH + B + E Equation 1.2 
in which A and BH represent substrates, AH and B represent products, and E 
represents an enzyme. This kind of reaction is classified into three mechanisms on the 
basis of the binding order of substrates and the release order of products, named as 
random ordered, compulsory ordered, and Ping-Pong Bi Bi mechanism (Scheme 1.1). 
 
E + A E A E A BH E AH B E AH
BH
B
E + AH  
(a) 
 
E + A
E + BH
E A
E A BH E AH B
E AH
A
BH
E BH
E B
AH
B
E + B
E + AH  
(b) 
 
E + BH E BH EH EH EH A E AHB
B A
E + AH  
(c) 
 
Scheme 1.1 The diagrams of Bi Bi mechanisms. a: compulsory ordered Bi Bi mechanism, b: random 
ordered Bi Bi mechanism, c: Ping-Pong Bi Bi mechanism. 
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Ordered and Ping-Pong Bi Bi mechanisms can be distinguished by double reciprocal 
plots. That is, the reaction velocity over a range of one substrate concentrations at 
several, fixed concentration of the other substrate and the resulting data is plotted as 
1/v vs 1/[substrate]. If the plots display a set of lines that converge to the left of the y 
axis, it means the reaction involves ternary complex formation, and follows an ordered 
Bi Bi mechanism. On the other hand, if the plots display a set of parallel lines, it means 
the reaction follows Ping-Pong Bi Bi mechanism. Unfortunately, it is not possible to 
further distinguish between compulsory and random ordered mechanism with the 
double reciprocal plot. Two methods, dead end inhibition and product inhibition, can 
be utilized to identify random ordered and compulsory ordered mechanism82. The 
patterns are summarized in Table 1.3 and Table 1.4. By measuring the initial velocity 
of the reaction in the presence of several concentrations of competitive inhibitor or 
product, and varying the concentration of substrates A and BH, the reaction 
mechanism can be diagnosed by reference to the corresponding table. 
 
The oxidation-reduction reaction catalyzed by B. subtilis IDH obeys a compulsory 
ordered Bi Bi mechanism, which was identified by product inhibition65,69, in which 
NAD+ binds first, and then inositol binds to form a ternary complex. After reaction, 
2-keto-myo-inositol is released first, and NADH is the last one to be released (as 
shown in Scheme 1.1a, in which, E: IDH; A: NAD+; BH: myo-inositol; B: 
2-keto-myo-inositol; AH: NADH.). 
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Table 1.3 Pattern of product inhibition observed for Equation 1.2 for differing kinetic mechanisms. 
  Varied [BH]  Varied [A] 
Bi Bi mechanism Product used 
as inhibitor 
Unsaturated  
[A] 
Saturated  
[A] 
 Unsaturated  
[BH] 
Saturated  
[BH] 
Compulsory ordered 
with BH binding first 
B Mixed Uncompetitive  Mixed Mixed 
Compulsory ordered 
with BH binding first 
AH Competitive Competitive  Mixed No inhibition 
Compulsory ordered 
with A binding first 
B Mixed No inhibition  Competitive Competitive 
Compulsory ordered 
with A binding first 
AH Mixed Mixed  Mixed Uncompetitive 
Random ordered B Competitive No inhibition  Competitive No inhibition 
Random ordered AH Competitive No inhibition  Competitive No inhibition 
Ping-Pong B Mixed No inhibition  Competitive Competitive 
Ping-Pong AH Competitive Competitive  Mixed No inhibition 
29 
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Table 1.4 Pattern of dead-end inhibition observed for Equation 1.2 for differing kinetic 
mechanisms. 
Bi Bi mechanism Competitive 
inhibitor  
for substrate 
Varied  
[BH] 
Varied  
[A] 
Compulsory ordered 
with BH binding first 
BH Competitive Mixed 
Compulsory ordered 
with BH binding first 
A Uncompetitive Competitive 
Compulsory ordered 
with A binding first 
BH Competitive Uncompetitive 
Compulsory ordered 
with A binding first 
A Mixed Competitive 
Random ordered BH Competitive Mixed 
Random ordered A Mixed Competitive 
Ping-Pong BH Competitive Uncompetitive 
Ping-Pong A Uncompetitive Competitive 
 
 
1.4.6 Catalytic residues identification 
 
Daniellou78 constructed a homology model of IDH which is mentioned in 1.4.2. On the 
basis of the sequence alignment of IDH and GFOR (Figure 1.11), the residues His176 
and Asp172 of IDH, corresponding to the catalytic residues Tyr269 and Asp265 of 
GFOR, were proposed as a catalytic dyad. His176 is the acid/base involved in proton 
transfer with the axial hydroxyl group of myo-inositol and Asp172 likely participates 
in this reaction in a secondary manner, as shown in Figure 1.16. The fact that mutant 
H176A leads to a 2000-fold decrease and mutant D172N leads to 5-fold decrease in 
activity strongly supports the catalytic dyad proposal78. A similar catalytic mechanism 
has been proposed for other dehydrogenases, such as glucose 6-phosphate 
dehydrogenase84 and 1,5-anhydro-D-fructose reductase85. 
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Figure 1.16 The proposed catalytic mechanism of IDH. 
 
The chirality of hydride transferred was assigned based on the IDH homology model 
docked with NADH, in which the proposed inositol active site exits in the re face of 
NAD+. The hydride transferred from inositol was assumed to attack from the re face of 
the nicotinamide ring of NAD+, thus the hydride occupies the pro-R position of NADH. 
This hypothesis is consistent with the two facts: first, Alizade et al reported the same 
stereospecific transfer in myo-inositol dehydrogenase from Klebsiella pneumoniae 
which was measured by the assay using [4-3H]-NAD+ and myo-inositol dehydrogenase 
coupled with glutamate dehydrogenase86; Second, pro-R hydride is transferred in 
GFOR and the motif EKP that orient nicotinamide ring of NADP+ binding in GFOR is 
conserved in IDH. 
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1.5 Objectives of research 
 
When I started the work in 2004, B. subtilis IDH gene iolG had been cloned into 
pET-28b (+) in this laboratory. The recombinant protein had been overexpressed69. At 
that time, little was known on this enzyme other than substrate specificity and kinetic 
mechanism65,69.  
 
The aim of this research is to: (1) investigate the reaction mechanism, (2) broaden the 
substrate specificity, (3) study the inhibition property, (4) alter coenzyme/substrate 
specificity, and (5) probe the inositol-IDH interactions. Multiple approaches were 
undertaken by utilizing a combination of techniques in molecular biology, 
enzymology, and organic chemistry. 
 
To begin with, the designed inositol analogues/derivatives were synthesized as 
proposed inhibitors/substrates of IDH since they were not commercially available. 
Once these compounds were obtained, research focused on characterizing inhibition 
property/dehydrogenase activity by steady-state kinetics. 
 
In addition, mutagenesis experiments were carried out to attempt to alter the coenzyme 
specificity and probe inositol-binding site. Three methodologies were employed to 
predict the target amino acid residues including sequence alignment, structure 
alignment, structure-based engineering. Steady-state kinetics was employed to 
characterize the rationally designed mutants  
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2. MATERIALS AND METHODS 
 
2.1 Reagents 
 
QIAprep spin miniprep kit was purchased from Qiagen Inc. QickChange site-directed 
mutagenesis kit and PfuUltra High-Fidelity DNA polymerase were purchased from 
Stratagene. Deoxynucleoside triphosphate (dNTP) mix (10 mM each) was purchased 
from Fermentas. DNA primers used for polymerase chain reactions (PCR) were 
synthesized by Integrated DNA Technologies (IDT). The restriction digestion enzymes 
used in mutagenesis and NDA analysis were purchased from New England Biolabs 
(NEB). Peptone, yeast extract, and agar were purchased from Becton, Dickinson and 
Company (BD). Prestained protein marker (7-175 kDa) and DNA ladder (1kb) were 
purchased from NEB. For kinetic studies, inositol analogues/derivatives were 
synthesized in this laboratory. All the other commercial available chemicals and 
solvents used in molecular biology, kinetic analysis, and chemical synthesis were 
purchased from Sigma-Aldrich Canada, VWR CanLab, or Tokyo Chemical Industry 
(TCI) and were used without further purification unless otherwise stated. 
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2.2 Instrumentation 
 
Distilled, deionized water (ddH2O) was purified by the nanopure diamond ultrapure 
water systems. All the sterile reagents were prepared using a VWR AccuSterilizer 
AS12. The Innova 4230 refrigerated incubator shaker and Innova 43 Large-Capacity 
Incubator Shaker were used to incubate bacterial cultures. The Beckman-Counter 
microfuge 18 and 22R centrifuges and the Beckman J2-HS centrifuge with 
JLA-10.500 and JA-25.50 rotors were used for DNA purification, cell harvesting, and 
protein preparation. Virsonic 600 ultrasonic cell disrupter was used for crude protein 
preparation. HiTrap Chelating HP columns purchased from GE Healthcare were used 
for protein purification. The BioCAD® Sprint Perfusion Chromatography system was 
used for large scale protein purifications. Spectra/Por 7 (MWCO: 25 kD) protein 
dialysis membrane was purchased from Spectrum Laboratories, Inc. BIO-RAD 
mini-protean 3 and sodium dodecyl sulphate-polyacrylamide gel electrophoresis (10% 
SDS-PAGE, stained with Coomassie blue) were used for protein analysis. BIO-RAD 
sub-cell GT agarose gel electrophoresis system and 1% agarose gel (visualized by 
ethidium bromide) were used for DNA electrophoresis. A Nanodrop ND-1000 
spectrophotometer was used to measure DNA concentrations. Gene amplifications 
were performed using an Eppendorf gradient thermocycler Polymerase chain reaction 
machine. Water bath purchased from Sheldon manufacturing was used to maintain 
restriction digestion temperature. DNA sequencing reactions were performed at the 
DNA Technologies Unit, National Research Council (NRC), Plant Biotechnology 
Institute (PBI), Saskatoon. Spectrophotometric assays were performed with a 
Beckman DU 640 spectrophotometer with a circulating-bath-controlled temperature 
block.  
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Thin layer chromatography (TLC) was performed on Merck precoated Kieselgel 
60F254 silica gel plates (0.25 mm thickness) and visualized by ultraviolet light with 
radiation at 254 nm. If necessary, TLC plates were further developed with 
phosphomolybdic acid-ethanol reagent or 10% sulfuric acid in ethanol reagent 
followed by heating. Flash column chromatography was performed with Merck silica 
gel 60 (230-400 mesh). NMR spectra were collected with a Bruker 500 MHz 
spectrometer. Chemical shifts were reported on the δ scale in parts per million (ppm) 
and were referenced to the corresponding deuterated solvents. Melting points were 
measured on a Gallenkamp melting point apparatus and were uncorrected. 
Experiments that required anhydrous conditions were performed under an inert 
atmosphere of dry argon gas. Glassware was dried in the oven set at 120 C and 
assembled under a stream of dry argon gas. The anhydrous solvents were dried by 
distillation under argon from an appropriate drying agent prior to use. For example, 
dry CH2Cl2, Et2O were distilled over calcium hydride; dry toluene and THF were 
distilled over sodium and benzophenone; dry CCl4 was dried over CaCl2 and distilled.  
 
2.3 Media and plates 
 
Luria-Bertani (LB) medium was used to grow E. coli cells. One liter of LB medium 
contained 10 g of peptone, 5 g of yeast extract and 10 g of NaCl and the pH was 
adjusted to 7.5. After autoclaving, the media was stored at 4C.  
 
LB plates were prepared with the same components as well as 15 g/L agar. When the 
autoclaved medium cooled down to about 60C, kanamycin was added as the antibiotic 
(final concentration was 50 g/mL). The sufficiently mixed medium was poured into 
the sterile plates. These plates were stored at 4C after cooling down to room 
temperature.  
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2.4 Plasmids, bacterial strains and growth conditions 
 
The gene iolG from operon iolABCDEFGHIJ in Bacillus subtillis was cloned into 
pET-28b previously in this laboratory69. All the iolG mutants were generated using 
wild-type recombinant plasmid as their template during polymerase chain reactions, in 
the other words, mutated iolG genes were also housed in pET-28b. E. coli XL1-Blue 
and BL21-Gold (DE3) were used as the host strain for the mutated plasmid 
construction and protein expression respectively. The E. coli strains harbouring the 
corresponding plasmids were routinely grown in LB medium with 50 g/ml 
kanamycin at 37C.   
 
 
 
 
2.5 Molecular biology techniques 
 
2.5.1 DNA isolation and purification 
 
LB medium (5 mL) containing 50 g/ml kanamycin was inoculated with a colony 
from XL1-Blue plate and grown overnight. The resulting pellets were harvested by 
centrifugation. The plasmid DNA was isolated by QIAprep miniprep kit following the 
manufacturer's protocol. The procedure is based on the alkaline lysis of bacterial cells 
followed by adsorption of DNA onto silica gel in the presence of high concentration 
of salt. The concentration of a DNA sample was measured using a nanodrop 
spectrophotometer based on the absorption at 260 nm.  
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2.5.2 Polymerase chain reaction (PCR) 
 
Standard PCR methodology87 was used in mutagenesis. The 50 l reactions were 
performed, which included: 40 L of sterile dd H2O; 5 L of 10 × PCR reaction buffer 
(200 mM Tris-HCl, pH 8.8; 100 mM KCl; 100 mM (NH4)2SO4; 20 mM MgSO4; 1% 
Triton X-100; 1 mg/mL BSA); 1l of DNA template (30-50 ng/l); 1.5 L of forward 
primer (100 ng/l); 1.5 L of reversed primer (100 ng/l); 1L of dNTP (10 mM of 
dATP, dTTP, dCTP, dGTP); and 1L of DNA polymerase. The thermocycler program 
was as follows: 1. denaturation at 95C for 30 seconds; 2. annealing at 55C or 53C for 
1 minute; 3. extention at 72C (PfuUltra High-Fidelity DNA polymerase) or 68C 
(PfuTurbo DNA polymerase) for 13 minutes. 4. repeating 17 cycles from 1 to 3; 5. 
final extension at 72C or 68C for 10 minutes. In the temperature program, double 
stranded DNA template was denatured to single stranded DNA. Short complementary 
piece of DNA (the primers) annealed to the complementary sequence of the single 
stranded fragments of DNA (template) upon coding. The 3'-end of the primers were 
used by DNA polymerase to synthesize a new DNA strand in the extension part. 
 
 
2.5.3 Site-directed mutagenesis 
 
The QuikChange Site-Directed Mutagenesis Kit was first used for introducing specific 
mutations. And then PfuUltra High-Fidelity DNA polymerase, dNTP mix, and Dpn1 
restriction enzyme were bought separately. Complementary primers were designed 
with the mutated nucleotides in the middle region, and appropriate GC content (GC%) 
and melting temperature (Tm). All of the primers used are listed in Table 2.1. The 
oligonucleotide primers, each complementary to opposite strands of the template, were 
extended during thermocycler of PCR. The amplification product was then digested at 
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37C with restriction enzyme Dpn1 which is specific for methylated and 
hemimethylated DNA and is used to digest the parental DNA template. This digestion 
did not affect the synthesized DNA containing the mutation. The more details about 
mechanism and procedure of this mutagenesis can be found in QuickChange 
Site-Directed Mutagenesis Kit instruction manual. After digestion, the nicked DNA 
containing the desired mutations was transformed into XL1-Blue competent cells for 
propagation. The QIAprep Miniprep kit was used for purification of the plasmid DNA. 
For the mutants with restriction sites designed in the primers, restriction analysis was 
performed on the plasmids with corresponding restriction enzymes. 
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Table 2.1 Primers used in site-directed mutagenesis. wt: wild-type; For each mutant, the first primer is forward, and the second primer is reverse. Red italic 
bases are mutated sites, bases underlined are restriction sites (some are created with silent mutations). Italic letters in red are mutated sites; Underlined letters 
are restriction sites. 
Primers Sequence (5' to 3') Template Substitution Restriction 
enzyme 
GTCATCAATGCTGAAATCTATGTTAACTGTAAATTCGGCTATGAC Y233F 
GTCATAGCCGAATTTACAGTTAACATAGATTTCAGCATTGATGAC 
wt IDH G687T,  
A698T 
Hpa1 
GCTGAAATCTATGTTAACTGTAAATACGGCTTTGACATTCAATGTG Y235F 
CACATTGAATGTCAAAGCCGTATTTACAGTTAACATAGATTTCAGC 
wt IDH G687T,  
A704T 
Hpa1 
CGTCATCAATGCTGAAATCTATGTTAACTGTAAACGCGGCTATGAC Y233R 
GTCATAGCCGCGTTTACAGTTAACATAGATTTCAGCATTGATGACG 
wt IDH G687T, 
TA697CG 
Hpa1 
GTGAACTGTAAATACGGCCGTGACATTCAATGTGAAATC Y235R 
GATTTCACATTGAATGTCACGGCCGTATTTACAGTTCAC 
wt IDH 
 
TA703CG 
 
Eae1 
GCCTTGTTCAGGTCGGCTTCGCGCGCCGTTATGAC M126A 
GTCATAACGGCGCGCGAAGCCGACCTGAACAAGGC 
wt IDH A366G 
AT376GC 
ECoN1 
GCCTTGTTCAGGTCGGCTTCTCGCGCCGTTATGAC M126S 
GTCATAACGGCGCGAGAAGCCGACCTGAACAAGGC 
wt IDH A366G, 
AT376TC 
ECoN1 
CGGAAATTGTAGCTGTAACGTCTGTTAACCAAGAAGCTGC D35S 
GCAGCTTCTTGGTTAACAGACGTTACAGCTACAATTTCCG 
wt IDH GA103TC, 
T111C 
Hpa1 
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CGCTTGTTCATGAAATTAACGTTCTCCACTGGC D179N 
GCCAGTGGAGAACGTTAATTTCATGAACAAGCG 
wt IDH G535A, 
G540T 
Acl1 
GGAACTGGAGCGATCGCAAAAGAACATATTAACCG G14A 
CGGTTAATATGTTCTTTTGCGATCGCTCCAGTTCC 
wt IDH A36G, 
G41C 
ASiS1 
 
GGAACTGGAGCGATCGCAAAAGAACATATTAACCG G14A/D35S 
CGGTTAATATGTTCTTTTGCGATCGCTCCAGTTCC 
D35S A36G, 
G41C 
ASiS1 
CTGTAAATTCGGCTTTGACATTCAATGTG Y233F/Y235F 
CACATTGAATGTCAAAGCCGAATTTACAG 
Y233F A704T 
GCTTTGTCGCTGCGTTTGATGTGGAAATCC Y280F 
GGATTTCCACATCAAACGCAGCGACAAAGC 
wt IDH A839T 
GCACTGATATTTTGATGGATGCGCAGAGACGCTTTGTCGC W272A 
GCGACAAAGCGTCTCTGCGCATCCATCAAAATATCAGTGC 
wt IDH TG814GC 
CACTGATATTTTGATGGATCACCAGAGACGCTTTGTCGCTGC W272H 
GCAGCGACAAAGCGTCTCTGGTGATCCATCAAAATATCAGTG 
wt IDH 
 
TGG814CAC 
CAGAAATATGTGTTCTGTGAAGTACCGCTCGCGACAACGGC K97V 
GCCGTTGTCGCGAGCGGTACTTCACAGAACACATATTTCTG 
wt IDH 
 
AA289GT 
40 
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GAAATATGTGTTCTGTGAACAACCGCTCGCGACAACGGC K97Q 
GCCGTTGTCGCGAGCGGTTGTTCACAGAACACATATTTC 
wt IDH 
 
A289C 
GAAATATGTGTTCTGTGAAAGACCGCTCGCGACAACGGC K97R 
GCCGTTGTCGCGAGCGGTCTTTCACAGAACACATATTTC 
wt IDH 
 
A290G 
CACTGCGCGCACCGCCGCCCGACTGTAGGAG N157R 
CTCCTACAGTCGGGCGGCGGTGCGCGCAGTG 
wt IDH 
 
AA469CG 
 
CTGCGCGCACCGCAGCCCGACTGTAGGAG N157S 
CTCCTACAGTCGGGCTGCGGTGCGCGCAG 
wt IDH 
 
A470G 
CTCTTATGATTCACTGCGCGAAGCGCAACCCGACTGTAGGAG H155K 
 CTCCTACAGTCGGGTTGCGCTTCGCGCAGTGAATCATAAGAG 
wt IDH 
 
CAC463AAG 
CTCTTATGATTCACTGCGCGTTCCGCAACCCGACTGTAGG H155F 
CCTACAGTCGGGTTGCGGAACGCGCAGTGAATCATAAGAG 
wt IDH CA 463TT 
GGCGTAATTGGAACTAAAGCAATCGGAAAAGAAC G11K/D35S 
GTTCTTTTCCGATTGCTTTAGTTCCAATTACGCC 
D35S GG31AA 
GTAGCTGTAACGTCTCGTAATCAAGAAGCTGCAC D35S/V36R 
GTGCAGCTTCTTGATTACGAGACGTTACAGCTAC 
D35S GT106CG 
41 
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GGCGTAATTGGAACTAAAGCAATCGGAAAAGAAC G11K/D35S/V
36R 
GTTCTTTTCCGATTGCTTTAGTTCCAATTACGCC 
D35S/V36R GG31AA 
GGCGTAATTGGAACTGGAAAAATCGGAAAAGAAC A12K/D35S 
GTTCTTTTCCGATTTTTCCAGTTCCAATTACGCC 
D35S GC34AA 
GGCGTAATTGGAACTGGAAAAATCGGAAAAGAAC A12K/D35S/V
36R GTTCTTTTCCGATTTTTCCAGTTCCAATTACGCC 
D35S/V36R GC34AA 
CGTCTGTTAACCAAGAAAAGGCACAAAAGGTCGTTGAGC D35S/A40K 
GCTCAACGACCTTTTGTGCCTTTTCTTGGTTAACAGACG 
D35S GCT118AAG 
GCCATCAAGCATCAGCTTGCAAAAAGAAGGCAGATTCAGC R259Q 
GCTGAATCTGCCTTCTTTTTGCAAGCTGATGCTTGATGGC 
wt IDH AG775CA 
GATTCACTGCGCGCACCAGAACCCGACTGTAGGAG R156Q 
CTCCTACAGTCGGGTTCTGGTGCGCGCAGTGAATC 
wt IDH GC467AG 
 
GCCATCAAGCATCAGCTTGGCAAAAGAAGGCAGATTCAGC R259A 
GCTGAATCTGCCTTCTTTTGCCAAGCTGATGCTTGATGGC 
wt IDH AG775GC 
GCCATCAAGCATCAGCTTGGAAAAAGAAGGCAGATTCAGC R259E 
GCTGAATCTGCCTTCTTTTTCCAAGCTGATGCTTGATGGC 
wt IDH AG775GA 
42 
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GCCATCAAGCATCAGCTTGTACAAAGAAGGCAGATTCAGC R259Y 
GCTGAATCTGCCTTCTTTGTACAAGCTGATGCTTGATGGC 
wt IDH AGA775TAC 
 
GCCATCAAGCATCAGCTTGGCAAAAGAAGGCAGATTCAGC Y233R/R259A 
GCTGAATCTGCCTTCTTTTGCCAAGCTGATGCTTGATGGC 
Y233R AG775GC 
GCCATCAAGCATCAGCTTGGAAAAAGAAGGCAGATTCAGC Y233R/R259E 
GCTGAATCTGCCTTCTTTTTCCAAGCTGATGCTTGATGGC 
Y233R AG775GA 
GCCATCAAGCATCAGCTTGCAAAAAGAAGGCAGATTCAGC Y233R/R259Q 
GCTGAATCTGCCTTCTTTTTGCAAGCTGATGCTTGATGGC 
Y233R AG775CA 
GCCATCAAGCATCAGCTTGTACAAAGAAGGCAGATTCAGC Y233R/R259Y 
GCTGAATCTGCCTTCTTTGTACAAGCTGATGCTTGATGGC 
Y233R AGA775TAC 
CGTCTCGTAATCAAGAAAAGGCACAAAAGGTCGTTGAG D35S/V36R/A
40K 
CTCAACGACCTTTTGTGCCTTTTCTTGATTACGAGACG 
D35S/V36R GCT118AAG 
CGTCTCGTAATCAAGAACGTGCACAAAAGGTCGTTG D35S/V36R/A
40R CAACGACCTTTTGTGCACGTTCTTGATTACGAGACG 
D35S/V36R GC118CG 
43 
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2.5.4 Restriction digestions 
 
Colonies visible on the plates were used to inoculate separate test tubes containing 5 
mL of LB with kanamycin. These cultures were allowed to incubate overnight. 
Plasmids were extracted in the same manner as 2.5.1 and subjected to a corresponding 
digest [tipically 8 L plasmid (about 400 ng), 1 L digest enzyme (500 units), 1 L 
digest buffer, 37C, 1 h, or follow corresponding instruction]. The conditions were 
performed according to the instruction with the enzymes. The resulting mutant digests 
were loaded onto a 1% agarose gel along with digested wild-type IDH plasmid. The 
digests were electrophoresed at 110V and visualized with ethidium bromide under UV 
light. The expected results (shown in Appendix 1) were calculated on the basis of the 
restriction map generated with online program NEB cutter 
(http://tools.neb.com/NEBcutter2/index.php). 
 
 
 
2.5.5 Transformation  
 
The competent cells XL1-Blue or BL21-Gold were prepared using the CaCl2 
method150. Competent cells were inoculated in 5 mL of LB medium containing 50 
g/mL of tetracycline at 37C overnight. Overnight culture (5 L) was transferred to 
50 mL of LB medium with 50 g/mL tetracycline. The culture was incubated at 37C 
until the optical density (O.D.) at 595 nm reached 0.4, and then the cells were 
harvested by centrifugation. The pellet was resuspended in 20 mL of transformation 
buffer (25 mM Tris, 50 mM CaCl2, pH 7.5) and incubated on ice for 30 min. The 
resuspended cells were centrifuged again and the pellet was resuspended in 1 mL of 
transformation buffer. The resulting cells were aliquoted into 100 L and were ready 
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to perform transformation. The unused competent cell aliquots were supplemented 
with glycerol (final concentration: 15%) and were stored at -80C. 
 
Competent cells (100 L) were transferred into a pre-chilled 14 mL Falcon 
polypropylene round bottom tube. Plasmid (1 L) from Miniprep (2.5.1) or PCR (2.5.3) 
mixture was added and the solution was incubated on ice for 30 minutes. The tube was 
heat-shocked in a 42C water bath for 45-60 seconds. After heat shock, the solution 
was incubated on ice for 2 minutes and 1 mL of preheated LB medium without any 
antibiotics was added. The medium was incubated at 37C with shaking at 250 rpm for 
1 h. After incubation, 50-500 L of the transformation mixture was spread on a LB 
agar plate with kanamycin. The plates were incubated at 37C overnight to allow 
colonies grow.  
 
 
 
2.6 Protein expression and purification 
 
2.6.1 Overexpression of wild-type IDH and mutants 
 
The iolG or mutated iolG pET-28b recombinant plasmids were isolated from 
XL1-Blue cells and transformed into BL21-Gold (DE3) cells which were used as the 
host for protein expression. The transformed cells were streaked on an agar plate with 
50 g/mL of kanamycin and incubated at 37C overnight. A single colony picked from 
the plate was incubated in 5 mL of LB medium containing 50 g/mL of kanamycin at 
37C overnight. 50 µL of the overnight culture was transferred into 50 mL of LB 
medium containing 50 µg/mL of kanamycin and kept shaking at 37˚C at 250 rpm until 
OD595 was about 0.5. The protein overexpression was induced by addition of isopropyl 
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β-D-thiogalactoside (IPTG, final concentration is 1 mM). After induction, the culture 
was incubated for three more hours. Cells were harvested by centrifugation and stored 
at -20˚C for purification. 
  
 
2.6.2 Purification of wild-type IDH and mutants 
 
Proteins (wild-type IDH or mutants) were purified from the bacterial extracts by using 
a HiTrap chelating HP column. Frozen cell pellets (2.6.1) from 50 mL of LB medium 
were thawed on ice and resuspended in 2.5 mL of binding buffer (20 mM Tris, 500 
mM NaCl, 5 mM imidazole, 10% glycerol, pH 7.9), then lysed by sonication for 4 × 
20 s (2 s on and 3 s off) on ice with the sonicator setting at level 3. The supernatant 
was separated from cell debris by centrifugation for 10 minutes at 4˚C and filtered 
through 0.45 µm membrane. The supernatant was loaded onto the 1 mL HiTrap 
chelating HP column, which had been rinsed with 5 mL of charging buffer (50 mM 
NiSO4, pH 4.0) and 3 mL of binding buffer. After the protein was loaded, the column 
was washed with 4 mL of binding buffer followed with 4 mL of washing buffer (20 
mM Tris, 500 mM NaCl, 60 mM imidazole, 10% glycerol, pH 7.9). The protein was 
then eluted with 9 mL of eluting buffer (1:1 v/v of binding buffer and strip buffer). The 
column was stripped with 6 mL of strip buffer (100 mM EDTA, 500 mM NaCl, 20 
mM Tris, 10% glycerol, pH 7.9). The purity of the resultant fraction of protein was 
verified by 10% SDS-PAGE88 in which target protein exhibited a molecular weight of 
approximately 40 kDa. The pure protein was combined and dialyzed against 50 mM 
phosphate buffer (1 L), pH 6.5, containing 50% (v/v) glycerol and 0.1 mM 
DL-dithiothreitol (DTT), and stored at -20˚C. 
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2.6.3 Protein concentration assay 
 
The purified protein concentration was determined by absorbance assay at 280 nm. 
Due to the presence of aromatic amino acids, mainly tyrosine and tryptophan, protein 
in solution absorbs UV light at the wavelength of 280 nm. The extinction coefficient (ε) 
of a protein at 280 nm can be predicted based on its amino acid composition 
(http://ca.expasy.org/tools/protparam.html) although an extinction coefficient can be 
affected by other factors, like pH, temperature, and ionic strengths. According to the 
Beer-Lambert law, protein concentration could be calculated as C = A280/(ε280 L). The 
protein solution was diluted two times to perform the same measurement, and the 
average concentration value is the final concentration used in kinetic studies.  
 
 
2.7 Sequence analysis 
 
Multiple sequence alignment was generated using ClustalW 2 multiple sequence 
alignment at EBI (http://www.ebi.ac.uk/Tools/clustalw2/index.html) utilizing default 
parameters (Gonnet scoring matrix, gap open penalty = 10, gap extension penalty = 
0.2). When generating structural based sequence alignment, DaliLite Pairwise 
comparison of protein structures online programme 
(http://www.ebi.ac.uk/Tools/dalilite/index.html) was used to superimpose the 
structures of homologous enzymes, and then structural based sequence alignment was 
performed utilizing software SEQUOIA 
(http://rotatingpenguin.com/sequoia/index.html), which is used for the superposition 
of homologous protein atomic coordinates. The aligned sequences of both sequence 
alignment and structure based sequence alignment were visualized by using ESPript 
2.2 (http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi). 
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2.8 Kinetic assays 
 
2.8.1 Kinetic measuring system 
 
As mentioned in 1.4.1, the pH dependence of the reactions catalyzed by IDH was 
characterized in 1979 by Ramaley et al65. Optimum activity for the oxidation reaction 
from myo-inositol to 2-keto-myo-inositol was observed at pH 9.5 in a 100 mM 
Tris-HCl buffer, and for the reverse reaction, the optimum activity was observed at pH 
7.0 in HEPES buffer. All the kinetic assays in this dissertation were measured in the 
oxidation reaction, and 100 mM Tris-HCl at pH 9.0 was used as a reaction buffer.  
 
Kinetic assays were performed in cuvettes with total reaction volume of 1 mL. 
Reaction progress was monitored spectrophotometrically at 340 nm by detecting the 
formation of NADH or NADPH (340 = 6220 M-1 cm-1) with measurements taken at 
10/15-second intervals. The spectrophotometer was blanked using corresponding 
assay solution and then the reaction was initiated by adding either IDH or 
myo-inositol. The measured data from spectrophotometer was converted into a 
Microsoft Excel file using DU600/700 file utility software (version 1.0), and then 
generated absorbance versus time plots to calculate initial velocity. 
 
 
2.8.2 Measurement of initial velocity 
 
During the steady-state period the product concentration increases linearly with time. 
The rate of the appearance of product is called the initial velocity (v0) of the reaction. 
The initial velocity phase typically persists for several seconds to several hundred 
seconds. This duration depends upon many factors, such as the equilibrium constant, 
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the fractional saturation of the enzyme with substrates and products, the buffering 
capacity of medium, and the concentration ratio of the least abundant substrate relative 
to the enzyme. A reliable initial velocity measurement is important for achieving a 
faithful analysis of an enzymatic reaction.  
 
One set of kinetic experiments was used to explain the measurement of initial velocity. 
For example, when IDH, 0.5 mM of NAD+, and 80 mM of myo-inositol were mixed 
together in Tris-HCl buffer at pH 9.0, the accumulation of product (NADH) was 
measured at 340 nm over time. A graph of A340 versus time was obtained (Figure 2.1) 
and was used to calculate initial velocity. In this kind of graph, at very early time 
points, the product concentration increases linearly with time. At later time, the curve 
starts to level off. Eventually the concentration of product reaches a plateau and does 
not change with time. In Figure 2.1, first 90 seconds was almost linear and used to 
calculate the initial velocity using equation v0 = slope/(ε×l) =ΔA340 ÷ (Δt × ε340 × l), in 
which ε340 = 6220 M-1cm-1, l = 1 cm, ΔA340 and Δt were measured, so v0 = 0.1654 ÷ (90 
s × 6220 M-1cm-1 × 1 cm) = 2.955 × 10-7 M·s-1 = 1.773 × 10-5 M·min-1. Velocity was 
expressed in terms of molarity changes per unit time.   
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Figure 2.1 A sample of A340 vs time graph. 
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2.8.3 Apparent Km ( appmK ) and kcat determination  
 
E + S ES E P+
k1
k-1
k2
           
Scheme 2.1 A general scheme for one-substrate enzymatic reaction. E: enzyme; S: substrate; ES: the 
complex of enzyme and substrate; P: product; k1: association constants of ES; k-1, k2: dissociation 
constants of ES.  
 
In general, the single substrate enzyme catalyzed reaction or the reaction can be 
simplified as Scheme 2.1, the relationship between substrate concentration and reaction 
rate can be expressed by Michaelis-Menten equation: 
][
][max
0 SK
SVv
m 
       
in which, maximum velocity Vmax = k2[E]; Michaelis constant Km = (k2 + k-1)/k1 and is 
equivalent to the substrate concentration at which V0 is one-half of Vmax. When k2 is 
rate-limiting, k2 << k-1 and Km reduces to k-1/k1, which is defined as the dissociation 
constant. Therefore, Km is an indication of the affinity of the enzyme with the substrate. 
The lower the Km, the higher is the affinity. 
 
IDH is a two-substrate enzyme, and Km was measured when NAD+ was saturated (50 
mM, Km = 80 m), consequently, the resulting Michaelis constant was an apparent Km 
( appmK ). To measure
app
mK , initial velocities were calculated at varied concentrations (5, 
10, 20, 40, 80, 160, 320 mM) of inositol and the data points ([S] and v0) were fitted to 
the Michaelis-Menten equation using Leonara software83. A saturation curve was 
generated as shown in Figure 2.2, and appmK  and Vmax values were obtained. 
 
The turnover number, kcat, which defines how fast the enzymatic reaction takes place, 
represents the number of substrate molecules converted to product in a given unit of 
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time on a single enzyme molecule when the enzyme is saturated with substrate, is 
calculated by equation kcat = 
0
max
][E
V  (kcat is equal to k2 in Michaelis-Menten equation). 
The ratio kcat/Km, the specificity constant, a second order rate constant, is a measure of 
how good the enzyme is at its catalysis. A high specificity constant means a reaction 
goes fast (kcat is high) and the enzyme does not need a high concentration of the 
substrate (Km is small). From the free energy point of view, the specificity constant 
relates to the activation energy (ΔGES‡). When the enzyme can catalyze different 
substrates, the substrate demonstrates highest specificity constant is the preferred 
substrate for the enzyme. The top value range for this value is 108-109 M-1s-1 due to the 
diffusion limit.   
 
K m = 19 mM,  V max = 34 mol/(min mg)
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Figure 2.2 A saturation curve in which the velocity increases with the increase of substrate 
concentration until approaches a maximum velocity Vmax. Empty square (□) represents measured 
data points. appmK  = 19 mM; Vmax = 34 mol· min-1 ·mg-1. 
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2.8.4 IC50 and Ki determination 
 
Inositol analogues were designed as the potential competitive inhibitors, which 
competed with inositol for active site to form an EI complex but without leading to 
products. In the presence of a competitive inhibitor, Vmax can still be reached if 
sufficient substrate is available; one-half Vmax requires a higher [S] than in the absence 
of inhibitor and thus Vmax is same as before and appmK  is larger.  
 
When a competitive inhibitor is present in the enzymatic reaction, the 
Michaelis-Menten equation becomes,  
 
][][1
][max
S
K
IK
SVv
i
m
i



 
  
In which, vi is initial velocity in the presence of an inhibitor; [I] is the concentration of 
inhibitor; Ki is dissociation constant of complex EI. 
 
IC50 represents the inhibitor concentration at which 50% enzyme activity is inhibited, 
so when [I] = IC50, vi = 2
1  v0, after rearrangement, 
 
m
i
K
S
ICK ][1
50

                         Equation 2.1 
since [S] is fixed during the kinetic assay and Km can be measured as mentioned in 
2.7.3.  If IC50 is known, Ki can be calculated using Equation 2.189. 
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Figure 2.3 Inhibitory property plots of 2-deoxy-2,2-difluoro-myo-inositol. a) vi/v0 vs [I] plot. b) v0/vi 
vs [I] plot. Empty triangle (Δ) represents the measured data points; [I] represents the concentration of 
compound 2-deoxy-2,2-difluoro-myo-inositol. 
a 
b 
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In this dissertation, all the inhibition experiments were performed under the same 
conditions. The assay mixture contained about 2 g/mL of IDH, 0.5 mM of NAD+, 20 
mM of myo-inositol and four to six varied concentrations of inhibitors in 100 mM 
Tris-HCl buffer at pH 9.0, and a total volume of 1 mL. The kinetic assays were 
performed at 25˚C for 10 min. Before the oxidation reactions were initiated, inhibitors 
were incubated with IDH for 5 min at room temperature. The inhibitory properties 
were determined by measuring the initial velocities in the absence and in the presence 
of various concentrations of inhibitors with the fixed 20 mM inositol. An inhibitor 
2-deoxy-2,2-difuoro-myo-inositol is used as an example here, 0, 10, 25, 50, 100 mM 
of 2-deoxy-2,2-difuoro-myo-inositol were incubated with IDH in the presence of 0.5 
mM NAD+ in Tris-HCl buffer for 5 min at room temperature, and then myo-inositol 
was added to initiate the reaction (final concentration was 20 mM) and the formation 
of NADH was monitored at 340 nm. After the calculation of initial velocities, 
inhibitory activity (vi/v0) was plotted against concentrations of inhibitor (Figure 2.3 a). 
IC50 was calculated by plotting reciprocal of inhibitory activity (vo/vi) against 
concentrations of the inhibitor (Figure 2.3 b). When y = v0/vi = 2, x = [I] = IC50= 82 
mM. According to Equation 2.1, Ki = 82/(1+ 20/18) = 39 mM. 
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2.8.5 Km (myo-inositol ) and Km (NAD+/NADP+) determination  
 
As mentioned in 1.4.5, the IDH catalyzed reaction follows a compulsory ordered Bi Bi 
mechanism, which is shown in Scheme 1.1a. The initial velocity equation of steady 
state for such kind of reaction is given in Equation 2.282 
 
]][[][][
]][[max
BHABHKAKKK
BHAVv
mAmBHmBHiA 
      Equation 2.2 
where [A] is the concentration of the substrate that first binds (NAD+), [BH] is the 
concentration of the second substrate (myo-inositol), KiA is the dissociation constant 
for E·A complex, KmA and KmBH are the respective Michaelis constants for the 
substrates A and BH, and Vmax is the maximum velocity when both substrates are in 
saturating condition. 
 
In this dissertation, Equation 2.2 was used to measure KmA and KmBH. For example, in 
the reaction catalyzed by IDH, Michaelis constants of two substrates NAD+ and 
myo-inositol could be determined by a series of kinetic experiments. Initial velocities 
were measured over a range of concentrations of myo-inositol (10, 20, 40, 80, 120, 200 
mM) at several fixed concentrations of NAD+ (0.1, 0.3, 0.6, 1.0, 2.0 mM) in 100 mM 
Tris-HCl pH 9.0 at 25˚C. These data points ([inositol], [NAD+], v0) were fitted to 
Equation 2.2 using Leonora software83 and the kinetic constants were determined 
(KmA = 0.075 ± 0.007 mM, KmBH = 4.36 ± 0.48 mM, and Vmax = 86 ± 1 
mol·min-1·mg-1). The fitted graphs are shown in Figure 2.4 and Figure 2.5. The 
catalytic constant kcat and the specificity constant kcat/Km were calculated in the same 
way as mentioned in 2.8.3. 
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Figure 2.4 Plot of the variation of velocity with varying myo-inositol concentrations at constant 
NAD+ concentrations: 0.1 mM (  ), 0.3 mM (  ), 0.6 mM (■), 1.0 mM (□), 2.0 mM (▲). 
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Figure 2.5 Plot of the variation of velocity with varying NAD+ concentrations at constant 
myo-inositol concentrations: 5 mM (  ), 10 mM (  ), 20 mM (■), 40 mM (□), 80 mM (▲), 120 mM 
(Δ), 200 mM (×). 
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2.9 Chemical synthesis and compound characterization 
 
O O
O
OH
OH
OH
 
myo-Inositol 1,3,5-monoorthoformate 5  
This compound was made as described in the literature90. 
1H NMR (D2O)  5.47(1H, s), 4.45 (2H, dd, J = 3.5 Hz), 4.20 (1H, m), 4.13 (1H, m), 
4.10 (2H, m). 
 
 
 
O O
O
O
OH
OH(±)
 
(±)-4-O-(4-tert-Butyl)benzyl-myo-inositol 1,3,5-monoorthoformate 7 To a solution 
of myo-inositol 1,3,5-monoorthoformate (2.0 g, 10.5 mmol) in 40 mL of DMF was 
added 0.42 g of NaH (60%). The suspension was stirred in ice-water bath for 15 min, 
and then 4-tert-butylbenzyl bromide (1.93 mL, 10.5 mmol) was added with syringe. 
The mixture was warmed to room temperature slowly and stirred overnight. After 
quenching and removing the solvent, the remaining syrup was partitioned between 
water and ethyl acetate. The organic layer was dried over MgSO4 and the solvent was 
removed. The remaining was purified by FCC [ethyl acetate-toluene (2:3)], and the 
product (±)-4-O-(4-tert-butyl)benzyl-myo-inositol 1,3,5-monoorthoformate (2.74 g, 
77%) was obtained as a white solid. 1H NMR (CDCl3) δ 7.40 (2H, d, J = 8.5 Hz), 7.24 
(2H, d, J = 8.5 Hz), 5.45 (1H, s), 4.64 (2H, dd, J = 11.5 Hz), 4.48-4.42 (2H, m), 
4.30-4.26 (2H, m), 4.22 (1H, m), 4.10 (1H, m), 1.33 (9H, s); 13C NMR (CDCl3) δ 
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152.03, 132.75, 128.01, 125.85, 102.75, 74.77, 73.97, 72.85, 72.22, 67.89, 67.25, 
60.74, 34.69, 31.03;  Mass: 336.1567 (EI, MW, calc. 336.1573); m.p. 113-114˚C. 
 
 
  
HO OH
OH
OH
OHO
(±)
 
(±)-4-O-(4-tert-Butylbenzyl)-myo-inositol 2 To a solution of (±)-4-O-tert- 
butylbenzyl-myo-inositol 1,3,5-monoorthoformate (2.67 g, 7.95 mmol) in methanol 
(50 mL) was added Dowex 50X8 (H+, 200-400 mesh). The suspension was stirred 
overnight, and then filtered and washed by water. Methanol in the filtrate was 
removed by vacuum evaporation and then dried by freeze dryer. White solid (2.50 g, 
97%) was obtained. 1H NMR (CD3OD) δ 7.39-7.35 (4H, m), 4.85-4.80 (2H, m), 3.94 
(1H, dd, J = 2.5 Hz), 3.66-3.60 (2H, m), 3.48 (1H, dd, J = 10 Hz, 2.5 Hz), 3.34-3.27 
(2H, m), 1.30 (9H, s); 13C NMR (D2O) δ 150.15, 136.14, 127.76, 124.63, 81.75, 75.07, 
74.50, 73.08, 73.05, 71.98, 71.89, 33.94, 30.42; Mass: 326.1727 (TOF, MW + HCO 2 , 
calc. 371.1706); m.p. 200-201˚C.  
 
 
 
O O
O
O
OH
OH(±)
 
(±)-4-O-Propargyl-myo-inositol 1,3,5-monoorthoformate 8 To the solution of   
myo-inositol 1,3,5-monoorthoformate (2.0 g, 10.5 mmol) in 40 mL of DMF was 
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added NaH (0.42 g, 60%). The suspension was stirred in an ice-water bath for 15 min. 
Propargyl bromide in toluene solution (1.13 mL, ~ 10.5 mmol) was then added 
dropwise. The mixture was warmed to r.t. slowly and stirred overnight. After 
removing the solvent, the remaining syrup was partitioned between water and ethyl 
acetate. The organic layer was dried over MgSO4 and the solvent was removed. The 
residue was purified by FCC [ethyl acetate-toluene (1:1)] to give a yellow oil (1.45 g, 
60%). 1H NMR (CDCl3) δ 5.47 (1H, s), 4.56 (1H, m), 4.47 (1H, s), 4.36 (2H, m), 4.31 
(2H, d, J = 2.5 Hz), 4.21 (1H, m), 4.06 (1H, s), 2.59 (1H, t, J = 2.5 Hz); 13C NMR 
(CDCl3) δ 102.73, 77.91, 76.75, 74.75, 74.64, 72.10, 67.81, 67.39, 60.54, 58.51; Mass: 
229.0715 (TOF, MW + H+, calc. 228.0634). 
 
 
 
HO OH
OH
OH
OHO
(±)
 
(±)-4-O-Propargyl-myo-inositol 3 To a solution of (±)-4-O-propargyl-myo-inositol 
1,3,5-monoorthoformate (1.3 g, 5.7 mmol) in methanol (30 mL) was added Dowex 
50X8 (H+, 200-400 mesh). The suspension was stirred overnight, and then filtered. 
Dowex was washed with water. The filtrate was concentrated and then dried by freeze 
drier. A white solid (1.0 g, 99%) was obtained. 1H NMR (D2O) δ 4.46 (2H, d, J = 2.5 
Hz), 4.01 (1H, m), 3.63-3.56 (3H, m), 3.47 (1H, dd, J = 10 Hz, 2.5 Hz), 3.34-3.30 (1H, 
m), 2.85 (1H, t, J = 2.5 Hz); 13C NMR (D2O) δ 83.21, 82.32, 78.31, 76.37, 74.84, 
74.75, 73.49, 73.30, 62.34; Mass: 236.1130 (TOF, MW + NH4+, calc. 236.1134); m.p. 
156-157˚C.  
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N3
 
Allyl azide91  
This compound was made as described in the literature. 
1H NMR (CDCl3) δ 5.88 (1H, m), 5.31 (2H, m), 3.77 (2H, s). 
 
 
HO OH
OH
OH
OHO
(±)
N N
N
 
(±)-4-O-(1-Allyl-4-methylene-1,2,3-triazole)-myo-inositol 4 (±)-4-O-propargyl-myo- 
inositol (0.5 g, 2.3 mmol) and allyl azide (0.29 g, 3.5 mmol) were dissolved in THF 
(10 mL). While stirring, CuSO4·5H2O aqueous solution (5 mL, 5% mol) and sodium 
L-ascorbate aqueous solution (5 mL, 10% mol) were added. The reaction mixture was 
stirred at r. t. for 24 h, and then the solvent was evaporated. The yellow residue was 
purified by FCC [chloroform-methanol (3:1, v/v) with 5% triethylamine], 
(±)-4-O-(1-allyl-4-methylene-1,2,3-triazole)-myo-inositol (0.49 g, 71%) was obtained 
as a yellow solid. 1H NMR (D2O) δ 7.98 (1H, s), 6.01 (1H, ddt, J = 16.9 Hz, 10.5 Hz, 
5.7 Hz), 5.28 (1H, d, J = 10.3 Hz), 5.15 (1H, d, J = 16.6 Hz), 4.98 (2H, d, J = 5.7 Hz), 
4.87 (2H, dd, J = 14.5 Hz), 3.98 (1H, m), 3.58 (3H, m), 3.43 (1H, dd, J = 10 Hz, 2.8 
Hz), 3.30 (1H, dd, J = 8.9 Hz); 13C NMR (D2O) δ 131.7, 125.6, 119.8, 118.33, 81.7, 
74.32, 72.79, 72.68, 71.38, 71.21, 65.35, 52.89; NOE difference spectrometry 
confirmed the 1,4-disubstituted triazole structure (anti). Irradiation of H1 resulted in 
enhancement of H2, H3, H4, H5, H6, and H7. (Spectrum shown in Appendix 2); Mass: 
300.1193 (TOF, MW-H, calc. 300.1196). 
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(±)-4-O-(1-Allyl-4-methylene-1,2,3-triazole)-myo-inositol 1,3,5-mono-orthoformate 
9 (±)-4-O-Propargyl-myo-inositol 1,3,5-monoorthoformate (2.16 g, 9.47 mmol) and 
allyl azide (1.18 g, 14.21 mmol) were dissolved in THF (30 mL). While stirring, 
CuSO4·5H2O aqueous solution (15 mL, 5% mol) and sodium L-ascorbate aqueous 
solution (15 mL, 10% mol) were added. The reaction mixture was stirred at r. t. for 24 h. 
The solvent was evaporated and the yellow residue was purified by FCC 
[chloroform-toluene (1:1) with 5% triethylamine], (±)-4-O-(1-allyl-4-methylene- 
1,2,3-triazole)-myo-inositol 1,3,5-monoorthoformate was obtained as light yellow oil 
(1.33 g, 45%). 1H NMR (CDCl3) δ 7.58 (1H, s), 6.01 (1H, ddt, J = 17 Hz, 10 Hz, 6 Hz), 
5.44 (1H, s), 5.38 (1H, d, J = 10 Hz), 5.33 (1H, d, J = 17 Hz), 4.99 (2H, d, J = 5.7 Hz), 
4.80 (2H, dd, J = 12 Hz), 4.51 (1H, m), 4.46 (1H, m), 4.29 (2H, m), 4.19 (1H, m), 4.05 
(1H, d, J = 10.5 Hz); 13C NMR (CDCl3) δ 143.41, 130.84, 122.64, 120.81, 102.74, 
74.65, 74.61, 72.12, 67.84, 67.31, 63.85, 60.55, 52.93; Mass: 312.1205 (TOF, MW + H, 
calc. 312.1196). 
 
 
N N
NH
HO OH
OH
OH
OHO
(±)
Cl
 
(±)-4-O-(1-Allyl-4-methylene-1,2,3-triazole)-myo-inositol hydrochloride 4 To a 
solution of (±)-4-O-(1-allyl-4-methylene-1,2,3-triazole)-myo-inositol 1,3,5- 
monoorthoformate (1.30 g, 4.18 mmol) in methanol (30 mL) was added Dowex 50X8 
(H+, 200-400 mesh). The suspension was stirred overnight, and then filtered. Dowex 
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was washed with water. After evaporation, 90 mg (7%) of white solid was obtained. 
The resin was then washed with 1M HCl. The aqueous solution was evaporated to 
dryness. 0.99 g (76%) of (±)-4-O-(1-allyl-4-methylene-1,2,3-triazole)-myo-inositol 
hydrochloride was obtained as a white solid. 1H NMR (D2O) δ 7.97 (1H, s), 5.93 (1H, 
ddt, J = 17 Hz, 10 Hz, 6 Hz), 5.22 (1H, d, J = 10 Hz), 5.11 (1H, d, J = 17 Hz), 4.93 
(2H, d, J = 6 Hz), 4.82 (2H, dd, J = 14.5 Hz), 3.90 (1H, dd, J = 2.3 Hz), 3.48 (3H, m), 
3.35 (1H, dd, J = 10 Hz, 3 Hz), 3.24 (1H, m).  
 
 
S
N Br
 
2-(Bromomethyl)benzothiazole  
This compound was made as described in the literature92. 
1H NMR (CDCl3) δ 8.02 (1H, d, J = 8.0 Hz), 7.87 (1H, d, J = 8.0 Hz), 7.50 (1H, dd, J 
= 8.0 Hz, 7.0 Hz), 7.42 (1H, dd, J = 8.0 Hz, 7.0 Hz), 4.81 (2H, s). 
 
 
O O
O
O
OH
OH
(±)
N
S
 
(±)-4-O-(2-Benzothiazolylmethyloxy)-myo-inositol 1,3,5-monoorthoformate 6 To 
the solution of myo-inositol 1, 3, 5-monoorthoformate (1.10 g, 5.79 mmol) in 40 mL 
of DMF was added NaH (0.23 g, 60%). The suspension was stirred in an ice-water 
bath for 15 min, then 2-(bromomethyl)benzothiazole (1.32 g, 5.79 mmol) was added. 
The mixture was warmed to r. t. slowly and stirred overnight. After removing the 
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solvent, the remaining syrup was partitioned between water and ethyl acetate. The 
organic layer was dried over MgSO4, filtered, and concentrated to a residue that was 
purified by FCC [ethyl acetate-toluene (1:1, v/v)]. (±)-4-O-(2-benzothiazolyl- 
methyloxy)-myo-inositol 1,3,5-monoorthoformate (1.39 g, 71%) was obtained as a 
yellow solid. 1H NMR (CDCl3) δ 8.04 (1H, d, J = 8.5 Hz), 7.91 (1H, d, J = 8.0 Hz), 
7.53 (1H, dd, J = 7.5 Hz, 7.0 Hz), 7.46 (1H, dd, J = 7.5 Hz, 7.0 Hz), 5.47 (1H, s), 5.13 
(1H, d, J = 13.5 Hz), 5.06 (1H, d, J = 14.0 Hz), 4.58 (1H, m), 4.55 (1H, m), 4.42 (1H, 
m), 4.37 (1H, m), 4.25 (1H, m), 4.18 (1H, m); 13C NMR (CDCl3) δ 166.61, 152.74, 
134.86, 126.67, 125.93, 123.44, 121.96, 102.78, 75.86, 74.60, 72.08, 70.06, 67.79, 
67.50, 60.65; Mass: 338.0684 (TOF, MW + H, calc. 338.0698); m. p. 139-140˚C. 
 
HO OH
OH
OH
OHO
(±)
HN
S
Cl
 
(±)-4-O-(2-Benzothiazolylmethyloxy)-myo-inositol 1 To a solution of 
(±)-4-O-(2-benzothiazolylmethyloxy)-myo-inositol 1,3,5-monoorthoformate (1.0 g, 
2.97 mmol) in methanol (30 mL) was added Dowex 50X8 (H+, 200-400 mesh). The 
suspension was stirred overnight, and then filtered. The resin was then washed with 
1M HCl. Methanol was evaporated and the aqueous solution was dried by freeze 
dryer. (±)-4-O-(2-Benzothiazolylmethyloxy)-myo-inositol (0.50 g, 59%) was obtained 
as a white solid. 1H NMR (D2O) δ 7.89 (1H, d, J = 8.0 Hz), 7.78 (1H, d, J = 8.5 Hz), 
7.47 (1H, dd, J = 7.5 Hz, 8.0 Hz), 7.39 (1H, dd, J = 7.5 Hz, 7.5 Hz), 5.17 (2H, s), 3.91 
(1H, m), 3.59-3.58 (2H, m), 3.51 (1H, dd, J = 9.5 Hz, 9.5 Hz), 3.39-3.33(2H, m); 13C 
NMR (D2O) δ 173.50, 147.60, 133.00, 127.50, 126.41, 122.65, 120.41, 83.11, 73.83, 
72.38, 72.89, 70.87, 70.76, 70.32; Mass: 328.0847 (TOF, MW, calc. 328.0849); m. p. 
113-115˚C. 
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2-Keto-myo-inositol (scyllo-Inosose or Inosose)  
This compound was made as described in the literature93. 
1H NMR (D2O) δ 4.3 (2H, d, J = 10.3 Hz), 3.7 (1H, dd, J = 9.4 Hz), 3.4-3.2 (2H, m). 
 
 
HO OH
OH
OHHO
DHO
 
2-2H-myo-Inositol 
This compound was made as described in the literature119 with modification. In a 
100-mL round bottom flask containing 27 mL of ddH2O, 2-keto-myo-inositol (0.53 g, 
3.00 mmol) and NaBD4 (0.30 g, 7.14 mmol) was added, and the reaction was allowed 
to stir at r. t. overnight. The reaction was quenched with 5 mL of acetone and stirred 
with Dowex 50X8 (H+, 200-400 mesh) for about 30 min to neutralize. After filtration 
and evaporation, 0.93 g of crude product was obtained as a solid.  
 
Purification of 2-2H-myo-inositol 1) acetylation of 2-2H-myo-inositol   Crude 
2-2H-myo-inositol (1.7 g) was added into a mixture of 60 mL of Ac2O and 25 mL of 
pyridine. The solution was heated at 100˚C for 24 h, and then poured into ice and left 
overnight. The suspension was filtered, washed with water (15 mL), and then dried. 
The resulting filtrate was concentrated and the residue was purified by FCC [ethyl 
acetate-hexanes (1:1, v/v)]. The product (1.06 g total) as a white solid was obtained. 
1H NMR (CDCl3) 5.51 (2H, dd, J = 10.3 Hz), 5.19 (1H, dd, J = 9.8 Hz), 5.10 (2H, d, J 
= 10.5 Hz), 2.22 (3H, s), 2.02 (15H, m). 
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2) Deacetylation A mixture of inositol acetate (1.58 g, 3.65 mmol) in 40 mL of 
methanol was heated to boiling. NaOCH3 (5 mL, 2 M solution) was added and heated 
to reflux for an additional 10 min, and then the solution was cooled to room 
temperature. A white solid was obtained by filtration. Since there was NaOCH3 in the 
solid, it was redissolved in water and stirred with Dowex 50X8 (H+, 200-400 mesh) to 
neutralize. After filtration and evaporation, 2-2H-myo-inositol (0.65 g, 98%) was 
obtained as a white solid. 1H NMR (D2O) δ 3.51 (2H, dd, J = 9.8 Hz, 9.5 Hz), 3.41 
(2H, d, J = 10.0 Hz), 3.16 (1H, dd, J = 9.3 Hz, 9.4 Hz); 2H NMR (H2O) δ 4.3 (s); 13C 
NMR (D2O) δ 74.73, 72.78, 72.13 (t, J = 22.4 Hz), 71.44; Mass: 204.0600 (TOF, MW 
+ Na, calc. 204.0593). 
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(±)-1,2-O-Isopropylidene-myo-inositol 15  
This compound was made as described in the literature94. 
1H NMR (D2O) δ 1.31 (3H, s), 1.45 (3H, s), 3.18 (1H, ddd, J = 9.6 Hz, 9.6 Hz, 1.6 
Hz), 3.48-3.58 (2H, m), 3.77 (1H, dd, J = 9.9 Hz, 4.2 Hz), 3.96-3.99 (1H, m), 4.40 
(1H, dd, J = 4.6 Hz). 
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(±)-3,4,5,6-O-Tetrabenzyl-1,2-O-isopropylidene-myo-inositol 16  
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This compound was made as described in the literature95.  
1H NMR (CDCl3), 1.39 (3H, s), 1.54 (3H, s), 3.45 (1H, dd, J = 9.0 Hz), 3.72 (1H, dd, J 
= 8.8 Hz, 3.8 Hz), 3.82 (1H, dd, J = 9.4 Hz, 6.9 Hz), 3.97 (1H, dd, J = 8.6 Hz), 4.13 
(1H, dd, J = 6.2 Hz), 4.30 (1H, dd, J = 5.5 Hz, 4.0 Hz), 4.75-4.90 (8H, m), 7.28-7.40 
(20H, m). 
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(±)-3,4,5,6-O-Tetrabenzyl-myo-inositol 17  
This compound was made as described in the literature95. 
1H NMR (CDCl3), δ 3.48-3.52 (3H, m), 3.86 (1H, dd, J = 9.5 Hz), 3.99 (1H, dd, J = 
9.5 Hz), 4.23 (1H, dd, J = 2.5 Hz), 4.71-4.98 (8H, m), 7.28-7.37 (20H, m). 
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1,3,4,5,6-O-Pentabenzyl-myo-inositol 18 
1) Preparation from (±)-3,4,5,6-O-tetrabenzyl-myo-inositol96 A mixture of 
3,4,5,6-O-tetrabenzyl-myo-inositol (5.4 g, 10 mmol), tetrabutylammonium bromide 
(3.54 g, 11 mmol), dibutyltin oxide (2.74 g, 11 mmol) and benzyl bromide (1.88 g, 
15.8 mmol) was heated to reflux in 150 mL of acetonitrile for 24 h. The reaction 
mixture was cooled to room temperature. After removing the solvent, the remaining 
syrup was partitioned between water and ethyl acetate. The organic layer was 
separated and stirred with an aqueous solution of NaHCO3 for 1 h, and then filtered 
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through celite and washed with ethyl acetate. The organic layer was dried over 
MgSO4, and then the solvent was removed. The solid was recrystallized from 
methanol to give white crystals (4.4 g). The remaining filtrate was purified by FCC 
[ethyl acetate-hexanes (1:5 to 1:3, v/v)]. Yellow solid (0.78 g) was afforded with total 
yield 82%. 
 
2) Preparation from 1,2,3,4,5,6-O-hexabenzyl-myo-inositol97 To a solution of 
1,2,3,4,5,6-O-hexabenzyl-myo-inositol (6.0 g, 8.3 mmol) in dry dichloromethane (50 
mL) was added tin chloride (8.3 mL, 8.3 mmol) dropwise at r. t. under argon. After 
the solution was stirred for 1 h, the reaction was quenched with water. The mixture 
was extracted with dichloromethane. FCC [ethyl acetate-hexanes (1:4 to 1:3, v/v)] 
gave 1,3,4,5,6-O-pentabenzyl-myo-inositol (2.1 g, 41%) as a light yellow solid. 
Starting material 1,2,3,4,5,6-O-hexabenzyl-myo-inositol (3.1 g 51%) was recovered. 
1H NMR (CDCl3) δ 3.42 (2H, dd, J = 9.7 Hz, 2.6 Hz), 3.49 (1H, dd, J = 9.4 Hz), 4.04 
(2H, dd, J = 9.5 Hz), 4.26 (1H, dd, J = 2.6 Hz), 4.71-4.77 (4H, m), 4.87-4.95 (6H, m), 
7.28-7.37 (25H, m). 
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1,3,4,5,6-O-Pentabenzyl-2-deoxy-2-fluoro-scyllo-inositol 19  
This compound was made as described in the literature98,99. 1H NMR (CDCl3) δ 
3.56-3.64 (3H, m), 3.69-3.75 (2H, m), 4.64 (1H, ddd, J = 51 Hz, 9 Hz, 9 Hz), 
4.78-4.95 (10H, m), 7.33-7.43 (25H, m). 
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2-Deoxy-2-fluoro-sycllo-inositol 11  
This compound was made as described in the literature100. 
1H NMR (D2O) δ 3.25-3.34 (3H, m), 3.53-3.61 (2H, m), 4.18 (1H, ddd, J = 52.0 Hz, 
9.2 Hz, 9.2 Hz); 13C NMR (D2O) δ 72.18 (d, J = 17.6 Hz), 72.88 (d, J = 11.8 Hz), 
73.75, 94.92 (d, J = 177.9 Hz). 
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1,3,4,5,6-O-Pentabenzyl-2-keto-myo-inositol 21 
This compound was made as described in the literature100.   
1H NMR (CDCl3), δ 3.65 (2H, dd, J = 9.5 Hz), 3.90 (1H, dd, J = 9.2 Hz), 4.21 (2H, d, 
J = 9.3 Hz), 4.57 (2H, d, J = 11.5 Hz), 4.80 (2H, d, J = 10.7 Hz), 4.91-5.00 (6H, m), 
7.21-7.41 (25H, m). 
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1,3,4,5,6-O-Pentabenzyl-2-deoxy-2,2-difluoro-myo-inositol 2298,101 Diethyl- 
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aminosulfur trifluoride (DAST, 0.23 ml, 1.76 mmol) was added to a stirred solution of 
1,3,4,5,6-O-pentabenzy-2-keto-myo-inositol (0.50 g, 0.80 mmol) dissolved in 
dichloromethane (10 ml). The stirring was continued at r. t. for 20 h before addition of 
water. The mixture was separated and the organic layer was concentrated. FCC 
[toluene, 100%] afforded product (0.41 g, 79%) as a white solid. 1H NMR (CDCl3), δ 
3.59 (1H, dd, J = 9.1 Hz, 9.0 Hz), 3.65-3.75 (4H, m), 4.80-4.98 (10H, m), 7.28-7.36 
(25H, m); 13C NMR (CDCl3) δ 76.34, 76.36, 76.54, 76.68, 80.10 (t, J = 18.6 Hz), 
81.25 (d, J = 9.4 Hz), 82.57, 120.82 (t, J = 250.0 Hz), 128.19, 128.20, 128.39, 128.45, 
128.65, 128.85, 128.88, 137.94, 138.63, 138.67; 19F NMR (CDCl3), δ -129.46 (1F, 
ddd, J = 252 Hz, 20 Hz, 20 Hz), -115.65 (1F, d, J = 252 Hz); Mass: 673.2748 (TOF, 
MW + Na, calc. 673.2741).  
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2-Deoxy-2,2-difluoro-myo-inositol 12100  A solution of 1,3,4,5,6-O-pentabenzyl- 
2-deoxy-2,2-difluoro-myo-inositol (1.23 g, 1.89 mmol) in THF-H2O (50 mL, 4:1, v/v) 
was stirred in the presence of 10% Pd-C (0.3 g). The suspension was hydrogenated at 
r. t. under H2 atmosphere using a balloon for 3 days. The mixture was filtered through 
celite and the filtrate was concentrated to dryness. Product was obtained as a light 
yellow solid (0.35 g, 97%). 1H NMR (D2O) δ 3.30-3.39 (3H, m), 3.66-3.72 (2H, m); 
13C NMR (D2O) δ 71.31 (t, J = 19.49 Hz), 72.43 (d, J = 8.9 Hz), 73.45, 119.63 (t, J = 
244.8 Hz). 
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1,2,3,4,5-O-Pentabenzyl-scyllo-inositol 24 was synthesized in 3 steps: 
1)Triflate derivative 20  
This compound was made as described in the literature99. 
1H NMR (CDCl3) δ 3.47-3.51 (3H, m), 3.89 (2H, dd, J = 9.6 Hz), 4.60-5.00 (10H, m), 
5.29 (1H, dd, J = 2.1 Hz), 7.26-7.36 (25H, m). 
 
2)Trifluoroacetate derivative 23  
This compound was made as described in the literature99. 
 
3) 1,2,3,4,5-O-Pentabenzyl-scyllo-inositol 24  
This compound was made as described in the literature99. 
1H NMR (CDCl3) δ 3.45 (2H, dd, J = 8.7 Hz), 3.57-3.66 (4H, m), 4.82-4.93 (10H, m), 
7.28-7.35 (25H, m). 
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1,3,4,5,6-O-Pentabenzyl-2-deoxy-2-fluoro-myo-inositol 25   
This compound was made as described in the literature102,103. 
1H NMR (CDCl3) δ 3.39 (2H, ddd, J = 28.8 Hz, 9.8 Hz, 1.7 Hz), 3.51 (1H, dd, J = 9.4 
Hz), 3.98 (2H, dd, J = 9.4 Hz), 4.72 (4H, s), 4.84-4.95 (7H, m), 7.28-7.36 (25H, m). 
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2-Deoxy-2-fluoro-myo-inositol 10100 1,3,4,5,6-O-Pentabenzyl-2-deoxy-2-fluoro- 
myo-inositol (1.11 g, 1.76 mmol) was dissolved in THF-H2O (60 mL, 4:1, v/v) 
containing 10% Pd-C (0.20 g) as a catalyst. The suspension was hydrogenated at r. t. 
using a balloon for 2 days. The mixture was filtered through a bed of celite, which 
was washed with water. The solvent was removed by rotary evaporation, resulting in 
2-deoxy-2-fluoro-myo-inositol (0.32 g, 99%) as a grey solid. 1H NMR (D2O) δ 3.23 
(1H, dd, J = 9.0 Hz), 3.51-3.60 (4H, m), 4.69 (1H, m); 13C NMR (D2O) δ 70.46 (d, J = 
17.2 Hz), 72.65 (d, J = 3.8 Hz), 73.23, 94.47 (d, J = 175.2 Hz). 
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1,3,4,5,6-O-Pentabenzyl-2-deoxy-2-iodo-scyllo-inositol 26104,105 To a solution of 
1,3,4,5,6-O-pentabenzyl-myo-inositol (4.4 g, 7.0 mmol), triphenylphosphine (3.7 g, 
14.0 mmol), and imidazole (1.2 g, 17.5 mmol) in dry toluene (100 mL) was added 
iodine (3.5 g, 14.0 mmol). The mixture was stirred at reflux for 24 h under argon, and 
then cooled to room temperature. Saturated NaHCO3 aqueous solution (50 mL) was 
added, and the stirring was continued for 5 min. After the mixture was transferred to a 
separatory funnel, the organic layer was diluted with toluene and washed with 
aqueous sodium thiosulphate to remove excess iodine. The yellow solid was obtained 
after the organic layer was dried and concentrated. Triphenylphosphine oxide was 
separated by redissolving the solid in diethyl ether, followed by filtration. The filtrate 
was concentrated and then subjected to FCC [petroleum ether-ethyl acetate (12:1, v/v)] 
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to afford the desired product as a white solid (4.28 g, 82%). 1H NMR (CDCl3) δ 3.61 
(2H, dd, J = 9.3 Hz, 9.5 Hz), 3.71 (1H, dd, J = 9.6 Hz, 9.5 Hz), 3.78 (2H, dd, J = 9.2 
Hz, 10.9 Hz), 4.18 (1H, dd, J = 11.0 Hz), 4.95-5.08 (10H, m), 7.36-7.53 (25H, m); 13C 
NMR (CDCl3) δ 34.44, 76.18, 76.32, 76.48, 82.95, 83.31, 84.65, 128.21, 128.23, 
128.32, 128.42, 128.53, 128.70, 128.89, 128.91, 128.95, 138.22, 138.68, 138.71. 
Mass: 763.1878 (TOF, MW + Na, calc. 763.1896). 
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1,3,4,5,6-O-Pentabenzyl-2-deoxy-myo-inositol 27104,106 A solution of 
1,3,4,5,6-O-pentabenzyl-2-deoxy-2-iodo-scyllo-inositol (4.79 g, 6.47 mmol), 
tri-n-butyltin hydride (3.43 mL, 12.94 mmol) and 2,2-azobis-(2-methylpropionitrile) 
(AIBN, 0.10 g, 11.00 mmol) in dry toluene (150 mL) was degassed by bubbling argon 
through for 15 min. The stirring mixture was heated to reflux under argon for 30 min. 
After evaporation, the residue was purified by FCC [petroleum ether-ethyl acetate 
(8:1, v/v)] to afford the desired product as a white solid (3.97 g, 100%). 1H NMR 
(CDCl3) δ 1.50 (1H, dd, J = 12.0 Hz), 2.43 (1H, ddd, J = 12.6 Hz, 4.3 Hz, 4.2 Hz), 
3.44-3.50 (3H, m), 3.58 (2H, dd, J = 9.3 Hz, 9.2 Hz), 4.69-5.02 (10H, m), 7.28-7.48 
(25H, m); 13C NMR (CDCl3) δ 33.31, 72.98, 76.17, 76.47, 83.64, 85.93, 127.96, 
128.07, 128.12, 128.31, 128.38, 128.75, 128.82, 138.82, 139.08, 139.17; Mass: 
615.3128 (MW + H, calc. 615.3110); 637.3000 (TOF, MW + Na, calc. 637.2924); m. 
p. 107-108˚C. 
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2-Deoxy-myo-inositol 13 To a solution of 1,3,4,5,6-O-pentabenzyl-2-deoxy-myo- 
inositol (1.74 g, 2.83 mmol) in THF-H2O (60 mL, 4:1, v/v) was added 10% Pd-C 
(0.20 g). The black suspension was hydrogenated at r. t. using balloon for 2 days. The 
mixture was filtered through a bed of celite, which was washed with water. The 
filtrate was evaporated to yield 2-deoxy-myo-inositol (0.45 g, 98%) as a white solid. 
1H NMR (D2O) δ 1.36 (1H, dd, J = 12.0 Hz), 2.10 (1H, ddd, J = 12.3 Hz, 4.6 Hz, 4.6 
Hz), 3.13-3.22 (3H, m), 3.43-3.48 (2H, m). 
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2-Deoxy-myo-inositol 1,3,5-monoorthoformate 28 A mixture of 2-deoxy-myo- 
inositol (0.72 g, 4.39 mmol), p-toluenesulfonic acid  monohydrate (0.20 g, 1.05 
mmol), and triethylorthoformate (2.2 mL, 13.17 mmol) in dry DMF (15 mL) was 
stirred in an oil bath at 120-130˚C for 2 h. The solvent was removed by evaporation. 
FCC [ethyl acetate-petroleum ether (3:1, v/v)] produced 2-deoxy-myo-inositol 
1,3,5-monoorthoformate (0.57 g, 75%) as a white solid. 1H NMR (D2O) δ 2.22 (1H, d, 
J = 14.6 Hz), 2.34 (1H, dd, J = 14.6 Hz, J = 4.1 Hz), 4.18 (2H, m), 4.25 (1H, m), 4.31 
(2H, m), 5.58 (1H, s) 
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(±)-4-O-Benzyl-2-deoxy-myo-inositol 1,3,5-monoorthoformate 29 2-Deoxy-myo- 
inositol 1,3,5-monoorthoformate (0.52 g, 3.0 mmol) was treated with sodium hydride 
(0.12 g, 60%, 3.0 mmol) in DMF (10 mL) in ice bath. After 30 min, benzyl bromide 
(0.35 mL, 3.0 mmol) was added dropwise at 0˚C, and then warmed to r. t. gradually 
and stirred overnight. The reaction mixture was quenched with water and the solvent 
was evaporated. The yellow residue was extracted with ethyl acetate and water. The 
organic layer was dried over MgSO4. After removing the solvent, the yellow residue 
was purified by FCC [ethyl acetate-toluene (1:12, v/v)]. The product (±)-4-O-benzyl- 
2-deoxy-myo-inositol 1,3,5-monoorthoformate (0.44 g, 56%) were yielded as a white 
solid, and byproduct 4,6-O-dibenzyl-2-deoxy-myo-inositol 1,3,5-monoorthoformate 
(0.04 g, 4%) was also obtained. 1H NMR (CDCl3) δ 2.23 (1H, dd, J = 14.1 Hz, 1.4 Hz), 
2.44 (1H, d, J = 14.0 Hz), 4.20-4.34 (5H, m), 4.68 (2H, s), 5.52 (1H, s), 7.33-7.40 (5H, 
m); 13C NMR (CDCl3) δ 22.86, 66.84, 68.04, 68.54, 70.52, 73.15, 73.46, 103.56, 
128.44, 129.07, 129.24, 136.65; Mass: 265.1078 (TOF, MW + H, calc. 265.1076). 
Byproduct 4,6-O-dibenzyl-2-deoxy-myo-inositol 1,3,5-monoorthoformate 1H NMR 
(CDCl3) δ 2.40 (2H, m), 4.25 (4H, m), 4.54 (1H, s), 4.61 (2H, d, J = 11.5 Hz), 4.72 
(2H, d, J = 11.5 Hz), 5.57 (1H, s), 7.27-7.32 (10H, m). 
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(±)-4-O-Benzyl-2-deoxy-myo-inositol 14 A solution of (±)-4-O-benzyl-2-deoxy- 
myo-inositol 1,3,5-monoorthoformate  (0.42 g, 1.6 mmol) in methanol (30 mL) was 
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stirred with Dowex 50X8 (H+, 200-400 mesh) at r. t. overnight. The mixture was 
filtered and washed with methanol. The solvent was evaporated, and 
(±)-4-O-benzyl-2-deoxy-myo-inositol (0.38 g, 95%) was yielded as a white solid. 1H 
NMR (D2O) δ 1.39 (1H, dd, J = 12.0 Hz), 2.09 (1H, ddd, J = 12.3 Hz, 4.6 Hz, 4.6 Hz), 
3.20-3.26 (3H, m), 3.41-3.44 (1H, m), 3.54-3.57 (1H, m), 4.73 (2H, s), 7.29-7.39 (5H, 
m); 13C NMR (D2O) δ 37.23, 68.66, 68.73, 74.23, 75.32, 77.26, 85.59, 128.74, 129.05, 
129.24, 138.01; Mass: 277.1036 (TOF, M + Na, calc. 277.1052). 
 
OH
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scyllo-Inositol To a solution of 1,2,3,4,5-O-pentabenzyl-scyllo-inositol (1 g, 1.6 mmol) 
in 40 mL of THF-H2O (3:1, v/v) was added 0.5 g of 10% Pd-C. The suspension was 
hydrogenated at r. t. for a day. The mixture was filtered and washed with water. The 
filtrate was dried by freeze drier, and scyllo-inositol (0.2 g, 70%) was obtained as a 
light yellow solid. 1H NMR (D2O) δ 3.22 (s); 13C NMR (D2O) δ 74.5. 
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(±)-4-(Dibenzyloxyphosphoryloxy)-myo-inositol 1,3,5-monoorthoformate  
This compound was made as described in the literature107. 
1H NMR (CDCl3) δ 7.35 (10H, m), 5.40 (1H, s), 5.16-5.02 (4H, m), 4.94 (1H, br s), 
4.50 (1H, br s), 4.30 (1H, br s), 4.14 (1H, br s), 4.04 (1H, br s), 3.94 (1H, br s). 
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(±)-myo-Inositol-4-phosphate  
This compound was made as described in the literature107. 
1H NMR (D2O) δ 3.95 (1H, m), 3.91 (1H, br s), 3.56 (1H, dd, J = 9.5 Hz), 3.48 (1H, d, 
J = 9.5 Hz), 3.42 (1H, d, J = 10 Hz), 3.27 (1H, dd, J = 9.5 Hz), 3.01 (2H, br s), 1.84 
(4H, br s), 1.67 (4H, br s), 1.51 (2H, d, J = 12.5 Hz), 1.20 (8H, br s), 1.04 (2H, br s). 
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3. RESULTS AND DISCUSSION 
 
3.1 Rate-limiting step 
 
The kinetic mechanism for IDH was established as a compulsory ordered Bi Bi 
mechanism, as mentioned in 1.4.5. The complete steady-state rate constants were 
determined by Daniellou in 2006108. On the basis of these values, it seems that the 
breakdown of the ternary complex and the liberation of NADH constitute the rate 
limiting step. The rate-limiting step of reactions catalyzed by dehydrogenases typically 
is not the chemical reaction step. To determine whether the chemical step is the 
rate-limiting step for IDH catalyzed reaction, a kinetic isotope effect experiment was 
carried out. 
 
3.1.1 Kinetic isotope effect  
 
Kinetic isotope effect (KIE), a useful method to elucidate the rate-limiting step in a 
reaction mechanism, has been used to study chemical reactions for almost half a 
century. A kinetic isotope effect is a change in the rate when an atom is replaced by its 
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isotopic atom in the same reaction109. This isotopic substitution can influence 
equilibrium and also affect reaction rates based on the differences in the mass of 
different isotopes. The calculated or observed isotope effect is normally presented by 
the ratio between the rate with an unlabeled molecule and the rate with the molecule 
containing a heavy isotope (for example, kH/kD)110. 
 
The magnitude of the isotope effect depends on the location of the isotope. KIE 
commonly is classified into primary KIE and secondary KIE. A primary KIE is 
observed when the rate change is due to isotopic substitution at a site of bond breaking 
or bond making in the rate determining step of a mechanism. On the other hand, if rate 
changes due to isotopic substitution at a site not undergoing bond breaking or bond 
making in the rate determining step of a mechanism, this is a secondary KIE111. A 
secondary KIE is weaker than a primary KIE.  
 
The magnitude of isotope effect also depends on the relative mass difference between 
the atom and its isotope. Hydrogen is a common atom used in KIE as the effect is 
significant since deuterium is twice as massive as hydrogen and tritium is three times 
as massive as hydrogen. Theoretically, the maximum value of primary deuterium KIE 
(kH/kD) is 6.9 and the maximum value of primary tritium KIE (kH/kT) is 18 at room 
temperature, whereas, the maximum value of secondary deuterium KIE (kH/kD) is only 
1.2110. 
 
The theory of kinetic isotope effects is applicable to enzymatic reactions, however, the 
chemical step(s) of an enzymatic reaction is often not totally rate limiting because of 
the strong binding affinity between the enzyme and its substrates/products111. A kinetic 
isotope effect on a rate constant of enzymatic reaction is normally presented by x maxV , 
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x(
mK
Vmax ), or x(
m
cat
K
k ). The superscript x is D, T, 13, 14, 15, 17, or 18 for deuterium, 
tritium, 13C, 14C, 15N, 17O, or 18O isotope effects. The magnitude of KIE observed for 
enzymatic reactions varies widely and the interpretation can be complex112,113. 
 
In many cases of dehydrogenases, the observed primary KIE on deuterium substituted 
substrate is in the range of 1-2, indicating that interconversion of substrates and 
products is not rate limiting or only partly rate limiting, and release of product(s) is 
primarily rate limiting114-118. In this research, deuterium labeling was employed to 
determine the rate limiting step of IDH catalyzed reaction. The deuterium-substituted 
compound 2-2H-myo-inositol, in which deuterium was incorporated into the reaction 
center C2, was designed as the substrate. A significant primary KIE should be detected 
if the hydride transfer is the rate-limiting step or part of the rate-limiting step.  
 
 
3.1.2 Synthesis of 2-2H-myo-inositol 
 
The compound 2-2H-myo-inositol was synthesized by using myo-inositol as starting 
material, and the synthetic route is shown in Scheme 3.1. Oxidation of myo-inositol to 
2-keto-myo-inositol was completed by Gluconobacter oxidans ATCC621 as described 
in the literature in 88% isolated yield93. The stereoselective reduction of 
2-keto-myo-inositol with NaBD4 in H2O at r. t. produced 2-2H-myo-inositol119,120. The 
deuterium is added to carbonyl from the face which is anti to the substituents at the 
two contiguous carbons, resulting in product 2-2H-myo-inositol. Acetylation and 
deacetylation were used for purification. Neutralization with Dowex 50X8 (H+ form, 
200-300 mesh) gave 2-2H-myo-inositol as a white solid in 35% overall yield. 
 
 80
OH
OHHO
HO
HO
HO
OH
HO
HO
HO
HO
O
OH
OH
HO
HO
HO
HO
H2
a bH
88% 40%
myo-inositol 2-keto-myo-inosose 2-2H-myo-inositol  
 
Scheme 3.1 Synthesis of 2-2H-myo-inositol. Reagents and conditions: a) Gluconobacter oxidans, 88%. 
b) (1) NaBD4, H2O, r. t., overnight; (2) Ac2O, pyridine, 100˚C, 24 h (overall yield of (1) and (2): 41 %); 
(3) NaOCH3, CH3OH, reflux 10 min, Dowex 50X8 (H+ form), 98 %.  
 
 
3.1.3 Rate-limiting step determination 
 
During the kinetic analysis, the cofactor NAD+ was kept constant and saturating, thus 
the two-substrate enzymatic reaction was simplified to a one-substrate reaction and the 
rate of the reaction depended on the amount of the IDH-NAD+ complex. Initial 
velocities, appmK , and 
appVmax  were determined as described in 2.8.2 and 2.8.3. The 
kinetic isotope effect upon appVmax /
app
mK  was measured via generating saturation curves 
with commercial myo-inositol and synthesized 2-2H-myo-inositol. In order to get 
consistent data to make the results more convincing, this assay was also carried out 
using synthesized myo-inositol made by sodium borohydride reacting with 
2-keto-myo-inositol. It turned out that the kinetic result using synthesized myo-inositol 
showed no difference from that using the commercial myo-inositol. The kinetic 
constants were shown in Table 3.1. 
 
No kinetic isotope effect was observed on D appVmax  (
DV = 1.0) and the isotope effect on 
D( app
m
app
K
Vmax ) was  1.1 ± 0.1, suggesting no KIE was observed. Therefore, the chemical 
reaction is not the rate-limiting step of the oxidation-reduction reaction that IDH 
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catalyzed. This result combined with those of rate constants determination108, reveals 
that the breakdown of ternary complex and liberation of NADH constitute the 
rate-limiting step. 
 
Table 3.1 Kinetic constants of the IDH catalyzed reactions using 2-2H-myo-inositol and 
myo-inositol as substrates.  
Substrate app
mK  (mM) 
appVmax [mol · min-1 (mg protein)-1] 
2-2H-myo-inositol 20 ± 1 9.0 ± 0.1 
   Commercial myo-inositol 18 ± 1 9.0 ± 0.1 
   Synthesized myo-inositol 18 ± 1 9.0 ± 0.1 
  Conditions: 100 mM Tris-HCl, pH 9.0, 25°C. 
 
 
 
3.2 Exploring the substrate spectrum of IDH  
 
3.2.1 Design of new potential substrates 
 
As mentioned in 1.4.3, IDH demonstrates broad substrate specificity. The 
1L-4-O-substituted myo-inositol derivatives listed in Figure 1.14 had been synthesized 
and proved to be substrates in this laboratory. In order to probe the pocket that 
accommodates 4-substituted groups, four new shapes of inositol derivatives were 
designed as potential substrates. These four compounds were 1L-4-O- 
(2-benzothiazolylmethyl)-myo-inositol 1, 1L-4-O-(4-tert-butylbenzyl)-myo-inositol 2, 
1L-4-O-propargyl-myo-inositol 3, and 1L-4-O-(1-allyl-4-methylene-1,2,3-triazol)- 
myo-inositol 4  as shown in Figure 3.1. Besides the shape differences, compounds 1 
and 4 also introduce heterocycles that possess the potential to interact with amino acid 
residue(s) of the binding pocket.  
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Figure 3.1 Structures of potential substrates of IDH. 
 
 
 
3.2.2 Synthesis of new potential substrates 
 
Three proposed IDH substrates 1, 2, and 3 were synthesized employing a similar 
synthetic route as published previously69. The method began with the commercially 
available myo-inositol as shown in Scheme 3.2. Selective protection with 
triethylorthoformate formed myo-inositol 1,3,5-monoorthoformate 5, in which all of 
the hydroxyl groups are in the axial orientation relative to the inositol ring except the 
hydroxyl at the C2. Compound 5 was an attractive structure because of the 
regioselectivity displayed by three free hydroxyl groups121. The axial hydroxyl groups 
of C4 and C6 are chemically equivalent and more acidic than C2 hydroxyl group. In 
the presence of 1.1 mole equivalent of NaH, a C4/6 hydroxyl group is deprotonated to 
the corresponding anion available for subsequent addition of an electrophile. 
Therefore, these anions allowed formation of racemic products 6, 7, and 8 after 
addition with 2-(bromomethyl)benzothiazole, tert-butylbenzyl bromide, or propargyl 
bromide respectively. After removal of orthoformate by treatment with Dowex 50X8 
(H+ form) in methanol, the racemic compounds 1, 2, and 3 were obtained. (±)-4 was 
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successfully synthesized from racemic compound 8 by two routes in which allyl azide 
was “clicked” on to compound 8 or 3 to form a triazole ring. The 1,4-disubstituted 
(anti) triazole structure of 4 was determined by NOE difference. The analogue of 
compound 4 that would be formed when “clicked” with methyl azide may show a 
lower value of Michaelis constant. Unfortunately, this analogue has not been tried 
since methyl azide exists as a gas at room temperature (b. p. 18˚C)91. 
 
Although only one enantiomer of myo-inositol derivatives (1L-4-O- attached) is the 
potential substrate, the other enantiomer will not affect the enzymatic reaction 
according to our previous measurements69. Therefore, the racemic compounds 1, 2, 3, 
and 4 were tested as potential substrates of IDH. 
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Scheme 3.2 Synthesis of inositol analogues. Reagents and conditions: a) (1) Triethylorthoformate, 
p-toluenesulfonic acid monohydrate, DMF, 120-130˚C; (2) Pyridine and Ac2O; (3) NaOCH3. b) 
2-(bromomethyl)benzothiazole, NaH, DMF. c) Dowex 50X8 (H+), methanol. d) tert-butylbenzyl 
bromide, NaH, DMF. e) Dowex 50X8 (H+), methanol. f) propargyl bromide, NaH, DMF. g) allyl azide, 
CuSO4·5H2O, sodium L-ascorbate, THF/H2O. h) Dowex 50X8 (H+), methanol. i) Dowex 50X8 (H+), 
methanol. j) allyl azide, CuSO4·5H2O, sodium L-ascorbate, THF/H2O.   
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3.2.3 Apparent Km ( appmK ) of new substrates 
 
Table 3.2 Kinetic constants of wild-type IDH with four synthesized substrates 1, 2, 3, 4 
and D-chiro-inositol.  
 
Compounds 
app
mK  
(mM) 
 appVmax  
[mol · min-1 (mg protein)-1] 
appVmax /
app
mK  
 
myo-inositol 18 ± 1 35 ± 4 1.9 
D-chiro-inositol 37 ± 3 22 ± 2 0.6 
(±) 1 16 ± 2 12 ± 1 0.8 
(±) 2 42 ±16 7 ± 2* 0.2 
(±) 3 83 ± 7 15 ± 1 0.2 
(±) 4 45 ± 4 15 ± 1 0.3 
Conditions: 100 mM Tris-HCl pH 9.0, 25°C, [NAD+] = 0.5 mM; 
          *20% DMSO in 100 mM Tris-HCl at pH 9.0. 
 
The kinetic method described in 2.8.3 was used to evaluate the proposed substrates. 
The results revealed that all four synthesized compounds, 1, 2, 3, and 4, were substrates 
of IDH. Since the solubility of compound 2 in aqueous buffers is very poor, the 
corresponding kinetics experiments were carried out in Tris-HCl buffer in the present 
of 20% DMSO (IDH is fully active in 20% DMSO78). As all four compounds are 
racemic compounds, the appmK  values of the reactive enantiomers are equal to half of 
the values listed in Table 3.2. Therefore, the values of appmK  of compounds 2 and 4 
were comparable to the value of myo-inositol, whereas the value of appmK  of 1L-1 was 
half and 1L-3 was twice that of myo-inositol. Hydrogen bonding interaction may be 
introduced by the nitrogen atom in the heterocycle of compound 1, which can act as 
hydrogen bond acceptor and enhance the binding affinity. In contrast, compound 4 also 
incorporates a nitrogen atom, but the appmK  value is almost three times of the value of 
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compound 1. It seems that the triazole ring armed with a long allyl side chain is not 
accommodated well by IDH compared to benzothiazole ring.  
 
In 2006, the in vitro interconversion of myo-inositol and D-chiro-inositol catalyzed by 
the enzymes IDH and IolI (encoded by genes iolG and iolI in Bacillus subtilis) was 
reported122, the details are shown in Scheme 3.3. Therefore, D-chiro-inositol was tried 
as a substrate for IDH in this laboratory. As expected, D-chiro-inositol is a substrate of 
IDH, but demonstrates higher value of appmK  and lower value of 
appVmax  than those of 
myo-inositol.  
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Scheme 3.3 Conversion of myo-inositol and D-chiro-inositol catalyzed by  
IolI and IDH(IolG). IolI is an inosose isomerase. 
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3.3 Inhibition studies   
 
3.3.1 Design of potential competitive inhibitors 
 
A competitive inhibitor typically competes with the substrate for binding in the same 
active site to form an enzyme-inhibitor complex which is not able to undergo a 
reaction. In most cases, a competitive inhibitor resembles the corresponding substrate. 
This character makes it possible to rationally design potential competitive inhibitors 
for IDH.  
 
The C2 alcohol of myo-inositol is oxidized during the IDH catalyzed reaction. Based 
on the proposed mechanism of dehydrogenases (Figure 1.16), removal of the axial 
hydroxyl group at the 2-position will produce inactive substrate. In order to probe the 
active site, a series of analogues of myo-inositol modified at the 2-position were 
synthesized and tested as inhibitors of IDH. These analogues are 
2-deoxy-2-fluoro-myo-inositol 10, 2-deoxy-2-fluoro-scyllo-inositol 11, 2-deoxy-2,2- 
difluoro-myo-inositol 12, 2-deoxy-myo-inositol 13, and 1L-4-O-benzyl-2-deoxy- 
myo-inositol 14. For clarity, the compounds are named using the 1L-myo-inositol 
numbering system, and the structures are shown in Figure 3.2. 
 
Fluorine, the most electronegative element, is a good hydroxyl surrogate since it is 
close in size (C-F bond length is 1.39 Å and C-O bond length is 1.43 Å). In addition, 
fluorine is able to act as a hydrogen bond acceptor, participating in interactions with 
-OH and -NH- donors, and also can form hydrogen-bonding interactions with H-C123. 
Thus fluorinated compounds 10 and 11 should provide good myo- and scyllo-inositol 
mimics respectively. Although fluorine and hydrogen demonstrate different van der 
Waals radii (rw: 1.47 Å vs 1.20 Å), fluorine is often regarded as an isostere of 
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hydrogen124. The replacement of hydrogen by fluorine in compound 12 alters 
electronically the properties of the molecule and affects the dipole moment. Deoxy 
compounds 13 and 14 were also expected to be inhibitors of IDH. Since the hydrogen 
atom is unable to act as hydrogen bond donor or acceptor, these inhibitors can probe 
the importance of having hydrogen bond accepting/donating functionality at the 
2-position of myo-inositol. The ability of fluorinated and deoxy analogues to inhibit 
IDH will indicate the role of hydroxyl group in binding to the active site. 
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Figure 3.2 Structures of potential competitive inhibitors of IDH. 
 
We considered that inositol analogues 10-13 substituted at 4-position would show 
inhibition since inositol 4-substituted derivatives are substrates of IDH69. 
1L-4-O-Benzyl-2-deoxy-myo-inositol 14 was evaluated as a competitive inhibitor for 
this purpose.  
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3.3.2 Synthesis of inhibitors 
 
All five compounds 10-14 were synthesized from the same intermediate 
1,3,4,5,6-O-pentabenzyl-myo-inositol 18. The synthetic route to compound 18 is 
shown in Scheme 3.4. The isopropylidene 15 was obtained in 90% yield by heating 
myo-inositol and dimethoxypropane in DMSO with p-toluenesulphonic acid as a 
catalyst94. Perbenzylation of 15 with sodium hydride and benzyl bromide in DMF 
gave a racemic mixture 16. The isopropylidene was removed by refluxing 16 in 80% 
acetic acid for 4 h to produce racemic vicinal cis-diol 1795. Diol 17 was 
regioselectively benzylated by utilizing dibutyltin oxide in the presence of benzyl 
bromide and tetrabutylammonium bromide in acetonitrile96,99. The desired 
symmetrical compound 18 was produced after crystallization from methanol in 82% 
yield. Thus, compound 18 was synthesized from myo-inositol in 4 steps with a 43% 
overall yield. 
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Scheme 3.4 Chemical synthesis of intermediate 18. Reagents and conditions: a) 
2,2-dimethoxypropane, toluene-p-sulfonic acid, DMSO, 90˚C, 90%. b) NaH, BnBr, DMF. c) 80 % AcOH, 
reflux, 58% (b+c). d) BnBr, Bu2SnO, Bu4NBr, CH3CN, reflux, 82%. 
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The synthetic routes used to make potential inhibitors 10, 11, 12 were very similar, as 
shown in Scheme 3.5. Fluorination with DAST generally proceeds with inversion of 
configuration at the reaction center. Therefore, the hydroxyl at the reaction center has 
to be of opposite configuration to the desired fluorinated inositol analogue. Treatment 
of compound 18 with DAST using dichloromethane as a solvent at r.t. gave the 
2-deoxy-2-fluoro derivative 19 in 55% yield. Subsequent removal of the benzyl 
groups by hydrogenolysis using hydrogen gas and Pd-C in THF-H2O (4:1, v/v) 
provided compound 11 in an excellent yield (> 95%). Difluoro derivative 12 was 
synthesized via the ketone 21, which was prepared by Swern oxidation of compound 
18, and was afforded by following the same procedure as synthesis of compound 11. 
In order to obtain the myo-configuration retaining compound 10, in which the 
stereochemistry of fluoride in 2-deoxy-2-fluoro-scyllo-inositol 11 was inverted to the 
axial orientation, scyllo-inositol derivative 24 was synthesized from compound 18 as 
described in the literature99. Esterification of the hydroxyl group with triflic anhydride 
produced the triflate derivative 20, and then SN2 displacement of the triflate group by 
trifluoroacetate formed the trifluoroacetic ester 23. This reaction was followed by an 
ester exchange reaction in methanol with Na2CO3. Thus, compound 24 was easily 
obtained by these three steps without the need of column chromatography, and 
compound 24 was crystallized from methanol in an overall yield of 79%. Our initial 
attempt at the fluorination of compound 24 with DAST was carried out at room 
temperature and yielded only a small amount of compound 19 instead of the desired 
compound 25. More than 70% of the starting material 24 was recovered. Compound 
24 was then fluorinated with DAST in the present of 4-(dimethylamino)pyridine 
(DMAP) in toluene at 80˚C102, which produced 1,3,4,5,6-O-pentabenzyl- 
2-deoxy-2-fluoro-scyllo-inositol 19 and 1,3,4,5,6-O-pentabenzyl-2-deoxy-2-fluoro- 
myo-inositol 25 in 18% and 43% yield, respectively. The protective benzyl groups of 
compound 25 were cleaved by hydrogenolysis catalyzed by Pd-C in the solvent 
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system of THF-H2O (4:1, v/v) to afford compound 10. Therefore, potential inhibitors 
10, 11, and 12 were synthesized from compound 18 in the corresponding overall 
yields of 33%, 54%, and 57%.  
 
 
OBnBnO
OH
OBnBnO
OBn
OBnBnO
OBnBnO
OBn
F
OHHO
OHHO
OH
F
OBnBnO
OBnBnO
OBn
O
OBnBnO
OBnBnO
OBn
FF
OHHO
OHHO
OH
FF
OBnBnO
O3SCF3
OBnBnO
OBn
OBnBnO
OCOCF3
OBnBnO
OBn
OBnBnO
OBnBnO
OBn
OH
OBnBnO
F
OBnBnO
OBn
OHHO
OHHO
OH
F
18
10
12
1119
21 2220
23 24 25
g h
i
j h
k
l
m n h
55% 98%
73%
79% 98%
98%k-m, 79% 43%
 
 
Scheme 3.5 Chemical syntheses of potential inhibitors 10, 11, 12 from intermediate 18. Reagents 
and conditions: g) DAST, CH2Cl2, r. t., 55 %. h) 10% Pd-C, THF-H2O (4:1, v/v), r. t., 98 %. i) DMSO, 
oxalyl chloride, Et3N, CH2Cl2, -78˚C, 73%. j) DAST, CH2Cl2, r. t., 79 %. k) Tf2O, pyridine, CH2Cl2, -63 
˚C to r. t. l) NaOCCF3, DMF, r. t. m) Na2CO3, MeOH, 79 % (overall yield of steps k, l and m). n) DAST, 
DMAP, toluene, 80˚C, 43 %. 
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Deoxy inositol analogues 13 and 14 were also synthesized from compound 18 
(Scheme 3.6). Deoxygenation of secondary alcohols was usually carried out by the 
Barton-McCombie method125, in which alcohol is first converted to a thiocarbonyl 
derivative, followed by radical reduction using tributyltin hydride (Bu3SnH)126-129. 
Our initial attempt at deoxygenation involved generating the thiocarbonyl derivative, 
derived from compound 18 by reacting with O-phenyl chlorothionoformate in the 
presence of sodium hydride in DMF. However, treatment of the resulting 
thiocarbonyl derivative with tributyltin hydride initiated by AIBN failed to react and 
thus an alternative procedure was sought. Previously, tributyltin hydride was reported 
to reduce halide to produce the corresponding alkane in good yield130, therefore, this 
method was applied to deoxygenation of compound 18. Treatment of compound 18 
with iodine in the presence of triphenylphosphine and imidazole in refluxing toluene, 
gave 1L-1,3,4,5,6-O-pentabenzyl-2-deoxy-2-iodo-scyllo-inositol 26 in 82% yield105. 
The radical dehalogenation of compound 26 into the 2-deoxy analogue 27 proceeded 
in quantative yield. Subsequent removal of benzyl protective groups of compound 27 
provided the 2-deoxy-myo-inositol 13. 
 
The strategy to prepare 1L-4-O-benzyl-2-deoxy-myo-inositol 14 is the same as that for 
the synthesis of substrate analogues shown in Scheme 3.2. The pentol 13 was treated 
with triethylorthoformate in DMF in the presence of p-toluenesulfonic acid to afford 
orthoformate 28 in 75% yield. Benzylation of 28 using 1.1 equivalent of benzyl 
bromide in DMF in the presence of sodium hydride gave the intermediate 29 in 56% 
yield. Acidic treatment of 29 with Dowex 50X8 (H+ form) in methanol removed the 
orthoformate protective group leading to the potential inhibitor 14 in 95% yield. 
Therefore, compounds 13 and 14 were synthesized from compound 18 in overall 
yields of 80% and 32%, respectively.  
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Scheme 3.6 Chemical syntheses of potential inhibitors 13, 14. Reagents and conditions: o) Ph3P, 
imidazole, I2, toluene, 82%. p) Bu3SnH, AIBN, toluene, 99%. q) triethyl orthoformate, toluene-p-sulfonic acid, 
DMF, 120˚C-130˚C, 75%. r) NaH, BnBr, DMF, 56%. s) Dowex 50X8 (H+ form), MeOH, 95%. 
 
 
 
3.3.3 IC50 measurement and inhibitory properties 
 
The synthesized inositol mimics were tested for their ability to inhibit IDH enzymatic 
activity. Low solubility of the fluorinated inositol analogues in aqueous buffer 
prevented very high concentrations of inhibitor from being used, but an IC50 value 
could be determined. All the experiments were performed under the methods described 
in 2.8.4. IC50 was obtained by plotting the reciprocal of inhibitory activity (vo/vi) 
against concentrations of inhibitors (the plots are shown in Appendix 3). The inhibition 
constant (Ki) was calculated using the Cheng and Prusoff equation89, Equation 2.1, and 
the results are shown in Table 3.3.  
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    Table 3.3 Kinetic constants of compounds 10-14 as potential competitive inhibitors of IDH. 
Compounds 10 11 12 13 (±) 14 
IC50 (mM)* 77 ± 2 No inhibition 82 ± 2 107 ± 3 74 ± 2 
iK  (mM) 37 ± 5 No inhibition 39 ± 5 51 ± 5 35 ± 5 
   *IC50 was measured when [myo-inositol] = 20 mM. Conditions: 100 mM Tris-HCl, pH 9.0, 25°C.  
 
 
According to the kinetic results, compound 11 is neither an inhibitor nor a substrate of 
IDH and compounds 12, 10, 13, and 14 are inhibitors. These inhibitors were designed 
as competitive inhibitors; this mode of inhibition was observed using -D-glucosyl 
fluoride with IDH108.  
 
No inhibition of enzymatic activity was observed for compound 11, and this result is in 
agreement with the fact that scyllo-inositol is neither a substrate nor an inhibitor for 
IDH65. It implies that the active site of IDH might preferentially bind inositol analogues 
with an axial electronegative group at the 2-position. The Ki value of 10 is the smallest 
of the inhibitors tests. This might be attributed to the fact that 10 is the one that most 
closely mimics myo-inositol. Compound 12 is a competitive inhibitor and the inhibition 
property is close to 10. These phenomena reveal that the presence of an electronegative 
equatorial substituent at C2 has little effect on the binding affinity when an axial 
electronegative group is present. Compound 13 is a competitive inhibitor with a higher 
Ki compared to 10, whereas 11 is not an inhibitor, suggesting that deoxy inositol 
analogues still can bind to the active site when no electronegative group at 2-position 
but binding affinity is weaker. In addition, considering the dipole moments, compound 
10 is consistent with the substrate of IDH, myo-inositol, and compound 12 is consistent 
with the product of IDH, 2-keto-myo-inositol. This might be the reason that these two 
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compounds can bind in the active site, whereas compound 11 can not, since it 
demonstrates a different direction of dipole moment. 
 
As expected, compound 14 is a competitive inhibitor and is the best one (recall that 
because 14 is racemic, the true Ki is equal to half the observed value). This result is in 
good accordance with previous hypothesis that there is a nonpolar cavity near the 
active site69. Unfortunately, there is no obvious hydrophobic cavity apparent in the 
apo-IDH and holo-IDH crystal structures solved recently. It is still not clear how IDH 
accommodates the benzyl group. If a high-resolution crystal structure of 
IDH-inhibitor complex, especially IDH complexed with 14, can be obtained, it will be 
very helpful to prove the roles of the active-site residues and the binding pocket for 
4-substituent groups. 
 
In summary, inositol analogues, 2-deoxy-2-fluoro-myo-inositol 10, 2-deoxy-2,2- 
difluoro-myo-inositol 12, 2-deoxy-myo-inositol 13, and 1L-4-O-benzyl-2-deoxy- 
myo-inositol 14, are competitive inhibitors of IDH, while 2-deoxy-2-fluoro-myo- 
inositol 10 is neither an inhibitor nor a substrate for IDH. Since IDH catalyzes the first 
step of the myo-inositol catabolism pathway in bacteria as mentioned in 1.2.2, 
inhibiting dehydrogenase activity becomes an effective way to prevent the 
decomposition of myo-inositol. 
 
 
3.4 Mutagenic studies 
 
IDH catalyzes the oxidation-reduction reaction by binding and orienting the coenzyme 
NAD and myo-inositol/2-keto-myo-inositol in the binding sites formed with many 
amino acid residues that bind them with a combination of hydrogen bonds, electrostatic 
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interacion, hydrophobic effects, van der Waals and other interactions. The substrate 
specificity is due to the size, shape, and chemical property of the active sites defined by 
these interactions. Site-directed mutagenesis, substituting targeted amino acid residue 
with selected amino acid, is a useful tool for studying the participation of an amino acid 
residue in catalysis. Each site-directed substitution provides a new mutated IDH that 
are compared with the wild-type IDH, and the difference could be assigned to the 
contributions of the two residues. However, such kind of study is an estimation of the 
importance of a residue. The change in activity should not be the only criterion for 
assessing the significance of a residue for catalysis. Any substitution possesses the 
potential to alter the structure of the enzyme and affect activity by steric and chemical 
effects131. 
 
 
3.4.1 Overview of IDH crystal structure 
 
The catalytic dyad of IDH was proposed in 2007 and the substrate specificity was also 
explored as mentioned in 1.4 and 3.2. However, further structural and mechanistic data 
were required to substantiate the previous hypotheses and elucidate substrate specificity. 
Fortunately, the X-ray structure of apo-IDH was solved shortly after. Just a few months 
prior to this thesis, the binary structure complexed with NADH (holo-IDH), and ternary 
structure complexed with NADH and myo-inositol were solved. However, the ternary 
complex was obtained by soaking binary crystals in myo-inositol, and myo-inositol 
binds in a non-productive mode. Nonetheless, some useful information can still be 
derived. 
 
An active IDH exits as a tetramer (Figure 3.3), and NAD and inositol/inosose bind in 
each monomer. The monomer is made up of two structural domains as shown in 
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Figure 3.4. The N-terminal domain (1-123 residues) is a Rossmann fold domain, a 
typical dinucleotide binding domain with a central -sheet surrounded by -helices. 
The C-terminal domain (124-344 residues) displays overall characteristic to enzymes 
that belong to glyceraldehyde-3-phosphate dehydrogenase-like protein family in the 
Structural Classification of Proteins (SCOP) database85,132. The C-terminal domain is 
the myo-inositol binding domain consisting of six helices, an antiparallel oriented 
six-stranded -sheet, and an antiparallel oriented two-stranded short-sheet which 
extends out to form a tetramer with the other three monomers. 
 
 
 
Figure 3.3 The model of a tetrameric IDH. Each color represents one monomer, respectively. The 
dinuleotide NADH and myo-inositol are shown in sticks. Atoms are shown in standard colors: grey for 
carbon, blue for nitrogen, orange for phosphorus, red for oxygen. myo-Inositol binds in a non-productive 
binding mode in each monomer. Image was generated using PyMOL68. 
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Figure 3.4 The model of one IDH monomer. One IDH monomer consists of two structural domains, 
they are N-terminal domain (residues1-123, -helices colored red and -strands colored yellow) and 
C-terminal domain (residues124-344, -helices colored cyans and -strands colored magenta). NADH 
and myo-inositol are given in stick representation. Atoms are shown in standard colors: grey for carbon, 
blue for nitrogen, orange for phosphorus, red for oxygen. Image was generated using PyMOL68. 
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3.4.2 Structure alignment and implications  
 
Comparisons of the primary structure of IDH from B. subtilis with those of SDRs and 
MDRs reveal that IDH is not a member of either superfamily although IDH is made up 
of 344 residues which is in the range of MDRs. However, IDH demonstrates 11% 
sequence identity with glucose 6-phosphate dehydrogenase (GPDH) from Leuconostoc 
mesenteroides that is claimed to belong to LDRs40,56. Structure alignment (Figure 3.5 
and 3.6) shows that 279 out of 344 amino acid residues of IDH can be superimposed 
onto corresponding residues in GPDH with root mean square (RMS) deviation 
difference in Cα atomic positions of 3.3 Å. Furthermore, it was reported that GPDH 
employs a His-Asp catalytic dyad mechanism (His240 and Asp177)133, and general 
base His240 is structurally aligned precisely with His176 in IDH. It implicates that 
IDH might be a member of LDRs. Unfortunately, the secondary residue, Asp172 of 
IDH, can not be aligned with Asp177 of GPDH (Figure 3.5).  
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Figure 3.5 Structure alignment of IDH from B. subtilis and GPDH from L. mesenteroides. GPDH is 
labeled as G6P. Red highlighted residues are identical residues; the residues written in red are similar 
residues. Residues His240 and Asp177 of GPDH are indicated with * , Asp172 and His176 of IDH are 
indicated with ▲. The structure alignment was performed by SEQUOIA134, and generated using ESPript 
2.277.  
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Figure 3.6 The structure alignment of the crystal structures of GPDH from L. mesenteroides (PDB 
code: 1DPG, blue) and IDH from B. subtilis (red). Structures are superimposed using Dali server, and 
the image was generated using PyMOL68. 
 
 
A fold similarity search of the protein data bank (PDB) using the Dali server revealed 
the structures homologous to IDH135, and the results were sorted by Z-score. The top 
eight structures and GPDH were chosen for comparison with IDH. The information of 
these nine enzymes is listed in Table 3.4, in which, only glucose-fructose 
oxidoreductase (GFOR) from Zymomonas mobilis and glucose 6-phosphate 
dehydrogenase (GPDH) from Leuconostoc mesenteroides have been characterized in 
terms of structure-function relationships.   
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Table 3.4 Nine of IDH homologous enzymes. These enzymes are obtained by searching with Dali server in RCSB protein data bank and are sorted by Z score.  
 PDB code Z score RMSD aligned amino acids identity% annotation and deposit year  
1 3EC7 48 0.9 336/336 49 NAD-dependent putative dehydrogenase from Salmonella 
typhimurium, 2008 
2 3EZY 38 1.9 319/334 30 putative dehydrogenase from Thermotoga maritima, 2008 
3 3CEA 36 2.6 323/342 23 NAD-dependent myo-inositol 2-dehydrogenase (IolG)  
from Lactobacillus plantarum WCFS1, 2008 
4 2GLX 32 2.7 301/332 23 NADP-dependent 1,5-anhydro-D-fructose reductase from 
Sinorhizobium morelense, 2006 
5 3EUW 36 2.2 317/333 24 myo-inositol dehydrogenase from Corynebacterium 
glutamicum, 2008 
6 3DB2 33 2.5 301/347 17 putative NADP-dependent oxidoreductase  from 
Desulfitobacterium hafniense, 2008 
7 1OFG  30 3.0 303/381 15 NADP-dependent glucose-fructose oxidoreductase from 
Zymomonas mobilis, 1996 
8 1ZH8 30 3.2 295/325 23 NADP-dependent oxidoreductase from Thermotoga 
maritima, 2005 
9 1DPG 18 3.3 279/485 11 NADP-dependent glucose 6-phosphate dehydrogenase from 
Leuconostoc mesenteroides, 1994 
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The multiple structure alignment of IDH and the top eight enzymes is shown in Figure 
3.8. From this comparison, several conserved regions are identified. First, a 
characteristic glycine rich motif GXGXXG(A), which is thought to be part of 
coenzyme binding site, is found in the 1-L1-1 region of Rossmann fold of these 
enzymes136. IDH contains the consensus sequence GXGXXG and they are numbered 
9-14. The first Gly residue is important for a sharp turn of the loop between 1 and 1. 
The second Gly residue allows a close contact between the protein back bone and the 
diphosphate of the coenzyme. The third Gly residue is replaced by Ala when the 
coenzyme is NADP instead of NAD, and Hanukoglu et al. postulated GX1-2GX1-2A as 
a consensus motif for NADP binding proteins137. This Ala in place of the third glycine 
residue along with the larger hydrophobic residues in the contact area between 1 and 
1 are proposed to widen the coenzyme binding pocket and make more space to 
accommodate the additional 2'-phosphate group of NADP138. 
 
Second, an Asp/Ser is located 19 or 20 residues downstream of the glycine motif, 
GXGXXGX19-20D(S). Asp35 (numbered from IDH), on the loop between 2 and 2 of 
Rossmann fold, may act as the direct coenzyme specificity determinant, which 
discriminates NAD from NADP by forming hydrogen bonds with the 2'- and 3'- 
hydroxyl groups of the adenosine ribose of NAD and repelling phosphate at the 
2'-position of the adenosine ribose of NADP, as reported previously139,140. Some 
enzymes possess dual specificity, binding both NAD and NADP. In these cases, 
normally Ser occupies that position (Asp/Ser), which can form hydrogen bonds with 
either coenzyme. Therefore, it is likely that LpIolG1, containing Ala at the 
corresponding Asp35 position, is a dual specificity enzyme although the protein 
contains NAD+ as a tight binding coenzyme since purification. 
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Third, motif EKP (residues 96-98, numbered from IDH) is strictly conserved in all 
these sequences, which indicates it might have some critical structural or functional 
role(s). Wiegert et al reported this motif as a putative fingerprint for a novel class of 
sugar dehydrogenases that are able to react with substrates structurally similar to 
glucose75. Examination of the crystal structures of these homologous enzymes shows 
the EKP motif is close to the oxidation-reduction reaction center. In addition, Lys is a 
frequently utilized catalytic center in dehydrogenases, especially in short chain 
dehydrogenases50,141. As a consequence, it is possible that the Lys residue of EKP is 
involved in the catalytic mechanism. The structural orientations of EKP in five 
homologous enzymes in Table 3.4 (PDB code: 1OFG, 3EC7, 3CEA, 2GLX and 1ZH8) 
that complexed with coenzymes NAD/NADP and IDH complexed with NAD have 
been compared. The coenzymes demonstrate very similar orientation at the 
nicotinamide end (Figure 3.7). However, the adenosine monophosphate (AMP) 
moieties of GFOR (yellow carbon) and AFR (green carbon) display different 
orientations from the others. The well conserved motif EKP is proposed to interact 
with nicotinamide to guide the binding orientation. The Glu residue forms a hydrogen 
bond with the carbonyl amide group of the nicotinamide ring. A peptide bond between 
Lys and Pro displays a cis conformation that might be important for the correct binding 
mode of the nicotinamide ring and the substrate71. The Lys residue is close to the 
nicotinamide ring and is believed to form a cation-interaction142. And the Lys residue 
also can form hydrogen bonds with 2'-, 3'- hydroxyl of the nicotinamide ribose.  
 
Fourth, it was reported that GFOR employed the catalytic dyad mechanism in which 
the Asp265 residue deprotonates Tyr269, allowing Tyr269 to abstract a proton from 
the substrate74. This Tyr269 aligns precisely with a His residue in the rest of the 
sequences, and this His may act as an acid-base catalytic residue. On the other hand, 
Asp265 is conserved through these nine sequences. Therefore, the catalytic dyad, Asp 
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and His (Asp172, His176, numbered from IDH, indicated with ▲ in Figure 3.8), is 
highly conserved, which is consistent with the theory that a similar mechanism is 
utilized by homologous enzymes. However, on the basis of IDH ternary complex 
structure (non-productive mode), the distance between His176 and Asp172 has been 
found to be too far away to form a hydrogen bond (~ 7.8 Å). Indeed, the strengthening 
of this hydrogen bond interaction is regarded as an important structural aspect of 
catalytic dyad mechanism. 
 
Finally, three Gly residues (Gly147, Gly220, Gly243, numbered from IDH) are strictly 
conserved in the C-terminal domain of these nine enzymes, in which there is no 
significant sequence identity, perhaps due to the substrate diversity. 
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Figure 3.7 Comparison of coenzyme (NAD or NADP) binding mode in IDH (magenta carbon), 
GFOR from Z. mobilis (PDB code: 1OFG, yellow carbon), AFR from S. morelense (PDB code: 
2GLX, green carbon), and a putative oxidoreductase from T. maritima (PDB code: 1ZH8, grey 
carbon), putative dehydrogenase from S. typhimurium (PDB code: 3EC7, cyan carbon), IolG1 
from L. plantarum (PDB code: 3CEA, purple carbon) by superimposing the backbones of 
complexed structures. The molecules of NAD/NADP are indicated in sticks (nitrogen colored blue; 
oxygen colored red; phosphorus colored orange). In order to show a clear picture, only motif EKP of 
IDH is shown. Image was generated using PyMOL68. 
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Figure 3.8 Multiple structure-based sequence alignment of IDH from B. subtilis and its homologs. 
IDH: myo-inositol 2-dehydrogenase from B. subtilis; 3EC7: dehydrogenase from S. typhimurium; 3EZY: 
dehydrogenase from T. maritima; 3CEA: myo-inositol 2-dehydrogenase (IolG1) from L. plantarum; 
3EUW: myo-inositol dehydrogenase from C. glutamicum; 3DB2: oxidoreductase from D. Hafniense; 
2GLX: 1,5-anhydro-D-fructose reductase from S. morelense; 1OFG: glucose-fructose oxidoreductase 
from Z. mobilis; 1ZH8: oxidoreductase from T. maritima. The structure alignment was performed by 
SEQUOIA134, and generated using ESPript 2.277. Red highlighted residues are identical residues; the 
residues written in red are similar residues. The other important residues are indicated with *. 
 
 
 
* 
* 
 111
3.4.3 Alteration of coenzyme specificity 
 
3.4.3.1 Overview of alteration of coenzyme specificity 
 
NADP differs structurally from NAD only by an additional phosphate group esterified 
to the 2-hydroxyl group of adenosine (Figure 1.5). As a consequence, the 
discrimination between NAD and NADP is an impressive example of the power of 
substrate recognition with enzymes. Since a large number of complex structures of 
NAD/NADP-dependent dehydrogenase are known, it provides a significant amount of 
structural data to analyze the discrimination. A better understanding of the 
protein-coenzyme interactions will contribute interesting results for protein 
engineering and redesign studies. Recently, the usage of enzymes as catalysts to 
synthesize chemicals has brought many challenges, such as developmental costs of 
biocatalysts as enzymes often require one or more costly cofactors. For example, 
NADP-dependent 2,5-diketo-D-gluconic acid reductase is a valuable catalyst for 
vitamin C production, but NADP is too expensive (nearly $500/mmol) to use in 
industry. Researchers tried to engineered this enzyme to NAD-dependent, which is 
more stable and less expensive (nearly $100/mmol)143. Regeneration of NADP/NAD 
thus became a challenge to allow addition of catalytic amount. So far, engineered 
formate dehydrogenase is the most successful example for this regeneration system140. 
 
A lot of work has been done to investigate the coenzyme specificity-determining 
region in dehydrogenase39,139,144. These studies have provided some common features 
of NAD- or NADP-dependent enzymes. Both NAD and NADP generally bind to 
enzymes that have domains folded in a Rossmann-type fold. In these binding domains, 
the N-teminal half involved in binding the adenosine diphosphate (ADP) moiety is less 
variable than the C-terminal half that binds nicotinamide moiety since the residues 
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around nicotinamide are substrate-dependent39. It was reported that the negatively 
charged Asp or Glu residue at the consensus motif GXGXXGX17-18D(E) is thought to 
play a significant role in coenzyme specificity for NAD by forming hydrogen bonds to 
both of the 2- and 3-hydroxyls of the adenosine ribose, whereas NADP-specific 
dehydrogenases typically have a positively charged residue Arg whose side chain faces 
the adenine plane to interact with 2-phosphate by electrostatic interaction and 
hydrogen bonding, and also form cation-stacking interactions with the adenine 
ring140. The Asp or Glu residue is therefore the fingerprint to discriminate NAD and 
NADP recognition. The Arg residue can help stabilize NADP but it is not a necessary 
residue. In many cases, Arg is substituted by other residues, such as Ser or His, and the 
interaction with NADP is mediated by water molecules144. Despite many attempts in 
mutagenic and structural analysis, alteration of coenzyme specificity remains a 
challenge since there is no clear recipe for completely switching specificity. To my 
knowledge, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is the only enzyme 
reported whose coenzyme specificity switched strictly from NAD to NADP145. 
myo-Inositol 2-dehydrogenase (IDH) from B. subtilis is highly specific to NAD and 
fails to catalyze the reaction with NADP as the coenzyme. In order to learn more about 
coenzyme recognition, the wild-type IDH is engineered in an attempt to improve its 
ability to use NADP as the coenzyme by means of site-directed mutagenesis. 
 
 
3.4.3.2 Alteration of specificity on the basis of sequence alignment 
 
Gly14, Asp35 
To identify amino acid residues that account for the coenzyme specificity of IDH, in 
the beginning, the choice of the mutations to be introduced into IDH was based on the 
sequence alignment with GFOR, a well characterized homolog at the time this work 
 113
was initiated. GFOR, which shares 18% sequence identity with IDH, is a strictly 
NADP-dependent enzyme. It was reported that the single mutation of Ser116 to Asp 
converted the strict NADP specificity of wild-type GFOR to a dual NAD/NADP 
specificity enzyme75. Examination of the complex structure of S116D shows that 
Asp116 is the residue which forms hydrogen bonds with 2-, 3- hydroxyls of ribose at 
the adenine end is found in many NAD-dependent enzymes70.  
 
Sequence alignment of GFOR and IDH (Figure 1.11) revealed the two residues Gly14 
and Asp35 in IDH which are corresponding residues of Ala95 and Ser116 could 
account for the observed coenzyme specificity of IDH75. The  
dinucleotide-binding fold fingerprint sequence GXGXXA in the NADP binding region 
of GFOR is changed to GXGXXG in the NAD binding region of IDH. Gly14 is the 
last residue in the GXGXXG fingerprint in IDH. Hanukoglu et al postulated 
GXGXXA as a consensus motif for NADP binding proteins137. This Ala residue along 
with the larger hydrophobic residues in the contact area between  and  are 
proposed to widen the coenzyme binding pocket and make more space to 
accommodate the additional 2'-phosphate group of NADP138. It has been reported that 
a single mutation Ala13 to Gly of 1,5-anhydro-D-fructose reductase (AFR) exhibited 
dual coenzyme specificity to both NAD and NADP while wild-type AFR is strictly 
NADP-dependent85. Ser116 of GFOR, located 21 residues downstream from the end of 
the fingerprint sequence GXGXXA, is displaced in NAD-binding enzyme IDH with 
Asp (numbered 35 in IDH). The Asp35 residue probably prevents NADP binding 
either by charge repulsion interaction or by steric hindrance with the adenosyl 2- 
phosphate group. 
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Figure 3.9 The model of N-terminal of IDH homology model with Gly14 and Asp35. Amino acid 
residue Gly14 and Asp35, and part of coenzyme NADH are indicated in sticks (oxygen in red, nitrogen 
in blue, phosphorus in orange, carbon in grey). Image was generated using PyMOL68. 
 
 
The relative position of the two residues Gly14 and Asp35 in the IDH homology 
model (Figure 3.9), in which NADH was docked manually, is consistent with the 
above hypotheses. Therefore, site-directed mutagenesis studies on the residues Gly14 
and Asp35 were carried out to generate single and double mutants (G14A, D35S, and 
G14A/D35S) and the ability of these mutants for utilizing both NAD+ and NADP+ as 
their coenzyme were measured, and the results are shown in Table 3.5. A single 
mutation Asp35 to Ser, substituted with a relatively small and uncharged side-chain, 
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alters the strict NAD coenzyme specificity of wild-type IDH to dual specificity for 
either NAD or NADP, suggesting that Asp35 might be the fingerprint which can 
discriminate NAD from NADP as a coenzyme. The mutant G14A is almost inactive 
with coenzyme NADP+, and the double mutant G14A/D35S presents worse activity 
with either NAD+ or NADP+ as a coenzyme than the single mutant D35S. Therefore, 
replacement of Gly14 leads no coenzyme alteration and this result is not consistent 
with the corresponding studies on GFOR and AFR75,85. Interestingly, mutant D35S 
demonstrates positive cooperativity (Hill constant h = 2) with NADP+, and no positive 
cooperativity (h = 1) with NAD+ was observed. Double mutant G14A/D35S 
demonstrates positive cooperativity (h = 2) with both NAD+ and NADP+. In this 
situation, when the coenzyme binds to one monomer of an active tetramer, the other 
monomer is stimulated, allowing the second coenzyme to bind more easily (D35S and 
G14A/D35 are assumed to follow compulsory ordered Bi Bi mechanism as wild type 
IDH since random ordered Bi Bi mechanism could demonstrate sigmoidal curve. The 
sigmoidal plots of D35S with NADP+ and G14A/D35S with NAD+ and NADP+ are 
shown in Appendix 4). 
 
The IDH-NADH complexed structure was solved thereafter, which let us revise some 
of our predictions. Examination of the complex structure reveals that the AMP moiety 
in IDH displays different orientation from those in GFOR and AFR. However, Asp35 
is located near the adenosine ribose and is able to chelate the diol of the ribose near the 
adenine as previously proposed (Figure 3.10). It thus can be concluded that Asp35 is 
the key residue to discriminate NAD and NADP. On the other hand, Gly14 is not on 
the loop between 1 and 1 as predicted by homology model, this residue exits in the 
1-helix instead. It is therefore not surprising that the substitution of Gly14 is not able 
to affect the coenzyme specificity. 
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Figure 3.10 The model of N-terminal NADH-IDH complex structure with Gly14 and Asp35. 
Amino acid residue Gly14 and Asp35, and part of coenzyme NADH are indicated in sticks (oxygen in 
red, nitrogen in blue, phosphorus in orange, carbon in grey). Image was generated using PyMOL68. 
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Table 3.5 Kinetic constants for the mutants D35S, G14A, and G14A/D35S.  
Enzymes Km(NAD(P)+) 
 (mM) 
Km (inositol) 
(mM) 
Vmax 
(mol· min-1· mg-1) 
kcat  
(s-1) 
kcat/Km NAD(P)+ 
(s-1·mM-1) 
kcat/Km NADP+
kcat/Km NAD+  
wild-type IDH 0.08 ± 0.01 4.4 ± 0.5 62 ± 2 42 ± 2 525 0 
NAD+ 1.7 ± 0.1 22 ± 7 223 ± 6 150 ± 4 89 D35S 
NADP+ 2.3 ± 1.0 809 ± 261 170 ± 43 114 ± 29 50 
0.6 
NAD+ 0.15 ± 0.02 4.7 ± 0.9 45 ± 1 30 ± 1 200 G14A 
NADP+   trace activity   
- 
NAD+ 3.4 ± 2.9 259 ± 71 47 ± 6 32 ± 4 10 G14A/D35S 
NADP+ 30 ± 16 190 ± 90 39 ± 17 26 ± 11 0.9 
0.1 
Conditions: 100 mM Tris-HCl, pH 9.0, 25°C. 
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3.4.3.3 Alteration of specificity on the basis of crystal structure 
 
Gly11, Ala12, and Val36   
 
Figure 3.11 Structure alignment of apo-IDH from B. subtilis and human 15-PGDH. IDH is 
indicated in green; 15-PGDH is indicated in magentas. The selected amino acid residues, Gln15, Asp36, 
and Trp37 of 15-PGDH corresponding to Ala12, Asp35, Val36 of IDH, are indicated in sticks. Image 
was generated using PyMOL68. 
 
15-Hydroxyprostaglandin dehydrogenase (15-PGDH)145, a strictly NAD-dependent 
short chain dehydrogenase, is the only enzyme reported to have its coenzyme 
specificity switched completely to NADP. Although 15-PGDH is a member of SDRs, 
the Rossmann fold is well-conserved throughout dehydrogenases. 15-PGDH provides 
therefore an interesting model for investigating conversion of coenzyme specificity for 
dehydrogenases. This complete alteration was accomplished by a triple mutant 
Q15K/D36S/W37R in which hydrogen bonding, cation-, and electrostatic interactions 
were introduced to establish potential interactions with NADP145. As the crystal 
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structure of 15-PGDH was deposited in the protein data bank and apo-IDH structure 
was solved at that time, structure alignment with apo-IDH and 15-PGDH (PDB code: 
2GDZ) was employed to predict the crucial residues which could convert the 
coenzyme specificity (Figure 3.11). On the basis of this structure alignment, the 
corresponding residues Ala12, Asp35, and Val36 in IDH were postulated to play the 
same roles as Gln15, Asp36, and Trp37 in 15-PGDH. Furthermore, Gln15 and Ala12 
exit at the beginning of 1 and Asp36, Trp37, Asp35, and Val36 exit on the loop 
between 2 and 2 of both Rossmann fold domains of 15-PGDH and IDH, 
respectively. Therefore, similar mutants, A12K/D35S, D35S/V36R, and 
A12K/D35S/V36R of IDH, were constructed. In addition, Gly11 of IDH, instead of 
Ala12, also could be aligned with Gln15 of 15-PGDH. Thus, Lys was introduced at 
this site and the corresponding mutants G11K/D35S and G11K/D35S/V36R were 
generated. Subsequently, the coenzyme specificities of these five mutants were 
measured and the kinetic constants are shown in Table 3.6. 
 
The mutants G11K/D35S and G11K/D35S/V36R lose all dehydrogenase activity with 
both NAD+ and NADP+. One reason might be that the substitution at site 11 in these 
two mutants ruins the fingerprint motif GXGXXG and further disturbs the Rossmann 
fold. Another possibility is that the longer side chain of Lys11 blocked NAD or NADP 
from binding since examination of the IDH-NADH complex structure shows the 
sidechain of Gly11 is pointing towards the diphosphate of NAD. 
 
When Ala12, which is on the loop between 1 and 1 of IDH, was mutated to a 
positively charged residue Lys, the Km values for both NAD+ and NADP+ decreased 
(the kinetic data shown in Table 3.5 and Table 3.6, D35S/V36R vs A12K/D35S/V36R, 
D35S vs A12K/D35S). It suggests that the long and positively charged side-chain of 
Lys might establish an ionic interaction with the diphosphate that stabilizes 
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NAD/NADP and thus the binding affinity increases. Introduction of Lys or Arg at site 
12 is therefore likely to favourably modify electronic interaction in this region. By 
contrast, the structure alignment shows the residue Arg or Lys located in the 
corresponding Ala12 position of IDH in five other homologs (Figure 3.8, 3EZY, 
3CEA, 3EUW, 3DB2, and 1OFG).  
 
Removal of the negatively charged Asp35 by replacement with a Ser residue makes the 
Km value for NAD+ increase, but this mutant can recognized NADP+ as a coenzyme. 
Consequently, amino acid residue Asp35 is identified as the direct coenzyme 
specificity determinant. Further substitution of Val36 to Arg (D35S/V36R) decreases 
the Km value of NADP+ from 2.3 mM to 0.16 mM, and increases the 7-fold preference 
for NADP+ compared to the single mutant D35S [[(kcat/Km)NADP+]D35S/V36R 
/[(kcat/Km)NADP+]D35S = 7], indicating that further stabilization of NADP+ by Arg was 
needed to increase the NADP specificity. Arg36 in mutant D35S/V36R is thus 
proposed as the typical residue whose side chain faces the adenine plane to interact 
with 2-phosphate of NADP+, and whose guanidinium group forms a cation- 
interaction with the adenine moiety of NADP as observed in other dehydrogenases144. 
 
Of the double/triple mutants, A12K/D35S/V36R demonstrates the lowest Km value 
with NADP+, which is comparable to the Km value of NAD+ with wild-type IDH. 
A12K/D35S displays equally specificity with NAD+ and NADP+ 
[(kcat/Km)NADP+/(kcat/Km)NAD+ = 1.0], and D35S/V36R and A12K/D35S/V36R display 
more preference for NADP+ than NAD+ [(kcat/Km)NADP+/(kcat/Km)NAD+ > 1.0]. These 
mutants are obviously more successful in specificity alteration than that of the single 
mutant D35S [(kcat/Km)NADP+/(kcat/Km)NAD+ = 0.6]. Particularly, the mutant D35S/V36R 
switches the coenzyme specificity of IDH from entirely NAD-dependent to a 6-fold 
preference for NADP+ over NAD+ [(kcat/Km)NADP+/(kcat/Km)NAD+ = 5.7]. 
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Table 3.6 Kinetic constants for the mutants G11K/D35S, G11K/D35S/V36R, D35S/V36R, A12K/D35S, and A12K/D35S/V36R.  
Enzymes Km(NAD(P)+) 
 (mM) 
Km (inositol) 
(mM) 
Vmax 
(mol· min-1· mg-1) 
kcat  
(s-1) 
kcat/Km NAD(P)+ 
(s-1·mM-1) 
kcat/Km NADP+
kcat/Km NAD+  
wild-type IDH 0.08 ± 0.01 4.4 ± 0.5 62 ± 2 42 ± 2 525 0 
NAD+ no activity G11K/D35S 
NADP+ no activity 
NAD+ no activity G11K/D35S/
V36R NADP+ no activity 
NAD+ 1.8 ± 0.2 7.4 ± 5.6 176 ± 15 118 ± 10 65 D35S/V36R 
NADP+ 0.16 ± 0.02 35 ± 4 88 ± 2 59 ± 2 369 
5.7 
NAD+ 1.9 ± 0.3 16 ± 7 262 ± 7 176 ± 7 95 A12K/D35S 
NADP+ 1.7 ± 0.8 185 ± 91 227 ± 31 153 ± 21 93 
1.0 
NAD+ 1.2 ± 0.2 4.2 ± 0.6 206 ± 10 139 ± 7 116 A12K/D35S/
V36R NADP+ 0.06 ± 0.01 24 ± 2 50 ± 2 34 ± 2 567 
4.9 
Conditions: 100 mM Tris-HCl, pH 9.0, 25°C. 
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Ala40 
Subsequently, the holo-IDH structure was solved. Examination of the structure found 
that Ala40 on 2, among the residues around the 2-hydroxyl group of ribose of NAD, 
was another putative site with the potential to interact with 2'-phosphate of NADP 
(Figure 3.12). Thus, introducing a residue with a positively charged side-chain at this 
position was thought to be able to establish a potentially stabilizing ionic interaction 
with the nearby phosphate of NADP. The structure alignment in Figure 3.8 shows that 
the residue Arg or Lys located at the corresponding Ala40 position in four homologs 
(1OFG, 3DB2, 2GLX, and 1ZH8) identified as NADP-dependent enzymes. The 
replacements of Ala40 with Lys and Arg were therefore carried out by means of 
site-directed mutagenesis, resulting in one double mutant D35S/A40K and two triple 
mutants D35S/V36R/A40K and D35S/V36R/A40R. Their ability to utilize NADP+ and 
NAD+ was measured and the results are presented in Table 3.7.  
 
Steady-state kinetic analysis revealed a noticeable decrease of the Km values of 
mutants D35S/A40K, D35S/V36R/A40K, and D35S/V36R/A40R for NADP+, 
compared to that of the parent mutants D35S and D35S/V36R. In particular, the 
mutant D35S/V36R/A40K displayed the lowest Km value for NADP+ (0.04 ± 0.01 
mM). Therefore, a further stabilization of NADP may be achieved by replacing Ala 
with Lys/Arg. However, this mutant also showed the lowest kcat for NADP+ (14 s-1). As 
a consequence, despite the fact that Lys with a long and charged side-chain might be 
an ideal amino acid for position 40 to bind NADP+, this substitution leads to a less 
productive binding of NADP+ and thus results in a poor catalytic efficiency with 
NADP+.  
 
Further analysis of kinetic constants showed that the three mutants (D35S/A40K, 
D35S/V36R/A40K, and D35S/V36R/A40R) displayed clear preference for NADP+ 
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over NAD+ as their coenzyme [2 < (kcat/Km)NADP+/(kcat/Km)NAD+ < 4]. The double 
mutant D35S/A40K displays a shift in its coenzyme specificity towards NADP+ 
compared to the parent mutant D35S ([(kcat/Km)NADP+/(kcat/Km)NAD+]D35S/A40K 
/[(kcat/Km)NADP+/(kcat/Km)NAD+]wt = 4), whereas, the triple mutants D35S/V36R/A40K 
and D35S/V36R/A40R display less NADP+ specificity than their parent mutant 
([(kcat/Km)NADP+/(kcat/Km)NAD+]triple mutant /[(kcat/Km)NADP+/(kcat/Km)NAD+]D35S/V36R = 0.6).  
 
 
 
 
Figure 3.12 The model of N-terminal domain of holo-IDH structure. The residues Ala12, Asp35, 
Val36, Ala40, and the coenzyme NADH are indicated in sticks (oxygen in red, nitrogen in blue, 
phosphorus in orange, carbon in grey). Image was generated using PyMOL68. 
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Table 3.7 Kinetic constants for the mutants D35S/A40K, D35S/V36R/A40R, and D35S/V36R/A40K.  
Enzymes Km(NAD(P)+) 
 (mM) 
Km (inositol) 
 (mM) 
Vmax  
(mol·min-1·mg-1) 
kcat  
(s-1) 
kcat/Km NAD(P)+ 
(s-1·mM-1) 
kcat/Km NADP+
kcat/Km NAD+  
wild-type IDH 0.08 ± 0.01 4.4 ± 0.5 62 ± 2 42 ± 2 525 0 
NAD+ 2.8 ± 0.8 9.0 ± 2.0 273 ± 16 184 ± 11 66  D35S/A40K 
NADP+ 0.9 ± 0.2 41 ± 18 217 ±12 146 ± 8 155 
2.3 
NAD+ 1.0 ± 0.1 43 ± 7  93 ± 4 63 ± 3 63 D35S/V36R/
A40R NADP+ 0.06 ± 0.01 8. 4 ± 1.0 21 ± 1 14 ± 1 233 
3.7 
NAD+ 0.9 ± 0.1 25 ± 5 125 ± 9 84 ± 6 93 D35S/V36R/
A40K NADP+ 0.04 ± 0.01 8.5 ± 1.3 21 ± 1 14 ± 1 350 
3.8 
Conditions: 100 mM Tris-HCl, pH 9.0, 25°C. 
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3.4.3.4 Summary 
 
Six amino acid residues (Gly11, Ala12, Ala14, Asp35, Val36, and Ala40) of wild-type 
IDH, which, according to sequence alignment, structure comparison, and structure 
analysis, could be important determinants of coenzyme specificity, were mutated in an 
attempt to accommodate NADP. Eleven IDH mutants bearing single, double, or triple 
mutations were produced and eight of them can utilize NADP+ as a coenzyme, but they 
are not entirely NADP+ specific. From these mutational analyses, it has been noticed 
that the regions of NAD- and NADP-binding sites differ to some extent and the 
difference is essential in determining the coenzyme specificity. Four regions around 
the coenzyme are identified in this work. First, Asp35 is identified as the discriminator 
that only chelates the diol of the ribose near adenine of NAD via hydrogen bonds. The 
single mutation (Asp35 to Ser) alters wild-type IDH, a strictly NAD-dependent 
dehydrogenase, to an enzyme with dual coenzyme specificity. Second, the successive 
residue Val36, its sidechain directed towards the plane of adenine, seems to play an 
important role in discriminating NAD and NADP. Replacement of this residue with 
Arg (mutant D35S/V36R) exhibits the highest ratio of specificity constants 
[(kcat/Km)NADP+/(kcat/Km)NAD+ = 5.7] among all the mutants. The double mutant 
D35S/V36R therefore is the most successful one for alteration of the coenzyme 
preference of IDH. The mutagenic results demonstrate that the combined steric factor 
and electrostatic interaction might comprise the main determinants responsible for 
coenzyme specificity. Third, structure-guided mutation of residue Ala40 on 2 
increases the ratio of specificity constants for mutant D35S/A40K compared to its 
parent mutant D35S and decreases the ratio of the specificity constants for mutants 
D35S/V36R/A40K and D35S/V36R/A40R compared to their parent mutant 
D35S/V36R. However, all of the three mutants display lower Km values than that of 
their parent mutants. Fifth, the loop between 1 and 1 of wild-type IDH fix the 
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diphosphate group of NAD through hydrogen bonding interactions. Mutations of 
residue Ala12 (A12K/D35S and A12K/D35S/V36R) on this loop exhibit lower Km 
values and little effect on the ratio of specificity constants, compared to their 
corresponding parent mutants (D35S and D35S/V36R).   
 
Although only the NAD binding pocket of IDH was modified and the mutated sites 
were far away from myo-inositol-binding site, the kinetic analyses revealed that the 
values of Km for myo-inositol of almost all mutants increased and the catalytic 
efficiency decreased compared to that of wild-type IDH. This can be explained by the 
compulsory Bi Bi mechanism that IDH obeys, which requires coenzyme binds first in 
order to accommodate the substrate myo-inositol. The mutants are not able to adopt the 
same active conformation as wild-type IDH after binding with coenzymes 
NAD/NADP, leading to non-optimal protein-coenzyme conformations. As a result, the 
binding property of myo-inositol is impaired to some extent. Therefore, the Km values 
of myo-inositol increases. It is proposed that the subtle change of protein-coenzyme 
conformation might bring the significant difference in substrate binding affinity/ Km 
values. This phenomenon has also been observed in the case of formate 
dehydrogenase140. 
 
Alteration of IDH to a NADP-specific enzyme may require further structural 
modification. In this regard, a 7-fold mutation was utilized to convert isocitrate 
dehydrogenase coenzyme specificity from 7000-fold preference for NADP+ to a 
200-fold preference for NAD+, and the enzymatic activity is comparable to that of 
wild-type isocitrate dehydrogenase146. These 7 residues include not only the ones 
which interact with the coenzyme directly but also the second-layer residue (Val351) 
which interacts with first-layer residues by steric packing. It is a challenge to find the 
second-layer residues which play critical roles in controlling specificity, but would be 
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interesting to try such mutations in IDH to increase the binding affinity and catalytic 
activity with NADP as a coenzyme.  
 
 
 
3.4.4 Alteration of substrate specificity from myo-inositol to myo-inositol 
4-O-phosphate  
 
IDH demonstrates a broad range of substrate spectrum including 4-substituted 
myo-inositol and glucose derivatives as mentioned in 1.4.3. However, IDH can not 
utilize 1L-myo-inositol-4-O-phosphate as a substrate. As IDH selectively reacts with 
1L-4-substituted-myo-inositol, it could be used to develop a method to resolve racemic 
mixture of negatively charged inositol derivatives, such as (±) 
1L-myo-inositol-4-O-phosphate69. Thus, several attempts have been made to engineer 
IDH to an enzyme that is able to recognize 1L-myo-inositol-4-O-phosphate as a 
substrate. 
 
During the time that no IDH structure was available, Tyr233, Gly234 and Tyr235 were 
proposed to be the basis of the hydrophobic pocket according to the homology model78 
(Figure 1.13). Introduction of Arg or Lys at sites 233 and 235 was therefore likely to 
modify electrostatic interaction in this region. The mutants Y233R and Y235R were 
postulated to be able to recognize a negatively charged group at the 4-position of 
myo-inositol such as 1L-myo-inositol-4-O-phosphate as a substrate. Unfortunately, 
both mutants Y233R and Y235R competely lose activity with myo-inositol and 
demonstrated no activity with 1L-myo-inositol-4-O-phosphate while mutants Y233F 
and Y235F demonstrated comparable activity with wild-type IDH (see Table 3.8).  
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When the crystal structure of IDH was solved, it was found that the homology model 
predicted IDH structure poorly, especially for inositol-binding domain. There is no 
obvious hydrophobic cavity in the crystal structure. However, it was identified in the 
structure alignment (Figure 3.8) that this YGY motif is conserved in the other three 
IDH homologs: dehydrogenase from Salmonella typhimurium (3EC7), dehydrogenase 
from Thermotoga maritima (3EZY), and myo-inositol dehydrogenase from 
Corynebacterium glutamicum (2EUW), suggesting that the motif YGY may play some 
structural or functional role in these dehydrogenases.  
 
 
 
Figure 3.13 The model of interface of IDH tetramer. Yellow, green, red, and blue are indicated the 
four monomers that consist of a tetramer. The amino acid residues Tyr233, Arg156, and Arg259 are 
indicated in sticks. Image was generated using PyMOL68. 
 
 129
Examination of the crystal structure of IDH shows that residue Tyr235, pointing into 
the putative inositol binding site, may interact with the substrate myo-inositol, 
whereas, Tyr233 is present in the interface of monomer and monomer. In the vicinity 
of sidechain of Tyr233, there are two amino acid residues, bearing positively charged 
sidechain, arginines Arg156' (' indicates Arg residue from another monomer) and 
Arg259 (Figure 3.13). The replacement of Tyr233 with Arg introduces positive 
charge-repelling interactions in this region, and the unfavourable interaction is likely 
to force the tetramer to fall apart to dimers/monomers, and mutant Y233R therefore is 
inactive. To obtain more evidence to support this hypothesis, double mutants or triple 
mutants were designed to recover the activity by removing a positive sidechain on 
Arg156 and Arg259. At first, single mutations were tried on these two residues. The 
mutant R156Q lost all the dehydrogenase activity. Mutants R259Q, R259A, and 
R259Y showed similar Michaelis constants with NAD+ and myo-inositol to wild-type 
IDH, but the values of kcat dropped compared to wild-type IDH. On the basis of these 
results, double mutations at Tyr233 and Arg259, mutants Y233R/R259A, 
Y233R/R259E, Y233R/R259Q, and Y233R/R259Y, were carried out. Unfortunately, 
no obvious activity of these double mutants was observed. By examining the 
tetrameric IDH structure, there are three negatively charged residues (Glu240'', 
Asp236, and Glu252) around Arg156' and Arg259. It seems difficult to get positive 
and negative charges balanced in this area, and more mutants may be necessary to 
rescue the enzymatic activity. 
 
On the basis of the apo-IDH crystal structure, Asn157 was proposed as the putative 
site that had the potential to interact with phosphate group of 
1L-myo-inositol-4-O-phosphate. Therefore, the site-directed mutagenesis of Asn157 
to a positively charged arginine was constructed to establish the ionic interaction. The 
kinetic data revealed that the activity of mutant N157R with myo-inositol decreased 
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7-fold and the specificity constant kcat/Km(inositol) decreased more than 30-fold 
(Table 3.8). Unfortunately, mutant N157R can not recognize either 
1L-myo-inositol-4-O-phosphate or 1L-4-O-benzyl-myo-inositol as the substrate. 
 
Inspection of the apo-IDH structure and homology model reveals that, even though 
this model was thought to be of good quality, it could not be used for identifying the 
residues determining the coenzyme specificity and the inositol-binding site (Figure 
3.14). The superposition of the two structures demonstrates that 286 out of 344 amino 
acid residues can be aligned with the RMS deviation of 3.5 Å. In particular, the 
extended conformations of binding NADs are different, especially in the adenine 
diphosphate (ADP) moiety. When the X-ray structures of apo- and holo-IDH are 
available, it is still quite difficult to predict which amino acid residues are important 
for myo-inositol binding. In fact, if the crystal structure of IDH was known at the time 
I started this project, we would probably never have found that the site Tyr233 is a 
critical residue for tetrameric formation by rational design.  
 
In the course of this mutational study on the alteration of substrate specificity, amino 
acid residues Tyr233, Tyr235, and Asn157 were postulated on the basis of IDH 
homology model and crystal structure, respectively. However, none of the mutants 
substituted on the targeted sites could alter substrate specificity.    
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Figure 3.14 Superpositioned models of the crystal structure of IDH (red) from B. subtilis and the 
homology model of IDH (blue). Two molecules of NADH are shown in sticks (carbon in magenta 
belongs to crystal structure, carbon in light blue belongs to homology model, oxygen in red, nitrogen in 
blue, phosphorus in orange). Image was generated using PyMOL68. 
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Table 3.8 Kinetic constants for the mutants at the sites of Asn157, Tyr233, Tyr235, Arg259, and Arg156.  
Enzymes Km(NAD+) (mM) Km (myo-inositol)  (mM)      Vmax   (mol·min-1· mg-1) kcat (s-1) 
wild-type IDH 0.08 ± 0.01 4.4 ± 0.5 62 ± 2 42 ± 2 
N157R 0.24 ± 0.05 356 ± 62 8.7 ± 1.3  6 ± 1 
Y233F 0.07 ± 0.01 4.0 ± 0.4 55 ± 3 37 ± 2 
Y235F 0.11 ± 0.02 39 ± 4 36 ± 5 24 ± 4 
Y233F/Y235F 0.12 ± 0.04 56 ± 6 37 ± 3 25 ± 2 
Y233R No activity 
Y235R No activity 
R259Q  0.05 ± 0.02 5.6 ± 1.1 24 ± 1 16 ± 1 
R156Q   No activity  
R259A 0.07 ± 0.01 3.4 ± 0.3 50 ± 1 34 ± 1 
R259Y 0.06 ± 0.01 3.5 ± 0.4 46 ± 1 31 ± 1 
Y233R/R259A  trace activity   
Y233R/R259E  trace activity   
Y233R/R259Q  trace activity   
Y233R/R259Y  trace activity   
Conditions: 100 mM Tris-HCl, pH 9.0, 25°C.
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3.4.5 Mutagenic study of the inositol-binding site 
 
3.4.5.1 Overview of the inositol-binding pocket 
 
 
Figure 3.15 Proposed inositol-binding pocket. Proposed inositol binding residues are represented in 
sticks and NADH is represented in lines (oxygen in red, nitrogen in blue, phosphorus in orange, carbon 
in grey). Image was generated using PyMOL68.  
 
 
The oxidation-reduction reaction catalyzed by IDH is a hydride transfer between the 
nicotinamide ring of the coenzyme NAD+ and the substrate myo-inositol. The 
myo-inositol binding site is thus located near the nicotinamide moiety, which is in the 
cleft between the N-terminal domain and the C-terminal domain according to the apo- 
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and holo-IDH crystal structures. Since His176 and Asp172 have been identified as 
catalytically important residues previously78, the inositol-binding pocket is easily 
identified (Figure 3.15). To gain insight into substrate binding, a series of site-specific 
mutations in the IDH gene at sites corresponding to Tyr280, Trp272, Lys97, Asn157, 
His155, Tyr235, Met126, and Asp179 were performed.  
 
 
 
3.4.5.2 Mutagenic studies of putative myo-inositol binding residues 
 
Lys 97  
Motif EKP is highly conserved among IDH homologs, and these Lys sidechains point 
toward substrate-binding pockets according to the crystal structures known. However, 
the role of Lys has not been identified yet. This intriguing lysine residue, Lys97 in 
IDH, is adjacent to the face of nicotinamide ring (~ 3.5 Å distant) in the holo-IDH 
structure, and a favorable cation- interaction is formed. It suggests that this 
conformation may be influenced by the oxidation state of NAD, and the orientation of 
Lys97 sidechain might rearrange during the oxidation-reduction reaction. To 
understand the effect of Lys97, this residue was mutated to Arg, whose sidechain is 
more likely than that of Lys to be in a cation- interaction142. However, the longer 
sidechain of Arg could cause the distortion of local geometry and thus decrease the 
activity. Comparing the kinetic parameters between K97R and wild-type IDH, the 
replacement not only decreased the Km value for both NAD+ and myo-inositol (Table 
3.9), suggesting they bound with mutant K97R tighter than wild-type IDH, but also 
decreased the turnover number kcat 600 fold. This result is consistent with the previous 
conclusion that product release is the rate-limiting step in IDH catalyzed reaction. Thus 
there are three possibilities: first, the conformation of K97R remains as wild-type IDH, 
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and Arg97 introduces stronger interactions with both coenzyme and myo-inositol than 
does Lys97; second, the conformation of the N-terminal domain remains as wild-type 
IDH, and Lys97 is not involved in myo-inositol binding, and the tighter binding NAD+ 
triggers C-terminal conformation change; third, replacement with Arg affects the 
conformation of both the N-terminal domain and C-terminal domain.  
 
The other mutation, Lys97Q, was meant to remove the charge and keep the -NH2 
group that would allow the formation of a hydrogen bond. This replacement abolished 
the enzymatic activity completely, suggesting that charge might be a necessary factor 
for the enzymatic activity. 
 
N-Acetylgalactosaminidase (PDB code: 2IXB)147, a hydrolase belongs to the GH4 
family, and shares 18% sequence identity with IDH. Comparing structures of 
N-acetylgalactosaminidase and IDH, 307 out of 344 amino acid residues of IDH can 
be aligned to this glycosidase with the RMS deviation of 2.9 Å. In addition, the 
catalytic residue His176 of IDH is well aligned with His228, which is the catalytic 
acid/base in N-acetylgalactosaminidase147,148. This N-acetylgalactosaminidase 
demonstrates a very similar NAD binding mode to IDH, but the motif EKP is 
substituted with EVS. On the basis of this evidence, Lys97 was replaced with Val, in 
which both the charge and hydrogen bonding property were removed. K97V also lost 
all the activity. It was found that the apo-K97V structure (Karin E. Van Straaten, 
unpublished result) is identical to apo-IDH, with RMS difference in Cα atomic 
positions of 0.4 Å after superposition (Figure 3.16). Apparently, this substitution does 
not change the IDH conformation. Clearly Lys97 plays a critical role in enzymatic 
function. 
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In summary, three mutants K97R, K97Q, and K97V were made to investigate the role 
of Lys97. On the basis of kinetic results, Lys97 was identified to relate to the binding 
properties of both coenzyme and substrate. Since Lys could also facilitate proton 
transfer by hydrogen bonding to the adjacent residue or act as catalytic acid/base 
directly, further elucidation of the exact role of Lys97 is necessary. 
 
 
 
Figure 3.16 Superpositioned models of apo-IDH and apo-K97V. apo-IDH colored in red; apo-K97V 
colored in blue. Amino acid residues Lys97 and Val97 are indicated in sticks. Image was generated 
using PyMOL68.  
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Table 3.9 Kinetic constants of mutants generated from the sites Lys97, Tyr280, Tyr235, and Trp272 in the proposed inositol-binding pocket. 
Enzymes Km(NAD+)  
(mM) 
Km (inositol) 
 (mM) 
Vmax  
(mol·min-1·mg-1) 
kcat  
(s-1) 
kcat/Km(inositol) 
  (s-1 mM-1) 
wild-type IDH 0.08 ± 0.01 4.4 ± 0.5 62 ± 2 42 ± 2 9.55 
K97R 0.03 ± 0.01 0.8 ± 0.2 0.11 ± 0.01 0.07 ± 0.01 0.09 
K97Q No activity  
K97V No acitivity  
Y280F 0.07 ± 0.01 7.9 ± 1.4 37 ± 4 25 ± 3 3.16 
Y235F 0.11 ± 0.02 39 ± 4 36 ± 5 24 ± 4 0.62 
Y233F/Y235F 0.12 ± 0.04 56 ± 6 37 ± 3 25 ± 2 0.45 
W272A 0.59 ± 0.07 351 ± 32 74 ± 7 50 ± 5 0.14 
W272H 0.70 ± 0.10 204 ± 32 92 ± 4 62 ± 3 0.30 
Conditions: 100 mM Tris-HCl, pH 9.0, 25°C. 
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Tyr280 
The sidechain of Tyr280 is adjacent to the carbonyl group of the nicotinamide ring of 
NAD+ (~ 3.0 Å) in the holo-IDH structure. It is likely that a hydrogen bond is formed 
between them. Among IDH homologs, this Tyr280 position is filled with Tyr or Phe 
(Figure 3.8), but it is still not clear what role the residue Tyr/Phe plays. Since the 
hydroxyl group of Tyr280 also could form a hydrogen bond with myo-inositol, Tyr280 
was replaced with Phe, which keeps the aromatic ring but is incapable of forming a 
hydrogen bond, to investigate the role of the hydroxyl group. Kinetic studies revealed 
that the Km value of NAD+ did not change after the replacement, but the Km value of 
myo-inositol was doubled (Table 3.9), suggesting Tyr280 was probably hydrogen 
bonding to myo-inositol, not NAD+. In addition, the apo-Y280F structure is identical to 
apo-IDH (Figure 3.17). All amino acid residues of Y280F can be superimposed onto 
corresponding residues of wild-type IDH with RMS difference in Cα atomic positions 
of 0.3 Å. Moreover, the aromatic rings of Tyr280 and Phe280 are oriented in the same 
direction. It therefore can be concluded that the substitution at site 280 does not alter 
the structure of the enzyme. 
 
Tyr235 
Tyr235 is the other Tyr residue in the substrate-binding pocket that could interact with 
myo-inositol directly. Like Tyr280, Tyr235 was substituted with Phe. The Km value of 
NAD+ of Y235F was comparable to that of wild-type IDH; however, Km value of 
myo-inositol was almost ten-fold of that of wild-type IDH. Also, this replacement 
decreased the turnover number to half of that of wild-type IDH. The double mutant 
Y233F/Y235F demonstrated similar properties with single mutant Y235F according to 
the measured kinetic constants (Table 3.9).  
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Figure 3.17 Superpositioned models of apo-IDH and apo-Y280F. apo-IDH colored in red; 
apo-Y280F colored in blue. Amino acid residues Tyr280 and Phe280 are indicated in sticks. Image was 
generated using PyMOL68. 
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Trp272 
On the basis of the structure of the ternary complex, which is believed to be a 
non-productive complex, Trp272 is expected to play important roles in substrate 
binding (Figure 3.18). Actually, Trp272 is not well conserved among IDH homologs 
(Figure 3.8), and Phe is usually present at this position. A bulky sidechain of Trp272 
was postulated to provide an important region for making the inositol binding pocket. 
In addition, The -NH- group might interact with myo-inositol by hydrogen bonding (~ 
3.3 Å). Considering this information, Trp272 was mutated to His and Ala, respectively. 
A smaller sidechain of His maintains aromaticity and the pattern of hydrogen-bonding 
interaction. Whereas, the accompanying change of the sidechain size is expected to 
alter the contacts with substrate. Replacing Trp272 with Ala was a large change in size 
and property, effectively removing all the functionality of the Trp sidechain. 
Surprisingly, kinetic results indicated this single mutation in the substrate-binding 
domain affected Michaelis constants of both coenzyme and substrate. Compared to 
wild-type IDH, the Km values of W272H and W272A for NAD+ increased almost ten 
times, and the Km values for myo-inositol increased fifty and eighty times respectively 
(Table 3.9). The increase in the Km values for both NAD+ and inositol could thus 
indicate that a single replacement of Trp272 in the vicinity of myo-inositol not only 
affects myo-inositol binding site, but also affects NAD+ binding site. It is likely that the 
change results from a disturbance of protein conformation by replacement on Trp272. 
Unfortunately, structures of these mutants have not been solved. 
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Figure 3.18 Proximity of bound myo-inositol and Trp272 in non-productive IDH ternary complex. 
myo-Inositol and Trp272 are indicated in sticks (oxygen in red, nitrogen in blue, and carbon in grey). 
Image was generated using PyMOL68. 
 
 
Asp179 
Asp179 is a conserved residue among IDH homologs (Figure 3.8), and could possibly 
participate in the catalytic dyad with His176 (Asp179 is ~ 6.8 Å away from His176 in 
holo-IDH). Based on this hypothesis, Asp179 was replaced isosterically with Asn, 
which can retain hydrogen-bonding ability. The substitution increased the Km values 
for both NAD+ and myo-inositol moderately, and increased turnover number slightly. It 
is apparent that Asp179 is not involved in the catalytic dyad. Although Asp179 is not 
in the first layer of residues interacting with substrate or coenzyme, this conserved Asp 
residue is still important since a single substitution changed the Michaelis constant and 
catalytic efficiency. A small increase in turnover number might result from the 
decrease substrate binding affinity as product release is the rate limiting step for IDH 
catalyzed reaction. 
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Table 3.10 Kinetic constants of mutants generated from the sites Asp179, Asn157, Met126, and His155 in the proposed inositol-binding pocket. 
Enzymes Km(NAD+) 
 (mM) 
Km (myo-inositol) 
 (mM) 
Vmax 
 (mol·min-1·mg-1) 
kcat  
(s-1) 
kcat/Km (myo-inositol) 
(s-1 mM-1) 
wild-type IDH 0.08 ± 0.01 4.4 ± 0.5 62 ± 2 42 ± 2 9.55 
D179N 0.35 ± 0.04 28 ± 5 79 ± 3 53 ± 2 1.90 
N157R 0.24 ± 0.05 356 ± 62 8.7 ± 1.3 6 ± 1 0.02 
N157S 0.08 ± 0.01 14 ± 3 33 ± 2 22 ± 2 1.57 
M126A 2.3 ± 2.2 > 1000 - - - 
M126S 5.7 ± 1.5 > 1000 - - - 
H155F No activity 
H155K > 5 > 1000 - - - 
Conditions: 100 mM Tris-HCl, pH 9.0, 25°C. 
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Asn157 
Examination of the ternary complex structure suggests that Asn157 likely interacts 
with myo-inositol (~ 3.0 Å to C5 hydroxyl). It was thus hypothesized that the Asn157 
sidechain forms a hydrogen bond with myo-inositol. Therefore, this residue was 
substituted by Ser. This replacement was meant to keep the hydrogen bond 
donor/acceptor that would allow the formation the hydrogen bond, however, the 
shorter side chain of Ser could make the bond strength weaker. Kinetic studies showed 
that the substitution of Asn157 did not affect the Km value of NAD+, but moderately 
increased the Km value of myo-inositol, and decreased turnover number (Table 3.10). 
Recently, structure of apo-N157S was solved, and it is quite similar to apo-IDH. All 
amino acid residues of N157S can be superimposed onto corresponding residues of 
wild-type IDH with RMS difference in Cα atomic positions of 0.4 Å (Figure 3.19). 
Moreover, the sidechains of Asn157 and Ser157 are pointing in the same direction. It 
can be therefore concluded that the proper formation and strength of the hydrogen 
bond between myo-inositol and Asn157 is related to the catalytic efficiency.  
 
N157R was made for the substrate specificity alteration mentioned in 3.4.4. The 
charged longer sidechain of Arg apparently disturbed the conformation of both 
coenzyme binding domain and substrate binding domain since the values of Km for 
both NAD+ and myo-inositol increased.  
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Figure 3.19 Superpositioned models of apo-IDH and apo-N157S. apo-IDH colored in red; 
apo-N157S colored in blue. Image was generated using PyMOL68. 
 
 
 145
 
Met126 
Met126 is not well conserved among IDH homologs (Figure 3.8), but the motif 
GFMRRYD, located between N-terminal domain and C-terminal domain, is conserved 
in dehydrogenase from Salmonella typhimurium and IolG1 from Lactobacillus 
plantarum. Within this motif, Met is the only residue whose sidechain might be 
involved in the first layer of inositol-binding pocket. This suggests that Met126 
possibly interacts with myo-inositol directly. Residue Met126 was therefore substituted 
by short chain residues Ala and Ser, respectively. The single mutations, M126A and 
M126S, were expected to change myo-inositol binding affinity. However, kinetic 
results (Table 3.10) showed both the Km values of NAD+ and the Km values of 
myo-inositol were affected by replacement on site 126, especially the Km values of 
myo-inositol since they are too high to be measured accurately due to the solubility 
limit of myo-inositol. It thus indicated that Met126 is a key residue for substrate 
binding. Fortunately, the structure of apo-M126A was solved, and it demonstrates a 
more open conformation in the N-terminal domain than that of wild-type IDH (Figure 
3.20). Thus, M126A undergoes conformational changes upon removal of sidechain of 
Met, which appears to be a key feature for maintaining the structure. We therefore 
reasoned that the C-terminal conformation of binary complex NAD-M126A was 
different from that of wild-type IDH, and this difference resulted in the higher 
Michaelis constant of myo-inositol with M126A than that of wild-type IDH. 
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Figure 3.20 Superpositioned backbones of apo-IDH and apo-M126A. apo-IDH colored in red; 
apo-M126A colored in blue; amino acid residue Met126 is indicated in stick colored in green. Image 
was generated using PyMOL68. 
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His155 
Although His155 is not a conserved residue among the sequence of IDH homologs 
(Figure 3.8), it is believed to bind with myo-inositol since it is 2.5 Å away from C6 
hydroxyl of myo-inositol in the non-productive IDH ternary structure. Surprisingly, the 
replacement of His155 with Phe gave an enzyme with no activity. However, the 
replacement with Lys, which maintained the charge and allowed the formation of 
hydrogen bonds, resulted in an enzyme with activity. Unfortunately, no precise kinetic 
data was measured for H155K because the value of Km is too high to attain saturated 
conditions. The long sidechain of Lys could cause the distortion of the local geometry 
and thus decrease myo-inositol binding affinity. Therefore, His155 might be a key 
residue for substrate binding or structure maintaining. 
 
 
 
3.4.5.3 Summary 
 
In summary, we have chosen eight amino acid residues (Tyr280, Trp272, Lys97, 
Asn157, His155, Tyr235, Met126, and Asp179), which, according to current theories 
based on sequence alignment and crystal structures, could be important residues 
involved in myo-inositol binding. In the course of mutational and kinetic studies, it was 
found that the replacements of these residues affected the Km values of myo-inositol 
more or less, three of them (K97Q, K97V, and H155F) even lost dehydrogenase 
activity. Out of eight targeted residues, the substitutions on the sites of Trp272, Lys97, 
Asn157, His155, Met126, and Asp179 affected the Km values for both NAD+ and 
myo-inositol. In particular, mutants M126S, M126A, and H155K increased the Km 
values of both NAD+ and myo-inositol dramatically. 
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The structures of apo-Y280F, apo-K97V, and apo-N157S were solved and found to be 
quite similar with the structure of wild-type apo-IDH. Whereas, it was found that the 
M126A mutant undergoes a conformation change upon replacement of Met residue, 
which appears to be the key feature for maintaining the IDH structure and activity. 
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4. SUMMARY AND FUTURE DIRECTIONS 
 
This dissertation describes mechanistic, inhibitory, and mutagenic studies of 
myo-inositol 2-dehydrogenase (IDH) from Bacillus subtilis. As reported in 1979, this 
enzyme catalyzes the reversible interconvertion of myo-inositol and 
2-keto-myo-inositol with transformation of NAD+ and NADH concomitantly65. When 
I started this project in 2004, no structural information was avaiblable about IDH. Our 
initial interest in IDH was the catalytic mechanism, including the chemical mechanism 
and the kinetic mechanism. It was discovered that His176 acted as a base/acid to 
catalyze the oxidation-reduction reaction. During the catalysis, IDH obeys compulsory 
Bi Bi mechanism like the other dehydrogenases, in which NAD+ binds first and 
NADH releases last after chemical reaction65. Since the chemical step is not the 
rate-limiting step for many of dehydrogenases, 2H kinetic isotope effect was utilized to 
explore whether IDH employs the same process. It turned out that no kinetic isotope 
effect was observed, and consequently the chemical step of the reaction IDH catalyzed 
was not rate-limiting. This evidence, as well as previous determined rate constants, 
suggests that the breakdown of ternary complex and liberation of NADH constituted 
the rate-limiting step. 
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The previous work in this laboratory regarding the substrate spectrum gave insight 
into the features of the IDH substrates69, which are 4-substituted myo-inositol 
analogues or 6-substituted -D-glucose analogues. It appears that the substrate 
binding site demonstrates a large range in size accommodating substituted groups, but 
it is sensitive to the charges born by the substituted groups. On the basis of this 
information, four compounds with new shapes, 4-O-(2-benzothiazolylmethyl)- 
myo-inositol 1, 4-O-(4-tert-butylbenzyl)-myo-inositol 2, 4-O-propargyl-myo- inositol 3, 
and 4-O-(1-allyl-4-methylene-1,2,3-triazol)-myo-inositol 4, were synthesized, and the 
steady-state kinetic parameters for these compounds with IDH were determined. It 
was found they were all substrates of IDH, in particular, compound 1 demonstrated 
lower appmK  than that of natural substrate myo-inositol. It is interesting to note that 
compound 1 differs from myo-inositol by such a large group. Therefore it was 
proposed that the additional group introduced more favourable interaction with IDH 
active site. However, how IDH accommodates this 4-substituted group is still 
unknown, even though crystal structures of apo- and holo-IDH have been obtained 
recently.  
 
By applying the knowledge gained from substrates exploring, five compounds, 
2-deoxy-2-fluoro-myo-inositol 10, 2-deoxy-2-fluoro-scyllo-inositol 11, 2-deoxy- 
2,2-difluoro-myo-inositol 12, 2-deoxy-myo-inositol 13, and 4-O-benzyl-2-deoxy- 
myo-inositol 14, were designed, synthesized, and tested as potential inhibitors of IDH. 
As shown by our data, compound 11, mimicking scyllo-inositol, is neither a substrate 
nor an inhibitor, and compounds 10, 12, 13, and 14, mimicking myo-inositol, are 
competitive inhibitors of IDH. It is likely that IDH can only bind compounds that 
demonstrate similar dipole moments as myo-inositol or 2-keto-myo-inositol. As a 
consequence, competitive inhibitors are discovered for inhibiting IDH dehydrogenase 
activity, as well as providing additional support evidence for the substrate recognition. 
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Since a large number of dehydrogenase-NAD/NADP complex structures are available, 
how a dehydrogenase discriminates NAD and NADP as its coenzyme has been a hot 
topic in the past decades. In addition, many enzymes as biocatalysts in industry are 
NAD/NADP-dependent. A lot of attempts have been carried out to try to convert the 
conenzyme specificity, and some of the successful ones have been already applied in 
enzymatic synthesis. However, no clear recipe is available to switch coenzyme 
specificity strictly so far. The previous accumulated knowledge about coenzyme 
specificity sheds light on our IDH coenzyme specificity. In the past few years, 
sequence alignment with glucose-fructose oxidoreductase (when no structure 
information was available), structure alignment with 15-hydroxyprostaglandin 
dehydrogenase (when the structure of apo-IDH was available), and structure-based 
engineering (when the structure of holo-IDH was available) were utilized to predict the 
residues that are crucial to discriminate NAD and NADP. During the course of the 
mutagenic study, six amino acid residues (Gly11, Ala12, Ala14, Asp35, Val36, and 
Ala40) were selected to modify, producing 11 mutated IDHs bearing single, double, or 
triple mutations. It is found that Asp35 is the crucial site to discriminate NAD and 
NADP, and the sites of Val36 and Ala40 are important for coenzyme binding affinity. 
Among the constructed mutants, mutant D35S/V36R is the most successful one, which 
converting coenzyme specificity from entirely NAD+-dependent to 6-fold preference 
for NADP+ over NAD+. So far, we have not yet obtained the engineered IDH that 
switches the coenzyme specificity competely. 
 
It was found that IDH catalyzes the oxidation-reduction reaction employed 
His176-Asp172, similar to catalytic dyad of His-Asp that was reported in 
glucose-fructose oxidoreductase (GFOR). Examination of the structure of IDH 
indicated that residues Tyr280, Trp272, Lys97, Asn157, His155, Tyr235, Met126, and 
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Asp179, apart from catalytic residues His176 and Asp172, could have direct 
interactions with myo-inositol. Therefore, modifications of these residues were carried 
out to determine their contributions, and the activities of the engineered IDH were 
measured. According to our kinetic results, the replacements of these residues led to 
enzymes with increased Km values of myo-inositol. Although the modifications were 
made at the C-terminal domain (substrate-binding domain), it also resulted in the 
increase of Km values of NAD+ which is bound at the N-terminal domain. In particular, 
M126A suffers from considerable conformation change compared to the structure of 
wild-type IDH. Thus, a single substitution can affect not only the local feature but also 
affect the global enzyme conformation, and further affect the dehydrogenase activity. 
 
Although a lot of work has been done on IDH, many questions concerning catalysis by 
IDH remain to be answered. One of the most interesting concerns would be how the 
1L-4-substituted myo-inositol is bound as a substrate and is oxidized. Further 
investigation to examine the structure-function relationships of IDH might need to 
concentrate on X-ray crystallography, solving structures of wild-type IDH and its 
mutants that complexed with synthesized substrates and inhibitors. 
 
I hope this work will provide a basis for exploring the other unknown aspects of IDH. 
Current and future studies on this enzyme will help elucidate the other putative 
inositol dehydrogenases, such as myo-inositol 2-dehydrogenase (IolG1) from 
Lactobacillus plantarum, myo-inositol dehydrogenase from Corynebacterium 
glutamicum, dehydrogenase from Salmonella typhimurium, and dehydrogenase from 
Thermotoga maritima. 
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Appendix 1.  Restriction digestions fractions after treated with corresponding 
digest enzymes. wt: wild-type. 
 
plasmids DNA pieces (bp) Restriction enzyme 
Y233F 4324+2077 
wt IDH 6401 
Hpa1 
Y235F 4324+2077 
wt IDH 6401 
Hpa1 
 
Y233R 4324+2077 
wt IDH 6401 
Hpa1 
Y235R 3738+1234+895+402+132 
wt IDH 3738+1297+1234+132 
    Eae1 
M126A 3680+1940+781 
wt IDH 2721+3680 
ECoN1 
M126S 3680+1940+781 
wt IDH 2721+3680 
 ECoN1 
D35S 1498 + 4903 
wt IDH 6401 
Hpa1 
D179N 2361, 1366, 1188, 1082, 394 
wt IDH 2326, 2269, 1386, 394 
Acl1 
G14A 4217+2180 
wt IDH 6399 
ASiS1 
 
G14A/D35S 4217+2180 
wt IDH 6399 
ASiS1 
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Appendix 2.   NOE difference spectrometry of (±)-4-O-(1-allyl-4-methylene- 
1,2,3-triazole)-myo-inositol. 
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Appendix 3. Inhibitory activity (vo/vi) against concentrations of inhibitors. 
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Appendix 4. Positive cooperativity demonstrated by mutants D35S and 
G14A/D35S with NADP+ or NAD+. No positive cooperativity observed with mutant 
D35S/V36R.  
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Appendix 5. Graphical representation of kinetic isotope effect measurement. 
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Appendix 6. Graphical representation of wild-type IDH using compounds 1, 2, 3, 4 , 
or D-chiro-inositol as the substrate.  
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Appendix 7. Graphical representation of IDH mutants using myo-inositol as the 
substrate.  
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D35S/A40K with NADP
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N157R with NAD
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R259Y with NAD
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N157S with NAD
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